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Sepsis is a condition that arises from the host’s own exaggerated response to an infection, 
directed towards pathogens, but causing multiple organ failure.  Sepsis is one of the most 
common causes of death, and a considerable absorber of healthcare resources.  This 
frequently fatal condition, despite progress in technology and improving knowledge of 
pathophysiology, is still poorly understood, carries high mortality and morbidity rates, 
and survivors are often left with permanent disabilities and poor health outcomes. 
Initial presentation of sepsis is often nonspecific, making diagnosis difficult, and 
causing lifesaving treatment delays.  Sepsis guidelines are derived from emerging 
evidence-based research.  While there is a general consensus that the optimal approach to 
sepsis management is early recognition and rapid intervention, evidence supporting 
treatment guidelines is evolving and inconsistent.  A mandatory quality improvement 
measure to implement Sepsis Early Management Bundle (SEP-1) went into effect on 
October 1, 2015, in the settings utilized for this project.  An evidence-based project was 
conducted to evaluate the interventions and the effectiveness of the sepsis protocol on 
patients’ health outcomes and assess whether implementation of the protocol reflected in 
reduced hospital length of stay, decreased mortality, morbidity, antibiotics utilization and 
rehospitalizations in a community hospital in the coastal region of South Carolina.  A 19-
month data collection, retrospective review, and data analysis included 158 participants 
in two groups, pre-and post-implementation of the protocol.
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Results showed that mortality and hospital stay were considerably reduced after 
the protocols were implemented; however, readmission rates increased, and morbidity 
increased.  Implementing the mandated protocol actually did not uniformly influence the 
efficiency of interventions.  Results of this study can be used to validate the need for 
improvement and recommend innovative approaches to therapeutic and diagnostic 
methods that could facilitate earlier and more targeted interventions. 
Future studies are needed to identify approaches that can help sepsis survivors to 
regain independence, return to prior living arrangements, and avoid rehospitalization.  
Measures of sepsis guideline effectiveness should focus on not only immediate results 
and mortality rates, but also return to function and long-term effects affecting survivors.  
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Sepsis, also known as blood poisoning, is a common, debilitating, and potentially 
deadly medical condition.  The word sepsis is derived from the ancient Greek word for 
rotten flesh, decay, and putrefaction (Marik, 2014).  Although clinical criteria that define 
sepsis remain controversial, the term refers to the systemic inflammatory response 
following microbial infection with the presence of some degree of organ dysfunction 
(Vincent, Opal, Marshall, & Tracey, 2013).  
Background and Significance  
Defined as a whole body inflammatory response to an infection (Bone, 1992), it is 
a serious widespread systemic overreaction.  Sepsis is more common than heart attack, 
and claims more lives than any cancer (World Sepsis Day, 2015).  It can rapidly progress 
to a substantial acute organ dysfunction known as severe sepsis, and by triggering a 
cascade of mechanisms can lead to septic shock, multi-organ failure, and death.  Septic 
shock is associated with overwhelming infection, usually by gram-negative bacteria, 
although it may be produced by other bacteria, viruses, fungi, and protozoa.  It is thought 
to result from the action of endotoxins or other products of the infectious agent on the 
vascular system causing large volumes of blood to be sequestered in the capillaries and 
veins; activation of the complement and kinin systems and the release of histamine, 




Dictionary, 2012).  Clinical characteristics of sepsis include initial chills and fever, warm 
flushed skin, increased cardiac output and hypotension, and specific inflammatory 
parameters; if therapy is ineffective, it may progress to the clinical picture associated with 
septic shock (Farlex Partner Medical Dictionary, 2012). 
This condition carries a high mortality rate and a positive outcome depends on 
early recognition, timely diagnosis, and prompt implementation of aggressive treatments.  
However, in its early stages sepsis often presents itself in a nonspecific manner making it 
difficult to recognize and diagnose.  Typical clinical characteristics of sepsis are not 
always obvious, sepsis is often underrecognized and its mortality remains high (Silva, 
Andriolo, Atallah, & Salomão, 2013).  
Sepsis is predominantly detrimental among vulnerable and susceptible populaces 
such as the immunocompromised, young children, and older adults.  Older age is an 
independent predictor of sepsis mortality (Martin, Mannino, & Moss, 2006).  Persons 
older than 65 years of age with multiple comorbidities are at a higher risk for 
complications from infections than the general population.  Presentation of early sepsis is 
particularly ambiguous in this age group; therefore, a lower threshold and a higher index 
of suspicion are required to identify sepsis in older patients (Nasa, Juneja, & Singh, 
2012).  
Similarly, recognizing sepsis can be delayed in patients with an impaired immune 
system such as those with diabetes, HIV/AIDS, hepatic failure, alcohol dependence, or 
who had organ transplants.  Other high-risk populations are those patients with altered 
physiology such as pregnant or postpartum women.  Neonates and young infants are at 




While sepsis affects people of all ages, races, and genders, it is especially 
damaging and more frequently fatal among underprivileged and disadvantaged 
populations (Martinet al., 2006).  Variations in age, gender, and medical comorbidities 
including diabetes and renal failure create additional complexity that influences the 
outcomes in septic patients (Iskander, Osuchowski, Stearns-Kurosawa, Kurosawa, 
Stepien, Valentine, & Remick, 2013).  
Currently, there is no specific single pharmacological intervention or therapeutic 
measure for sepsis, with the exception of antibiotics; therefore, the care of septic patients 
remains mainly supportive, and even with optimal currently available therapy, septic 
patients still experience unacceptably high morbidity and mortality (Iskander, et al., 
2013).  Saving lives depends not just on treatments specific to a particular infection, but 
rather a focus on early recognition and awareness of sepsis, rapid antimicrobial therapy 
and resuscitation, and vital organ support (World Sepsis Day, 2015). 
Scope of the Problem 
Sepsis is a medical emergency where each hour matters.  Chances of survival can 
be greatly improved by rapidly recognizing the condition and responding with 
appropriate approaches such as appropriate antimicrobial therapy (AAT) and prompt 
resuscitation.  For many years, the inflammatory dynamics of sepsis have been 
incompletely understood.  Over two decades ago, sepsis was first recognized as an 
inflammatory response to infection, and our understanding of the mechanism of the septic 
process and pathophysiology has evolved over time.  Years of research and multiple 
clinical trials have been conducted; however, optimal treatments and best practice 




still not entirely understood.  Despite best available treatment, sepsis continues to be a 
major cause of morbidity and death (Iskander, et al., 2013).  
Although implementation of early, rapid, aggressive treatment has improved 
mortality, those who survive sepsis frequently suffer from severe long-term consequences 
of later onset morbidity, permanent disability, and premature death.  Septic patients often 
develop recurrent infections, nutritional deficiency, and sustainable organ injury before 
leaving the hospital in a debilitated functional state and often are rehospitalized with 
returning infection (Iskander, et al., 2013).  Many are left with sustainable physical and 
mental impairments; some are on permanent hemodialysis or have amputated limbs.  
While some studies have shown a positive effect of early aggressive treatment, others 
have found no benefit compared with usual care.  Optimal sepsis management strategies 
still need to be determined, and more research is needed to address the best practice.  Our 
understanding of the mechanisms and complexity of sepsis pathophysiology presents 
substantial challenges to finding innovative treatments.  Despite extensive research, 
currently available therapies do not provide a cure.  A more individualized approach to 
developing improved therapeutic response is needed (Iskander, et al., 2013). 
It is expected that the incidence of sepsis will continue to grow in a milieu of 
antimicrobial resistance, aging populations, wider use of immunosuppressive therapies, 
and more accessible medical technology and interventions.  Despite an overall decline in 
the proportional mortality from sepsis, the total number of patients dying from sepsis is 
greater than in the past; moreover, sepsis survivors have increased long-term mortality, 
and are often left with considerable functional deficits and decreased the quality of life 





Sepsis is a serious global healthcare problem.  More common than heart attack 
and claiming more lives than any cancer, sepsis remain major global health problems 
with an estimated number of deaths between 15-19 million per year worldwide (Tiru, et 
al., 2015).  Although sepsis accounted for approximately 2% of all hospitalizations in 
2008 in the United States, it was responsible for 17% of hospital deaths, and patients 
hospitalized with sepsis were sicker, and stayed longer (Hall, Williams, & DeFrances, 
2014).  Sepsis is currently the 10
th
 leading cause of death in the United States and the 10
th
 
leading cause of death in South Carolina (Centers for Disease Control and Prevention, 
2014).  
In developed countries, sepsis is a leading cause of mortality.  In the United States 
alone, there are 750,000 cases and 200,000 deaths from severe sepsis annually (Wang et 
al., 2010).  Each year in the United States, sepsis results in 570,000 emergency 
department visits, and has a 20% to 50% mortality rate (Perelman School of Medicine at 
the University of Pennsylvania, 2013).  In 2011, nearly 40% of sepsis cases resulted in 
death within 28 days (Stearns-Kurosawa, Osuchowski, Valentine, Kurosawa, & Remick, 
2011).  In 2014, the overall mortality rate increased to above 50%, with even higher 
mortality rates in patients with ischemic bowel, central nervous system (CNS) infection, 
disseminated infection, and other intra-abdominal infection.  Somewhat lower mortality 
rates occur in those with obstructive uropathy-associated urinary tract infection, 
enterocolitis/diverticulitis, pyelonephritis, cholecystitis/cholangitis, and intravascular 




Figure I.1. Sepsis Hotspots in the U.S.  
Credit: Penn Medicine (Perelman School of Medicine at the University of Pennsylvania, 2013) 
Regional Distribution 
The regional distribution of sepsis provides important insights.  Researchers have 
created the first United States map that pinpoints hotspots for infection and severe sepsis 
related-deaths (Figure I.1).  Areas with the highest sepsis mortality form contiguous 
clusters in the Southeastern and mid-Atlantic regions.  Researchers have sought to 
determine the geographic distribution of sepsis to determine which areas of the country 
require vital public health resources and identified “hotspots” with notable clusters 
located in the Midwest, mid-Atlantic, and the South (Perelman School of Medicine at the 




Sepsis in South Carolina.  South Carolina has one of the highest sepsis attributed 
death rates, ranking 37th in the nation, carrying an inpatient hospitalization mortality rate 
of 14%.  The annual sepsis incidence rate is 74.4 per 100,000 residents, as compared to 
Minnesota’s 41.0 per 100,000 inhabitants (Wang, Devereaux, Yealy, Safford, & Howard, 
2010).  In South Carolina, sepsis is one of five top all-payer admission drivers; for 
Medicare beneficiaries, it is the number one driver of 30-day readmissions (21.3%).   
Higher rates of sepsis have been reported among South Carolina’s minorities, 
underprivileged, and the elderly.  According to United States Census Bureau (2014), 5% 
of the Beaufort County population that is 65 years and older lives below poverty level. 
Per DHEC’s publicly available data on Hospital Compare website for Beaufort County, 
hospitals show the same or lower than the state average rate of the diagnosis of sepsis 
(DHEC 2015). 
Risk factors 
Risk factors for sepsis and death from septic shock include chronic debilitating 
conditions such as diabetes, treatment with immunosuppressant drugs, use of invasive 
procedures and devices, the presence of lines, catheters, intravascular or prosthetic 
devices, and genetic factors (Dellinger et al., 2013).  Factors associated with increased 
risk of developing sepsis also include complicated obstetric delivery, certain surgeries, 
and trauma to the gastrointestinal tract, such as perforation of the small intestine, 
infections such as urinary tract infection, pneumonia, cellulitis, meningitis, and many 
others (Dellinger, et al., 2013).  Additional risk factors for progression to septic shock 
include prolonged time between onset of manifestations and initiation of treatment for 




hospitalization is associated with additional health complications, nosocomial infections, 
and increased costs.  Elderly patients are more prone to prolonged length of hospital stay 
(LOS). 
Survivors of sepsis are at increased risk of recurrent infections during the year 
following their septic episode.  They are 2.83 times more likely to develop a subsequent 
infection, 3.78 times more likely to require rehospitalization for infection, and 3.61 times 
more likely to die after hospital discharge (Wang et al., 2014).  Sepsis has been 
associated with the development of at least one new physical limitation for survivors and 
a 3-fold risk of developing moderate to severe cognitive impairment (Iwashyna, Ely, 
Smith, & Langa, 2010).  Sepsis survivors report deterioration in the quality of life related 
to poor physical function and overall declined health (Turi & Ah, 2013).  
Epidemiology 
Incidence.  Sepsis can be acquired both in the community and in healthcare 
facilities.  CDC’s National Center for Health Statistics (NCHS, 2011) estimated 
hospitalization with sepsis increased from 621,000 in the year 2000 to 1,141,000 in 2008.  
Every minute one patient presents to emergency rooms with severe sepsis (Palleschi, 
Sirianni, O’Connor, Dunn & Hasenau, 2014).  It is projected that by the year 2020 an 
additional 1,000,000 sepsis cases per year will occur in the United States due to the aging 
population, the longevity of persons with chronic diseases, the spread of antibiotic-
resistant organisms, an increase in invasive procedures, and increased use of 
immunosuppressive and chemotherapeutic agents (Palleschi, Sirianni, O’Connor, Dunn 
& Hasenau, 2014). Although epidemiologic data from 2004 to 2009 demonstrated a 




common cause of death in the United States, after heart disease and malignant neoplasms 
(Marik, 2014).  Moreover, the incidence of sepsis increases an average of 13% every year 
(Tiru et al., 2015).  As a comparison to the rest of the world, this trend is also seen in 
Australia, New Zealand, and in Europe.  Population-based studies in the developed world 
showed considerably increasing the burden on healthcare systems as populations in these 
countries aged (Tiru et al., 2015). 
Severe sepsis occurs disproportionally in hospitalized patients, 0.2:1,000 in 
children and 26.2:1,000 in adults who are older than 85 years of age (Schub & Schub, 
2015).  The incidence of severe sepsis and septic shock is growing in the United States 
due to the growing number of older adults, as well as high-risk patients in the general 
population such as those immunocompromised with diabetes, on chemotherapy, or with 
organ transplants.  Moreover, increased sepsis occurrence is associated with greater use 
of invasive procedures in healthcare settings, the use of broad-spectrum empiric 
antimicrobials, and inappropriate prescribing of antibiotic, which promotes breeding of 
resistant organisms.   
Pathogenesis 
The pathogenetic mechanisms associated with sepsis are remarkably complex.  In 
humans, pathogens are normally eradicated by immune and physiologic responses 
restricted to a local infection site and the system returns to homeostasis.  Normally the 
immune system reacts to a source of infection by localized inflammation, where blood 
vessels swell to allow more blood to flow, and become leaky so that the infection-
fighting cells and clotting factors can get out of the blood vessels and into the tissues 




Sepsis is characterized by inappropriate regulation of these normal reactions and 
rapid acceleration of the pathologic processes.  The normal immune reaction goes to 
overdrive affecting all of the body organs and tissues, leading to widespread 
inflammation, poor perfusion, organ failure and septic shock (World Sepsis Day, 2015).   
A number of biological mechanisms are activated leading to a cascade of events 
on molecular and cellular levels, such as upregulation of lymphocyte costimulatory 
molecules and rapid lymphocyte apoptosis, delayed apoptosis of neutrophils, enhanced 
necrosis of cells and tissues, consequently dysfunctional coagulation mechanisms, 
namely inappropriate intravascular fibrin deposition and disseminated intravascular 
coagulation (DIC) (Stearns-Kurosawa, Osuchowski, Valentine, Kurosawa, & Remick, 
2011).  The paradox of DIC in the late stage of sepsis is that the patients are undergoing 
nearly unrestricted clotting and, as a result, are at high risk for bleeding because platelets 
and coagulation factors are consumed faster than they can be replaced, resulting in 
prolonged clotting times.  In septic shock organ damage may occur because small clots 
form faster than they can be broken down, and they lodge in the microvascular beds of 
organs, causing ischemia (Stearns-Kurosawa et al., 2011).   
Pathophysiology.  Sepsis is a potentially fatal host response to infection that 
occurs in association with systemic inflammatory response syndrome (SIRS).  SIRS is a 
severe inflammatory reaction that is diagnosed when two or more specific criteria are 
present, such as high or low temperature, increased heart rate, and respiratory rate, 
decreased oxygenation, leukocytosis or leukopenia, and the presence of immature 




or without an infection, but sepsis can only be diagnosed when SIRS occurs in a person 
with a suspected or confirmed infection (Schub & Schub, 2015). 
The sepsis response is a characteristic cascade of mechanisms leading to massive 
vasodilation and results in a drop in blood pressure, which in turn inhibits adequate tissue 
perfusion that can be associated with a multiple-organ failure.  Severe sepsis is 
characterized by multiple-organ dysfunction that results in septic shock, which is a severe 
sepsis with persistent hypotension despite adequate fluid resuscitation, consequently 
leading to death (Schub & Schub, 2015).  The pathophysiological basis of sepsis has been 
subject to constant change over the last decades.  In today's understanding, sepsis is 
primarily pathology of the immune system, triggered by an underlying infection but 
perpetuated by the host's response itself (Uhle, Lichtenstern, Brenner, & Weigand, 2015). 
Sepsis Etiology 
The mechanisms of sepsis are not fully understood, making treatment difficult.  
Infection is the most common cause of sepsis; however, in many sepsis patients, the 
etiology is not clearly identified.  Bacteria are by far the most common culprits, but most 
types of microbes can cause sepsis, including bacteria, fungi, viruses and parasites such 
as those causing malaria (World Sepsis Day, 2015).  The bloodstream, skin, respiratory, 
gastrointestinal, and genitourinary tracts are common sites of infection associated with 
sepsis.  Most infections are bacterial in origin but can also be fungal, viral, rickettsial, or 
parasitic (Schub & Schub, 2015).  The most common pathogens that cause sepsis are 
associated with a high risk of hospital mortality are gram-positive bacteria including 




Escherichia coli, Pseudomonas, Klebsiella, Proteus, and Pseudomonas.  A list of 
common pathogens is shown in Appendix C Table C.1. 
Presentation 
Sepsis occurs as a result of infections such as pneumonia, urinary tract infections, 
skin and wound infections, or from invasive medical procedures.  Sepsis presentation 
might include fever or hypothermia, hyperventilation, tachycardia, shaking chills, warm 
skin, skin rashes, lethargy, confusion, coma, hyperglycemia, muscle weakness, bleeding 
diathesis, increased cardiac output, and signs and symptoms that reflect the primary site 
of infection (e.g., diarrhea, abdominal pain, and abdominal distention in cases of 
gastrointestinal infection; severe headache, neck stiffness, and cervical/submandibular 
lymphadenopathy in cases of head and neck infection).  Severe sepsis and septic shock 
are demonstrated by single or multiple organ failures such as a liver dysfunction (e.g., 
jaundice), cool skin, pancreatitis, renal failure, decreased cardiac output, acute respiratory 
distress syndrome, multiple organ dysfunction syndrome, encephalopathy, neuropathy, 
and DIC (Kalil, 2015). 
Sepsis and Health Disparities  
Biology, Geography, Climate, Environment 
The type of organism causing severe sepsis is an important determinant of 
outcome.  Gram-positive organisms as a cause of sepsis have increased in frequency over 
time and are now almost as common as gram-negative infections, likely due to greater 
use of invasive procedures and the increasing proportion of hospital-acquired infections.  




for longer periods of time resulted in an increased bacterial resistance to antibiotics 
(Mayr, Yende & Angus, 2014).  
Severe sepsis is more common in colder months.  The fatality rate for sepsis is 
also higher in winter, despite similar severity of illness.  Sepsis related to respiratory 
infections has the highest incidence in colder months, whereas genitourinary infections 
are more frequent in summer.  This seasonal variation relates to climate and is reflected 
by the regional differences within the US: incidence variation is highest in the Northeast 
and lowest in the South (Mayr et al., 2014). 
Disparities among gender, race, age and socioeconomic status.  Low 
socioeconomic status, older age, male gender, African American race, and increased 
burden of chronic health conditions are important risk factors for severe sepsis.  
Psychosocial stressors, such as coping styles, housing and neighborhood quality, 
consumption potential (e.g. the financial means to buy healthy food, warm clothing, etc.), 
and the physical work environment shape health outcomes (WHO, 2010). 
Epidemiological studies consistently report a higher incidence of severe sepsis 
among Black compared to White patients.  The underlying mechanisms of racial 
disparities in infection and severe sepsis are poorly understood.  A higher prevalence of 
chronic kidney disease and diabetes, higher infection rates, overall lower socioeconomic 
status and education levels among Black patients may partly explain higher sepsis rates 
(Mayr, Yende & Angus, 2014).   
Women appear to be at lower risk of developing sepsis than men.  Men and 
alcoholics are particularly prone to developing pneumonia while genitourinary infections 




that shape health outcomes are behavioral factors such as nutrition, physical activity, and 
tobacco and alcohol consumption.  Mayr et al., (2014) reported an inverse relationship 
between socioeconomic status and the risk of blood stream infection.  A combination of 
race, age, comorbidities and social and environmental factors all contribute to severe 
sepsis-related hospitalization rates and poor outcomes.  Other risk factors include 
residence in long-term care facilities and institutions, malnutrition, immunocompromised 
state and utilization of prosthetic devices (Mayr et al., 2014). 
Disparities in sepsis incidence and mortality rates are higher for those 
underprivileged who live in medically underserved areas (DHHS, 2014).  Racial 
disparities are associated with residence in medically and economically underserved 
areas, median income, percent below the poverty level and educational attainment.  
African Americans in South Carolina have a higher overall incidence rate of 
hospitalization for sepsis than Caucasians (6.09 vs. 4.74 per 1,000; p<0.0001) (Rice, 
Nadig, Simpson, Ford, & Goodwin, 2014).  Large disparities exist in the incidence of 
sepsis in African Americans, males, and in older adults in South Carolina (Esper, Moss, 
Lewis, Nisbet, Mannino, & Martin, 2006).  
The risk of dying from severe sepsis is considerably higher in elderly people, with 
age as an independent risk factor for mortality (Nasa et al., 2012).  Additional risk factors 
for the elderly population include the presence of multiple comorbidities, inadequate 
financial and healthcare resources, poor nutritional status, and lack of social support.  
Infections in older adults often have ominous signs and are underrecognized in this high-




atypical, posing challenges in regards to sepsis recognition and leading to a delayed 
diagnosis (Girard, Opal, & Ely, 2005). 
Sepsis in the elderly population.  Sepsis in the elderly population is a common 
problem associated with considerable mortality and major consumption of healthcare 
resources, and its incidence increases with age.  Sepsis carries an unfavorable prognosis 
for all age groups, but the elderly are among the most vulnerable and particularly 
predisposed to sepsis (Martin et al., 2006).  This is attributable to many risk factors such 
as the age itself, multiple comorbidities, and the fact that older patients tend to be treated 
less aggressively (Destarac & Ely, 2001).  Clinicians must be keenly aware of 
nonspecific expression of sepsis in this patient population, which include delirium, 
weakness, anorexia, malaise, urinary incontinence, or falls (Girard, Opal, & Ely, 2005).  
Fever may be blunted or absent, tachycardia and hypoxemia incidences can be lower 
among patients with sepsis who were >75 years of age, and compared with younger 
patients, tachypnea and altered mental status were more common among older patients 
(Girard et al., 2005).  Many elderly patients respond well to the evidence-based 
diagnostic and management strategies if initiated in a timely manner.  Delayed 
recognition can lead to treatment failures (Girard et al., 2005).   
An estimated 60-65% of all patients who develop sepsis in the United States are 
65 years of age or older (Girard et al., 2005).  The population of those aged 65 and older 
in the United States increased 13.2% from 1990 to 2000 and continues to grow.  In 2050, 
the number of adults aged 65 and older is projected to double from 2012 and reach 83.7 




The aging of the population in developed countries is believed to be largely 
responsible for the increased incidence of sepsis (Martin et al., 2006).  Those aged 65 and 
over tend to be hospitalized for sepsis longer than the average length of stay (LOS), and 
had an average LOS that was 43% higher than that of other patients.  In those aged 65 
and over, 20% of sepsis hospitalizations ended in death compared with 3% for other 
reasons for hospitalizations in general (Hall, Williams, & DeFrances, 2014). 
Financial Implications 
Sepsis is the costliest diagnostic condition.  Sepsis ranks number one for all-payer 
hospital discharges, exceeding one million discharges a year and representing 5.2% of all 
healthcare costs, and consuming 6.9% of Medicare payments annually.  Sepsis 
contributes to $20.3 billion in aggregate hospital costs to the annual economic burden of 
the national healthcare system (Torio & Andrews, 2013).  A major factor driving these 
expenditures is that the average length of hospitalization for sepsis patients is 75 percent 
longer than stays for other conditions (Hall, Williams, & DeFrances, 2014).  However, 
long-term consequences of sepsis draw attention to the true magnitude of this problem.  
The total cost of sepsis treatment and care in the United States has been estimated at $400 
billion annually (Lopez-Bushnell, Demaray, & Jaco, 2014).  The cost of treating a patient 
in the ICU with severe sepsis is 6 times greater than the cost of treating a patient in the 
ICU who does not have sepsis (Ahrens & Tuggle, 2004).  
As the impact of survivorship increases, the cost to society extends well beyond 
lives lost (Tiru et al., 2015).  Increased dependence and rehospitalizations of sepsis 
survivors increase healthcare consumption and, along with increased mortality, all 




socioeconomic positions shape specific determinants of health status, sepsis accounts for 
disproportionate resource utilization and substantial mortality. 
Description of the Clinical Problem 
Sepsis is a major public health problem.  Early identification and treatment save 
lives and resources.  It is a life-threatening condition that can rapidly progress to severe 
sepsis, septic shock, multi-organ failure, and death.  It is a serious, costly, often lethal 
condition, and a common problem for most hospitals.  Despite advances in technology 
and some improvement in survival rate over last decade, sepsis continues to have high 
mortality and poor outcomes.  
Like the rest of the nation, a community-based, 100-bed hospital located in 
coastal South Carolina has been experiencing a high incidence and mortality of sepsis 
and struggling with poor patient outcomes.  This hospital is a part of a large healthcare 
organization that is composed of hospitals across the United States.  This facility has 
implemented the Surviving Sepsis Campaign (SSC) clinical guidelines as new protocols 
for sepsis care in efforts to improve outcomes.  Prior to the launching of the Sepsis 
Bundle program the hospital was using previously established standards of care based on 
evidence-based practice, however, these were applied inconsistently per individual 
provider discretion.  As of October 1, 2015, this hospital has implemented a set of new 
protocols for sepsis management, as proposed by SSC guidelines, including the updated 
3- and 6-hour management bundles.  It included all the newest components of SSC 
guidelines and preparation for implementation included staff education.  An update to 
existing Electronic Medical Record software was also implemented to recognize and 




computer-assisted sepsis alert to improve early recognition.  The EMR now includes 
clinical decision support system that helps to detect patients at risk of sepsis based on 
entered values.  The system alert is triggered by pre-programmed specific to sepsis vital 
signs and laboratory values, and once activated, generates tasks for clinical staff.  The 
alert is delivered as a pop-up notification to the patients’ designated nurse, who then 
electronically contacts a provider.  The provider also receives an alert and is obligated to 
document that action was taken (Amland, Lyons, Greene, & Haley, 2015).  A sepsis 
screening assessment task was also integrated into admission order sets in order to 
improve the process of determining sepsis risk and facilitate recognition early in the 
admission process. 
Patient demographic characteristics in this hospital are diverse, but many are 
elderly, over the age of 65, and many visiting the area.  This demographic profile 
accurately reflects population distribution in the county (Table I.1) (United States Census 
Bureau, 2014).  
Table I.1. South Carolina and Beaufort County Population >65 Demographic 
 
 Selected County SC State 
 count count 
Population, 2014 estimate 175,852 4,832,482 
 % % 
Persons 65 years and over, % 2013 23.3 15.2 
 (United States Census Bureau 2014).  
Project Background 
Given the specific population characteristic for this hospital, with an average age 
of patients with sepsis being 74 years, the original intent of this project was to 




who developed sepsis while hospitalized.  Diagnosing sepsis in this population is more 
difficult because elderly patients may have an atypical response and a subtle, ambiguous 
presentation of sepsis, such as altered mental status or falls.  Therefore, lifesaving 
treatments and therapeutic interventions for this population may often be delayed 
(Destarac & Ely, 2001).  Altered mental status in elderly patients may sometimes be the 
sole symptom of sepsis on initial presentation; as a result, there is a high possibility that a 
number of these patients are underdiagnosed.  Given the atypical presentation of sepsis in 
elderly patients, potential underdiagnosis likely contributed to negative outcomes in my 
practice setting.   
The initial purpose of this project was to illustrate an innovative approach to 
initial sepsis screening in the emergency room and inpatient care that could facilitate 
earlier recognition of sepsis among the elderly, and potentially improve sepsis survival in 
this patient population.  This would have been accomplished by adding a short cognitive 
assessment to evaluate for acute mental status change, and including it as one of the SIRS 
manifestations and a diagnostic criterion for severe sepsis.   
While the core clinical staff and leaders were initially supportive, and the majority 
of staff agreed that it would be a good step towards improving sepsis recognition among 
the elderly, the idea met solid resistance for any attempt for implementation.  Upon 
further assessment, it became clear that the nursing and clinical staff in both the 
emergency department and on units already felt overwhelmed with the number of 
assessments required of them, and the notion of one more, even a brief one, was not 
welcomed.  Additionally, integration of a new assessment into the existing module in the 




Given this development, the project was re-routed to focus on current sepsis guidelines 
effectiveness and evaluation of their impact on patients’ health outcomes after the 
protocol implementation.  I am a member of an interdisciplinary team dedicated to 
improving sepsis outcomes in this setting, and we are considering potential improvements 
in diagnostic technology that would allow earlier identification of pathogens and targeted 
treatment.  
Evaluation of the success of changes that have already been implemented will 
provide valuable data to guide the direction of future practice innovation.  For 
innovations that require organizational financial outlays, it is necessary to demonstrate 
the need for such an investment as well as the potential benefit relative to cost.  
Therefore, the first step is to assess the impact of recently implemented protocols. 
Purpose of the Project 
The purpose of this project was to evaluate the utilization and effectiveness of 
current sepsis protocols in a community hospital in coastal South Carolina on health 
outcomes.  Specifically, to assess whether the protocol affected hospital length of stay, 
mortality, morbidity, readmissions, appropriateness of antibiotics utilization, and 
influenced the timing of initiating of interventions.  Facilitators and barriers were 
identified and examined.  Findings are to be integrated with collaborative sepsis team 
efforts, and the best practice recommendations will be presented to the hospital 
administration.  The ultimate goal of the project was to facilitate innovative approaches to 






The PICO question was formulated using the format developed by Melnyk and 
Fineout-Overholt (2011) to identify the specific target population, the intervention of 
interest, comparison of intervention, outcomes and the time frame. 
 [P] Population- Population of Selected Subjects  
 [I] Intervention- Experimental Intervention 
 [C] Comparison - Comparison of Intervention  
 [O] Outcomes- Results and Outcomes of Interventions  
 [T] Time -Time Frame  
(Melnyk &. Fineout-Overholt, 2011, para. 4). 
The PICO question used to guide this project was: In adult patients presenting with sepsis 
before and after October 1, 2015, does implementation of a new sepsis protocol reflect in 
improved outcomes such as reduced hospital LOS, decreased mortality, morbidity, 
readmissions, and appropriate antibiotics utilization, and does it result in initiating early 
treatments as compared to previous approaches? 
The focus of the question was to evaluate the effectiveness of early interventions, 
further identify the components of the current sepsis “bundles” protocol that are most 
effective in the treatment and the most accurate in early recognition of sepsis, and explore 
the degree to which the components favor clinical staff compliance and contribute to 





Appropriate Antibiotic Therapy (AAT) in patients with severe sepsis and septic shock 
means prompt achievement of antimicrobial’s therapeutic concentration in blood, tissue 
penetration, and maintenance of optimal exposure at the infection site with broad-
spectrum antibiotics administered in a timely manner – as per the guideline protocol (Pea, 
& Viale, 2009).   
Bacteremia: Invasion of the bloodstream by bacteria (Gale Encyclopedia of Medicine, 
2008). 
Blood cultures: Incubation of a sample of blood in a suitable culture medium so as to 
encourage reproduction of bacteria, which are possible causes of disease, for purposes of 
identification (Collins Dictionary of Medicine, 2004). 
Bundle: A group of interventions related to a disease process that, when executed 
together, result in better outcomes than when implemented individually (Dellinger 
&Vincent, 2005, p. 635). 
Coagulation: Clotting; the process of changing from a liquid to a solid, said especially of 
blood (that is, blood coagulation).  In vertebrates, blood coagulation is a result of cascade 
regulation from fibrin (Farlex Partner Medical Dictionary, 2012). 
Comorbidity: Coexisting medical conditions or disease processes that are additional to an 
initial diagnosis (Mosby's Medical Dictionary, 2009). 
Crystalloid: A hydration solution that contains only electrolytes; a substance in a solution 





Extravascular: Outside the blood vessels or lymphatics or of any special blood vessel 
(Farlex Partner Medical Dictionary 2012). 
Fibrin: An insoluble protein that is essential for clotting of blood, formed from fibrinogen 
by the action of thrombin (Dorland's Medical Dictionary, 2007). 
Hyperventilation: Unusually or abnormally deep or rapid breathing; hyperventilation is 
defined as breathing in excess of the metabolic needs of the body, eliminating more 
carbon dioxide than is produced, and, consequently, resulting in respiratory alkalosis and 
an elevated blood pH.  The traditional definition of hyperventilation syndrome describes 
"a syndrome, characterized by a variety of somatic symptoms induced by physiologically 
inappropriate hyperventilation and usually reproduced by voluntary hyperventilation" 
(Folgering, 1999, p. 365).  
Hypoperfusion: A condition of acute peripheral circulatory failure due to derangement of 
circulatory control or loss of circulating fluid.  It is marked by hypotension and coldness 
of the skin, and often by tachycardia and anxiety (Miller-Keane Encyclopedia, 2003): 
Hypotension: Diminished tension; lowered blood pressure, systolic pressure less than 100 
millimeters of mercury (mmHg) (Miller-Keane Encyclopedia, 2003). 
ICU: Intensive Care Unit. 
Immunocompromised: Also immunosuppressed, having impaired immune system, prone 
to infection and more severe infection course.  
Initial sepsis presentation:  “Time zero” or sepsis onset, or onset of manifestations.  
While pinpointing exactly the time of sepsis onset is difficult, if not impossible, it is the 
time of reference that specific symptoms characteristic to sepsis were observed and 




In vitro: Within a glass; observable in a test tube; in an artificial environment (Miller-
Keane Encyclopedia, 2003). 
Lactic acid: A compound formed in the body in anaerobic metabolism of carbohydrate 
and also produced by bacterial action (Dorland's Medical Dictionary, 2007). 
Length of Stay (LOS): It is the length of an inpatient episode of care, the number of days 
patient stays in a hospital, calculated from the day of admission to day of discharge, and 
based on the number of midnights spent in the hospital.  Patients admitted and discharged 
on the same day have a length of stay of less than one day (McGraw-Hill Concise 
Dictionary of Modern Medicine, 2002)  
Leukocytosis: An increase in the number of white cells in the blood, especially during an 
infection.  The presence of more than 11,000 white cells in a cubic millimeter of blood is 
considered high.  
Morbidity: A diseased condition or state. 
Morbidity rate: The number of cases of a particular disease occurring in a single year per 
a specified population unit, as x cases per 1000.  It also may be calculated on the basis of 
age groups, sex, occupation, or another population unit (Mosby's Medical Dictionary, 
2009). 
Mortality: The death rate, which reflects the number of deaths per unit of population in 
any specific region, age group, disease, or other classification, usually expressed as 
deaths per 1000, 10,000, or 100,000 (Mosby's Medical Dictionary, 2009). 
Multi-drug resistance: The resistance of bacteria, especially against more than two of the 




Oliguria: Scant urine production, diminished capacity to form and pass urine, less than 
500 mL in 24 hours.  
Organ hypoperfusion: It may be demonstrated by an increase in serum lactate level, 
oliguria, an acute alteration in mentation, or altered circulation to the peripheral 
extremities.  Organ dysfunction is often evidenced by arterial hypoxemia, acute 
respiratory distress syndrome (ARDS), acute renal failure, thrombocytopenia, and/or 
disseminated intravascular coagulation (DIC). 
Pathogen: Any disease-producing agent or microorganism (Miller-Keane Encyclopedia, 
2003): 
Pathophysiology: The study of structural and functional changes in tissue and organs that 
lead to disease, also derangement of function seen in disease; alteration in function as 
distinguished from structural defects (Farlex Partner Medical Dictionary, 2012). 
Perfusion: The act of pouring through or over; especially the passage of a fluid through 
the vessels of a specific organ (Miller-Keane Encyclopedia, 2003). 
Permeability: A condition of the capillary wall structure that allows blood elements and 
waste products to pass through the capillary wall to tissue spaces (Mosby's Medical 
Dictionary, 2009).  
Polymerase chain reaction (PCR): A rapid technique for in vitro amplification of specific 
DNA or RNA sequences, allowing small quantities of short sequences to be analyzed 
without cloning (Miller-Keane Encyclopedia, 2003). 
Readmission or rehospitalization: Defined as an admission to a hospital within 30 days of 
a discharge (CMS, 2014).  The return of a patient to inpatient hospital care shortly after 




Sepsis: Referred to as bloodstream infection or blood poisoning, infections are the cause 
of sepsis and can originate anywhere from within the body.  It is the presence of various 
pathogenic organisms, or their toxins, in the blood or tissues (Farlex Partner Medical 
Dictionary, 2012).  Some of the more common sites include liver or gallbladder, kidneys, 
lungs, bowel, and skin (Medline Plus, 2006). 
Severe Sepsis: It is the presence of defined sepsis in addition to organ damage, 
hypoperfusion, organ dysfunction, or hypotension.  A condition defined clinically as 
'Sepsis associated with organ dysfunction, hypotension, or hypoperfusion abnormalities 
such as lactic acidosis, oliguria, or an acute alteration in mental status; it is part of a 
continuum of a biologic inflammatory response to infection that evolves toward septic 
shock (McGraw-Hill Concise Dictionary of Modern Medicine, 2002). 
Septic shock: A possible consequence of bacteremia; bacterial toxins, and the immune 
system response to them, cause a dramatic drop in blood pressure, preventing the delivery 
of blood to the organs, despite resuscitative attempts.  Septic shock can lead to multiple-
organ failure including respiratory failure, and may cause rapid death (Gale Encyclopedia 
of Medicine, 2008). 
Tachycardia: An abnormally rapid heart rate, especially one above 100 beats per minute 
in an adult (American Heritage Dictionary, 2011). 
Vasodilation: Widening of the lumen of blood vessels (Farlex Partner Medical Dictionary 
2012).  
Vasopressor: A drug producing vasoconstriction and a rise in systemic arterial blood 




Supporting Framework  
Model for improvement 
A model for improvement was utilized as the framework and  guide for this 
quality improvement project.  The model is based on W. Edwards Deming’s Plan-Do-
Study-Act (PDSA), which has been widely used in healthcare improvement programs 
(Langley et al., 2009).  PDSA cycles provide a structure for iterative testing of changes to 
improve the quality of systems.  This method tests a change before its implementation by 
planning it, trying it, observing the results and acting on what is learned with the overall 
objective of improving the process or outcome (Van Tiel et al., 2006).  The PDSA cycle 
presents a pragmatic scientific method for testing changes in complex systems (Moen & 
Norman, 2006) and in a small scale.  These pragmatic principles of PDSA cycles endorse 
measurements over time to assess the impact of interventions, promote prediction of the 
outcome, and allow the use of small-scale, iterative approaches to test interventions, 
which enables rapid assessment and provides flexibility to adapt the change (Taylor et al., 
2014).  
The four stages - plan, do, study, and act - mirror the scientific experimental 
method of formulating a hypothesis, collecting data to test this hypothesis, analyzing and 
interpreting the results and making inferences to iterate the hypothesis (Speroff & 
O'Connor, 2004).  There are two similar approaches to process improvement: a Plan-Do-
Study-Act (PDSA) (Langley et al., 2009) and Plan-Do-Check-Act (PDCA) (Bushell, 
1992).  The PDSA cycle was originally developed by Walter A. Shewhart as the PDCA 
cycle.  W. Edwards Deming modified Shewhart's cycle to PDSA, replacing "Check" with 




method (Taylor et al., 2014).  For the purpose of this project, both PDSA and PDCA are 
considered but I refer to the methodologies generally as ‘PDSA’ cycles unless otherwise 
stated.  Both methods are broadly accepted in healthcare process improvement activities 
(Taylor et al., 2014). 
The process’ cycles provide a structure for repetitive testing of changes to 
improve the quality of systems, and require that plans be tested on a small scale before 
implementing them system-wide.  The method also builds continuous improvement into 
planning through data collection on the effectiveness of the new process or change 
(Bushell, 1992).  The PDSA method to improve quality in healthcare is a change model 
that aims to generate advance in processes and outcomes. 
The PDSA model includes two components, which comprise three improvement 
questions, and the PDSA cycle (Langley et al., 2009).  Figure I.2 provides a visual 
representation of the model for improvement.  The objectives of the improvement 
questions are to establish groundwork to guide improvement efforts, subsequently to set 
measurable goals, quantify measures to demonstrate improvement, and choose variables 
(Institute for Healthcare Improvement, 2014).  The three improvement questions are:  
1. What are we trying to accomplish? 
a. Set aims: identify sepsis protocols’ features (individually selected 
components) that made a difference in the specific population. 
b. Summarize outcomes and compare findings for both pre-
implementation and post-implementation groups.  
c. By using data, substantiate the need for improvement and recommend 




d. Establish and corroborate support system for this evidence-based 
project. 
2. How will we know that a change is an improvement?  
a. Based on scientific literature establish benchmarks for review, collect 
data and measure outcomes.  Changes should reflect in the measures. 
3. What changes can we make that will result in improvement?   
a. Form a dedicated team, stakeholders buy-in and involve people in the 
decision-making process (Langley et al., 2009). 
The second part of the model in the PDSA cycle, also called the Deming Cycle, is 
a four-step approach to solving problems, described as the trial-and-learn process 
allowing identification of the most effective solution before implementation.  The method 
follows a prescribed four-stage cyclic learning approach to adapt changes aimed at 
improvement.  In the ‘plan’ stage a change aimed at improvement is identified, the ‘do’ 
stage sees this change tested, the ‘study’ stage examines the success of the change and the 
‘act’ stage identifies adaptations and next steps to inform a new cycle (Taylor et al., 2014, 
para. 7).   
Step one: Plan 
The process starts by identifying the problems (i.e., delayed recognition and 
treatment of sepsis) and pinpointing the root cause(s), and this was accomplished by 
asking a cascade of why questions.  
1. Define objectives and identify problems such as delayed recognition and 




time for culture results, consequently inappropriate antibiotic utilization that 
promotes breeding of MDR organisms. 
2. Ask the PICO question and plan to answer the question.  
3. Plan data collection to answer the question. 
4. Recognize barriers, enabling factors, and potentially modifiable factors for 
sepsis management in hospitalized adults, while attempting to pinpoint the 
root cause.  
5. Develop a pragmatic strategy to overcome barriers.  Determine which issues 
are most significant and modifiable, which can be influenced by interventions, 
and which factors to manipulate in order to create changes.  
Step two: Do 
Potential solutions were assessed and the most practical solution determined.  
Many options must be taken into consideration such as stakeholders buy-in and the 
budget.  In my practice setting, new sepsis protocols have been implemented, while 
additional solutions are under consideration.  
1. Start to conduct study protocol by collecting baseline data and illustrating 
demographic characteristics. 
2. Collect data for follow-up measures and data analysis. 
3. Analyze data. 
Step three: Study, or Check  
In this phase data were analyzed, outcomes evaluated and results summarized, 
and any problems in the implementation of the designed intervention were identified 




2. Compare patients’ outcomes before and after sepsis guidelines 
implementation, and evaluate the impact of practice change on outcomes. 
3. Evaluate compliance with each element of the new sepsis guidelines to 
compare the post-intervention group to prior performance to achieve a clearer 
picture of Sepsis Bundles impact on health outcomes. 
4. Based on obtained results evaluate the need for practice change.   
Step four: Act 
This stage is to determine the overall success or failure of the intervention and to 
identify potential modifications to improve the intervention strategy.  If necessary, new 
changes are implemented, and the cycle repeats again starting at the first step.  This step 
is implemented in the practice setting following completion of the project. 
1. Prepare and plan for the next PDSA cycle. 
It is important to remember that this plan is circular.  The benefits of PDSA are that it 
provides standardized methods to achieving continuous improvement.  If used correctly it 
is time efficient, prevents implementing ineffective solutions and promotes teamwork.  
This project reflects the evaluation of outcomes following the implementation of initial 
practice changes, and the review of evidence may result in recommendations for further 
action.  (See Appendix D, Figures D.1 and D.2 for PDCA cycle template and PDSA 
worksheet). 
The cycle can be refined and repeated for Continual Process Improvement (CPI).  
Process evaluation is used to monitor and document program implementation and can aid 




outcomes.  The evaluation model is based on CDC’s Framework for Program Evaluation 
Steps: (German et al., 2001). 
1. Engage stakeholders.  
2. Describe the program.  
3. Focus the evaluation design.  
4. Gather credible evidence.  
5. Justify conclusions.  
6. Ensure use and share lessons learned.  
Plan-Do-Study-Act Worksheet can be used as a tool for documenting the test of change.  
See Appendix D, Figure D.1 and D.2 for PDSA worksheets and a template. 
 
Figure I.2.2Model for Improvement 
(Institute for Healthcare Improvement, 2014). (Langley et al., 2009, p. 24) 
Used with permission; source: The Improvement Guide: A Practical Approach to Enhancing 
Organizational Performance, 2nd Edition, Gerald Langley, Ronald Moen, Kevin Nolan, Thomas 
Nolan, Clifford Norman, Lloyd Provost. Jossey-Bass Pub., San Francisco, 2009. 





Despite advancing technology, availability of broad-spectrum antibiotics, 
improved ability to manage infections, and modern intensive care, sepsis is still 
associated with a substantial morbidity and mortality.  Severe sepsis and septic shock 
represent challenging problems for the healthcare system.  While aggressive supportive 
care with intravenous fluids and prompt antibiotics administration are critical, early 
recognition is paramount.  Precise isolating and identification of causative pathogens will 
result in earlier de-escalation from broad-spectrum antimicrobials to targeted treatment 
with the most appropriate antibiotics.  Consequently, this can result in lowering the 
chances of breeding multi-drug resistant organisms, reducing readmission rates, and lead 
to improved outcomes and reduced costs.  Collaborative work of interprofessional teams 
and appropriate use of resources in approaches to sepsis treatment will positively affect 
healthcare outcomes (Vazquez-Grande & Kumar, 2015).  The following chapter contains 







 This chapter describes the results of a search for evidence for best practices to 
promote early identification and management of sepsis in the clinical setting.  It outlines 
the search process and analysis of the evidence that was used to guide the project and 
subsequent recommendations.  
Search Process 
A comprehensive literature review was conducted in search of evidence to 
support recommendations for the practice innovation proposed in this paper.  The process 
of literature review and analysis of evidence utilized the Cumulative Index of Nursing 
and Allied Health Literature (CINAHL), and CINAHL Plus, Cochrane Library, PubMed, 
OvidSP, EbscoHost, Agency for Healthcare Research and Quality (AHRQ), National 
Guideline Clearinghouse databases, Google Scholar, and other evidence-based resources.  
Keywords and phrases used in the search for literature were: sepsis, severe sepsis, septic 
shock, septicemia, sepsis guidelines, inpatient sepsis, sepsis bundle, bundle treatment, 
SSC, and EGDT.  Initial literature searches returned 27,773 articles; however, many of 
those were either not supportive or not pertinent to the PICO question.  Therefore, limits 
and modifiers were applied to the search process in order to narrow results to studies that 




 interventions, and relevant to this project.  Filters included human subjects, adults, 
articles published in the last ten, then last five years, clinical trials, randomized controlled 
trials, controlled clinical trials, meta-analysis, systematic review, and peer-reviewed 
journal articles.  
A CINAHL database search was conducted and it was limited to full-text journal 
articles published within last 10 years, between the year 2006 and 2016 which produced 
2932 text results.  Abstracts were reviewed, and in order to narrow the search and capture 
the most recent publications, the search was further constricted to include a new time 
frame from the year 2010 to 2016, with the same keywords and phrases used.  Inclusion 
criteria were hospitalized adults who were diagnosed with sepsis.  After duplicates were 
removed, a total of 66 potentially relevant publications were identified, of which 46 were 
excluded, and 26 articles that could potentially contribute to answering the PICO 
question were saved for further appraisal as supporting evidence.  Cochrane Library 
database search limited to trials published within last five years included the same search 
terms: sepsis outcomes, treatment, guidelines, hospitalization, returned 28 full-text 
results.  Three of those results of high scientific power were relevant to the clinical 
problem for this project.  OvidSP database search returned 53 text results (search terms 
used: malnutrition and elderly and hospital), and four were found to be relevant to the 
clinical question.  Lastly, further reapplication of the review inclusion criteria was 
performed and search narrowed to full-text articles, and a final list of a total of 32 




Review of the Literature 
Overview of the Evidence 
The following PICO question guided this extensive literature review and this 
project: In adult patients presenting with sepsis before and after October 1, 2015, does 
implementation of a new sepsis protocol reflect in improved outcomes such as reduced 
hospital LOS, decreased mortality, morbidity, readmissions, and appropriate antibiotics 
utilization, and does it result in initiating early treatments as compared to previous 
approaches?  
Several studies provided evidence-based practice strategies that focused on sepsis 
management.  Subsequently, by utilizing the criteria for evaluating studies (Melnyk & 
Fineout-Overholt, 2011), 21 publications that offered supporting evidence and were 
relevant to this project were selected.  Articles were organized by type of study, and 
quality rating.  An evidence table was developed, highlighting threats to validity and 
reliability, findings, and conclusions for each of the 21 articles selected (Appendix A, 
Table A.1).  Consequently, upon completion of the selection process, articles were 
systematized accordingly to the level of evidence rating using the Evidence Level and 
Quality Guide by Johns Hopkins Nursing Evidence-Based Practice: Model and 
Guidelines (Dearrholt, 2012) (Appendix B, Table B.1). 
The quality rating system provided an evaluation guide methodology where 
studies were assigned a numerical and alphabetical value based on their level of evidence.  
Level I was applicable for experimental studies, randomized controlled trial (RCT), and 
systematic review of RCTs with or without meta-analysis.  Level II was appropriate for 




experimental, or quasi-experimental studies only, with or without meta-analysis.  Level 
III applied to non-experimental study, a systematic review of a combination of RCTs, 
quasi-experimental and non-experimental studies, or non-experimental studies only, with 
or without meta-analysis, qualitative study or systematic review.  Level IV applied for the 
opinion of respected authorities and/or nationally recognized expert committees or 
consensus panels based on scientific evidence.  Level V was assigned to studies based on 
experiential and non-research evidence.  Articles were also rated using quality guides and 
assigned a letter A for high quality, B for good quality, C for low quality or presence of 
major flaws. 
Analysis of Evidence 
Historical development of sepsis definition and guidelines 
In 1991, a North American consensus conference introduced the idea that sepsis is 
the host's inflammatory response to infection, and SIRS was defined by four variables: 
temperature, heart rate, respiratory rate, and white blood cell count (Bone et al., 1992).  
In 2001, a second consensus conference revisited the SIRS definition, expanded the list 
of potential clinical criteria, but inadvertently made it less specific (Vincent et al., 2013). 
As of October 1, 2015, the Center for Medicare and Medicaid Services (CMS) has 
issued new benchmarks for the care of severe sepsis and septic shock (Figure II. 1) that 
all hospitals in the U.S. must meet (Baciak, 2015).  Current guidelines utilize several 
different definitions for sepsis, including sepsis, severe sepsis, and septic shock along 
with complicated strategies for systemic inflammatory response syndrome (SIRS) criteria 
(Table II.1 and Figure II.2).  Both SIRS and severe sepsis definitions raise controversies 




guidelines published in 2012 and based on 2003 International Sepsis Definition 
Conference (Dellinger et al., 2013).  SIRS and organ dysfunction definitions may be 
inconsistent in some cases.  For example, based on the current definitions virtually all 
end-stage kidney or liver disease patients experiencing mild viral upper respiratory 
infection producing fever or leukocytosis would meet the criteria of severe sepsis and 
may consequently be overtreated (Baciak, 2015). 
 
Figure II.1.3Sepsis Treatment Benchmarks  




Table II.1.2Criteria for SIRS  
 
Criterion  Value 
Temperature  >38°C or <36°C 
Heart rate  >90 beats per minute 
Respiratory rate  >20 or PaCO2<32 mm Hg 
White blood cell count  >12 K or <4 K mm−3, or >10% bands 




Figure II.2.4Severe Sepsis, Organ Dysfunction, and Septic Shock Definitions 




Systemic Inflammatory Response Syndrome  
The Systemic Inflammatory Response Syndrome (SIRS) concept creates many 
controversies by being very nonspecific but very sensitive at the same time, meaning that 
a great majority of patients admitted to an ICU every day meet the SIRS criteria (Table 
II.1).  SIRS can be caused by many non-infectious clinical processes or sterile 
inflammation such as severe trauma, burns, pancreatitis, and ischemic events.  If SIRS is 
defined in the presence of infection, almost every acutely ill patient would meet the SIRS 
criteria; therefore, all septic patients have a known or unknown source of infection, but 
not all infected patients are septic (Vincent et al., 2013).  Further, almost all infections, 
minor of major, are associated with fever - a natural body response to the presence of the 
pathogens.  Fever is usually associated with tachycardia, leukocytosis, and even 
hyperventilation; nevertheless, the absence of this response may occur in the presence of 
microbial colonization or host’s immunocompromised status, two very different clinical 
scenarios, not necessarily meaning sepsis (Vincent et al., 2013).  Moreover, several such 
stressors might be present simultaneously in any patient, making sepsis difficult to 
diagnose.  Since symptoms of sepsis can be vague especially in its early stage, all the 
more difficult, if not impossible, is zeroing in on the time of initial sepsis onset, such an 
important point of reference in current treatment guidelines and a marker for quality 
measures.  The more accurate is a different definition of sepsis, where sepsis is not 
simply the host response to an infection or inflammation, but it is the “host's deleterious, 
non-resolving inflammatory response to infection that leads to organ dysfunction” 





In 1991, sepsis was first recognized as a systemic inflammatory reaction to 
infection.  In the following decade, a spotlight was shone on sepsis treatment and a new 
approach was introduced to emergency departments (ED).  In 2001, a landmark article by 
Rivers et al. titled “Early Goal Directed Therapy (EGDT) in the Treatment of Severe 
Sepsis and Septic Shock” (2001) documented a noteworthy short-term and long-term 
mortality benefit when EGDT was implemented at the earliest stages of severe sepsis and 
septic shock.  The concept of EGDT was treating septic patients early while still in the 
ED. (Rivers et al., 2001).  Rivers et al. (2001) showed that utilizing EGDT resulted in 
marked improvement in mortality compared to standard care.  
The EGDT was the first structured approach that guided the first six hours of 
resuscitation with more IV fluids, ionotropic support, blood transfusions; it involved 
insertion of central line and central venous pressure (CVP), central venous oxygen 
saturation (ScVO2) and mean arterial pressure (MAP) measures (Yealy et al, 2015).  
Interventions were delivered according to specific hemodynamics, including CVP 
endpoint 8-12 mmHg, MAP ≥ 65 and ScVO2 > 70% (Rivers et al., 2001).  The single 
center randomized trial enrolled relatively a small sample of 130 treatment and 133 
control patients.  The study demonstrated in-hospital mortality was 30.5% in the group 
assigned to EGDT, compared to 46.5% in the standard therapy group in short-term 
treatment (p=0.009).  Mortality was 33.3% in EGDT group (p=0.01) compared to and 
49.2% in the control group in 28-day mortality rate, and 44.4% EGDT group (p=0.03) to 




2001).  Given those findings, central catheter driven approach became a mainstream 
treatment for sepsis at that time. 
In 2002, a collaborative effort among the Society of Critical Care Medicine, the 
European Society of Intensive Care Medicine, and the International Sepsis Forum 
resulted in the formation of the Surviving Sepsis Campaign (SSC) (Society of Critical 
Care Medicine, 2014).  SSC is a global initiative formed to reduce sepsis-related 
mortality and improve short and long-term outcomes.  For the past decade, SSC has been 
in the frontline leading the efforts to improve sepsis outcomes worldwide.  Based on 
literature and expert opinion, SSC developed, and published, clinical practice 
recommendations for management of severe sepsis and septic shock, which are focused 
on increasing provider awareness and promoting early intervention (Haddad, Slesinger, 
Wie, & LoVecchio, 2015).  The SSC endorsed EGDT and proposed this approach as a 
key strategy to decrease mortality among patients with severe sepsis or septic shock. 
Since 2002, the Surviving Sepsis Campaign (SSC) has been promoting best 
practice guidelines that optimize oxygen delivery and tissue perfusion, thus increase 
patients’ chances of survival.  EGDT involving a six-hour resuscitation protocol became 
at that time the best practice strategy with objectives to maintain adequate organ 
perfusion, control infection, limit barotrauma due to mechanical ventilation, and control 
hyperglycemia (Haddad et al., 2015).  
In 2010, another study demonstrated the superiority of lactic acid measurement 
that involved simple peripheral venous blood draw over invasive CVP and ScvO2 
measurements which required central line insertions (Jones, Shapiro, Trzeciak, Arnold, 




Jones et al. (2010) evaluated lactate clearance efficacy versus central venous oxygen 
saturation measurement.  The results of this randomized controlled trial indicated that 
measurement of lactate clearance; a quicker and more non-invasive measurement can be 
an equally effective alternative to ScvO2 monitoring in goal-directed resuscitation.  In 
light of this evidence, the guidelines were revised and incorporated 3- and 6-hour 
management bundles.  The updated 2012 recommendations guidelines included these 3- 
and 6- hour management bundles.  They mandated measurement of lactate level, 
obtaining blood cultures prior to administration of antibiotics, administering broad-
spectrum antibiotics, and infusing crystalloid fluids at a rate of 30 mL/kg for hypotension 
or lactate > 4mmol/L (36 mg/dL) to maintain adequate MAP within three hours from 
onset of sepsis.  If hypotension does not respond to initial fluid resuscitation, the 
guideline recommended administering within six hours vasopressors (for refractory 
hypotension) to maintain MAP ≥ 65.  In the event of persistent arterial hypotension 
despite volume resuscitation, or if initial lactate was > 4 mmol/L (36 mg/dL), it is 
recommended to monitor CVP and ScvO2 and re-measure lactate if initial lactate was 
elevated.  Targets for quantitative resuscitation included in the guidelines are CVP of > 8 
mm Hg, ScvO2 of > 70%, and normalization of lactate (Haddad et al., 2015).  
Dellinger, Levy, and Townsend (2010) showed an association between 
compliance with the SSC Sepsis Bundles and decrease in sepsis mortality.  In 2012, the 
first national practice guidelines were endorsed by National Quality Forum (NQF) for the 
management of severe sepsis and septic shock (Dellinger, 2015).  These NQF 2012 
guidelines named Sepsis 0500 included the seven components to be completed within 




Under those guidelines, septic patients were undergoing invasive procedures such 
as central venous catheters (CVC) insertion that unnecessarily delayed lifesaving 
treatments.  In 2014, the guidelines were revised in view of more new evidence based on 
multicenter randomized trials the ProCESS and the ARISE studies.  Both trials 
demonstrated the lack of necessity for using invasive CVC insertion procedure for 
monitoring CVP and ScvO2 as resuscitation measures.  Given these results, NQF 
guidelines were revised taking into account the above findings (SSC, 2014).  
The paramount underpinning of these protocols has been an aggressive and early 
treatment.  SSC partnered with Institute for Healthcare Improvement (IHI) to incorporate 
the concept of sets of sepsis management strategies into the diagnosis and treatment of 
sepsis (SSC, 2014).  The new guidelines included the same recommendation for 
maximum allowed time frames for drawing blood cultures and lactic acid levels, 
administering empiric antibiotics and providing IV fluids to patients with suspected 
sepsis, but did not mandate CVP and ScvO2 measurements if other conditions are met.  
For instance, patients presenting to ED with symptoms suspicious for sepsis, should have 
blood drawn for serum lactate level and blood cultures, prior to administration of 
antibiotics and broad spectrum IV antibiotics administered within three hours of triage 
(time zero).  However, delaying antibiotic administration in order to obtain blood cultures 
was not recommended.  If lactate level is 4mmol/L or higher or patients are hypotensive, 
IV fluids are infused at a rate of 30 mL/kg.  Subsequently, if patients do not respond to 
initial fluid resuscitation, vasopressors are administered to maintain MAP at or above 
65mmHg.  If no adequate response is achieved, fluid volume is re-assessed by a focused 




ScvO2, bedside cardiovascular ultrasound or dynamic assessment of fluid responsiveness 
with passive leg raise or fluid challenge (Table II.2 and Table II.3) (SSC, 2014). 
The guidelines were recognized and incorporated as new protocols for standards 
of care, and have been serving as benchmarks for quality measurements (Haddad et al., 
2015).  Since October 1, 2015, Center for Medicare and Medicaid Services (CMS) 
mandated measurement of sepsis outcomes (SEP-1).  This performance measure named 
Early Management Bundle; Severe Sepsis/Septic Shock has been endorsed by NQF.  
Consistent with Surviving Sepsis Campaign guidelines, it assesses measurements of 
lactate, obtaining blood cultures, administering broad spectrum antibiotics, fluid 
resuscitation, vasopressor administration, reassessment of volume status and tissue 
perfusion, and repeat lactate measurement within three and six hours of presentation 
(Joint Commission, 2014). 
Current Practice 
The SSC has been the leader in putting forth sepsis management guidelines and 
best practice recommendations based on recent literature and expert opinion for decades.  
In October 2012 NQF endorsed the management bundles and came forth the first national 
sepsis guidelines in the United States (NQF 0500) that also currently serve as a 
benchmark for healthcare quality measures for healthcare providers and federal 
government (D’Amore et al., 2015).  In light of new evidence published in the ProCESS 
and the ARISE trials; the NQF Patient Safety Standing Committee reviewed the 0500 
measure in April 2014, and removed mandatory CVP and ScvO2 monitoring (SSC, 
2014).  The protocol continues to be considered the appropriate approach to sepsis at this 




Table II.2.3SSC 3- and 6- hour Bundles 
.  
To be completed within 3 hours of 
time of presentation*:  
To be completed within 6 hours of time of 
presentation 
1. Measure lactate level  5.  Apply vasopressors (for hypotension that does 
not respond to initial fluid resuscitation) to maintain 
a mean arterial pressure (map) ≥65mmhg  
 
2. Obtain blood cultures prior to 
administration of antibiotics  
6.  In the event of persistent hypotension after initial 
fluid administration (map < 65 mm hg) or if initial 
lactate was ≥4 mmol/l, re-assess volume status and 
tissue perfusion and document findings according to 
Table II.3.  
 
3. Administer broad-spectrum 
antibiotics  
7.  Re-measure lactate if initial lactate elevated.  
 
4. Administer 30ml/kg 
crystalloid for hypotension or 
lactate ≥4mmol/L  
 
* “Time of presentation” is defined as the time of triage in the emergency department or, if 
presenting from another care venue, from the earliest chart annotation consistent with all elements 
of severe sepsis or septic shock ascertained through chart review (SSC, 2014, para. 3). 
 
Table II.3.4Sepsis Reassessment.  
 
Document reassessment of volume status and tissue perfusion with the following:  
Either  Or two of the following: 
 Repeat focused exam (after initial 
fluid resuscitation) by licensed 
independent practitioner including  
 Measure CVP 
 Vital signs  Measure ScvO2 
 Cardiopulmonary, capillary refill  Bedside cardiovascular ultrasound 
 Pulse  Dynamic assessment of fluid 
responsiveness with passive leg raise 
or fluid challenge 
 And skin findings  
(SSC, 2014, para. 4) 
Updated definition of sepsis. 
The terms of sepsis, severe sepsis, and septic shock have been used sometimes 
interchangeably or inappropriately, and the actual definition of sepsis has not been 




technology since 2001.  The sepsis definition was recently updated for the first time in 15 
years by an international task force that included 19 experts in sepsis pathology, 
epidemiology, and clinical trials.  Definitions and clinical criteria were generated through 
meetings, Delphi processes, analysis of electronic health record databases, and voting, 
followed by circulation to international professional societies, requesting peer review and 
endorsement.  In 2016, the Society of Critical Care Medicine and the European Society of 
Intensive Care Medicine released the Third International Consensus Definitions for 
Sepsis and Septic Shock (Sepsis-3) re-defining sepsis (Singer et al., 2016).  New criteria 
were added for septic shock, and the standards for rapid sepsis shock recognition were 
simplified.  The concept of SIRS with its low specificity and high sensitivity lead to 
misinterpretations and discrepancies in reported incidence and observed mortality, 
therefore, it was eliminated (Singer et al., 2016).  
According to Singer et al. (2016), too much emphasis has been placed on 
inflammation, which is misleading, giving the impression that the sepsis process moves 
in a sequence from sepsis through severe sepsis to septic shock.  Singer et al. (2016) 
defined sepsis as a “life-threatening organ dysfunction caused by a deregulated host 
response to infection” (para. 4).  The new definition offers better consistency for 
epidemiologic studies and clinical trials.  It allows for more reliable uniform data 
collection methods for incidence and mortality reporting, and would facilitate earlier 
recognition of sepsis, thus better timely management of this serious condition (Singer et 
al., 2016).  
Instead of diagnostic criteria known as SIRS, the new definition relies on known 




score ≥ 2, or a modified quick SOFA.  However, adoption of the new approach in many 
hospitals will likely be hindered by CMS that still uses the SIRS-plus suspected infection 
approach for description of sepsis as a benchmark for quality measures, for determining 
payment and compliance with performance metrics such as the SEP-1 measure. 
Shortly after the publication of the new sepsis definition, Simpson (2016) 
expressed concern that the new definition may de-emphasize interventions at earlier 
stages of sepsis when the syndrome is actually at its most treatable phase.  Moreover, 
over-simplifying the definition of sepsis, especially in light of still not precisely 
understood pathophysiological features that define sepsis may inadvertently cause more 
confusion (Simpson, 2016).  
While the key is to simplify, not to further complicate, initial patient assessments 
in order to expedite appropriate treatment initiation, ultimately all patients with sepsis 
must receive optimal aggressive treatment.  Regardless of definition, it is critical to 
continue to strive to recognize sepsis early and initiate aggressive treatments for all forms 
of sepsis.  
Controversies of Sepsis Guidelines 
Early Goal Directed Therapy: EGDT 
In 2001, Rivers et al. published a single-center, randomized trial of protocolized 
resuscitation for patients presenting to the emergency department (ED) with a septic 
shock.  The protocol included specific, 6-hour resuscitation algorithm, namely the EGDT.  
Prior to the introduction of EGDT, goal-directed therapy (GDT) was utilized for severe 
sepsis and septic shock in ICUs.  Rivers et al. (2001) utilized a small sample of 236 




concerns for generalizability of the results.  EGDT targeted primarily arterial and central 
venous pressure and a ScvO2.  SSC guidelines have endorsed EGDT since 2004, and a 
number of following non-randomized, predominantly before–after studies subsequently 
reported the benefit of EGDT on outcomes (Angus et al., 2015).  However, based on new 
evidence, the overall effectiveness of EGDT is uncertain.  Recent studies have shown 
conflicting results, including questionable benefits of some components of EGDT on 
survival rate and length of hospital stay (LOS) (Zhang, Zhu, Han, & Fu, 2015). 
Recently, the efficiency of EGDT has been called into question.  Three 
multicenter prospective randomized trials investigated the efficiency of EGDT: ProCESS 
(Protocolized Care for Early Septic Shock), ARISE (Australasian Resuscitation in Sepsis 
Evaluation) and ProMISe. (Delaney et al., 2013; Mouncey et al., 2015; Yealy et al., 
2014).  Results of these three multicenter prospective randomized trials demonstrated no 
significant decrease in sepsis morbidity or mortality when patients were treated with a 
strict protocol-based resuscitation strategy over usual care at the discretion of the treating 
physician.  
The ProCESS trial evaluated whether all aspects of the original EGDT protocol 
(Rivers, 2001) were necessary.  Thirty-one academic EDs across the United States 
participated in this study.  A total of 1,341 patients meeting criteria for severe sepsis and 
septic shock were included in data analysis; 439 patients received EGDT according to the 
original protocol, 456 control patients received standard care, and 446 patients received 
protocol-based standard therapy.  Despite more aggressive therapy in the protocol-based 
groups, there was no significant difference in 60- and 90-day mortality between the 




cardiovascular or respiratory failure, LOS, in sepsis morbidity or mortality when patients 
were treated with a strict protocol-based resuscitation strategy over usual care at the 
discretion of the treating provider.  This study outlined a protocol for administration of 
fluid and vasoactive agents to reach goals for systolic blood pressure, shock index, and 
fluid status, without mandating invasive venous access, aggressive blood transfusion, and 
inotropic support.  A combination of EGDT and protocol based therapy offers no survival 
benefits as compared to not-protocol-based usual care.  Generalization across various 
healthcare settings and outside of the United States is uncertain, and more evidence is 
needed (Yealy et al., 2014). 
The ARISE multicenter prospective, randomized trial was designed to test the 
EGDT hypothesis as compared to usual care (Delaney et al., 2013).  This trial was 
conducted from 2008-2014 at 51 tertiary care and non-tertiary care metropolitan and rural 
hospitals across Australia and New Zealand, with 796 patients receiving care based on 
the original EGDT resuscitation algorithm, and 804 control patients receiving usual care 
at the discretion of the treating physician.  The study results demonstrated that patients in 
the EGDT group were more likely to receive vasopressor infusion, red-cell transfusion, 
and dobutamine infusion.  However, despite an increased rate of aggressive therapy, there 
was no significant difference in 28- and 90- day mortality, hospital mortality, organ 
support and LOS between the two treatment groups.  Adherence to the EGDT algorithm 
offered no survival advantage over usual care for patients presenting to the emergency 
department with early septic shock (Delaney et al., 2013).  This trial could not be blinded, 
but the risk of bias was minimized through central randomization.  In this study, EGDT 




emergency department with early septic shock.  Therefore, the value of incorporating 
EGDT into international guidelines as a standard of care is questionable (Peake et al., 
2014). 
The ProMISe trial, a multicenter, pragmatic, open, parallel group randomized 
controlled trial with integrated economic evaluation was conducted in 56 hospitals in 
England from 2011- 2014 (Mouncey et al., 2015).  The study included 1260 patients, 630 
in the EGDT group and 630 receiving usual care.  Interventions could not be blinded, but 
the risk of bias was minimized through central randomization.  There were no significant 
differences between the EGDT and usual care groups in mortality (29.5% and 29.2% 
respectively) or other outcomes including serious adverse events and health-related 
quality of life.  Moreover, on average, EGDT was associated with increased costs.  
Adherence to a strict EGDT strict protocol and the addition of SCVO2 monitoring did not 
lead to improvement in outcomes.  Since the death rate was lower than anticipated in this 
study, the outcomes may not apply to settings with higher mortality rates.  Of note, 
decreasing mortality is a trend in recent years, and many aspects of sepsis care have 
evolved since the Rivers et al. (2001) study 15 years ago (Mouncey et al., 2015).  This 
trial of early goal-directed resuscitation for septic shock raised concern for the 
effectiveness of this treatment; specifically, in patients with septic shock who were 
identified early and received intravenous antibiotics and adequate fluid resuscitation 
(Mouncey et al., 2015).  These patients received strict EGDT protocol management and 
despite that, improve outcomes were not demonstrated (Mouncey et al., 2015).  The 
aforesaid studies did not demonstrate the superiority of required use of a CVC to monitor 




and fluid resuscitation, compared with controls or in all patients with lactate >4 mmol/L 
(Mouncey et al., 2015). 
SSC guidelines promote EGDT as means for reduction of mortality; however, 
conflicting results can be found in several recently published meta-analyses regarding 
benefits of EGDT in patients with severe sepsis and septic shock.  A recent meta-analysis 
by Chelkeba, Ahmadi, Abdollahi, Najafi, & Mojtahedzadeh (2015) comprising RCTs 
performed in different geographical regions of the world and including aforementioned 
trials, showed that while EGDT does not significantly impact outcomes, it reduces 
mortality especially in low to middle-income countries (Chelkeba et al., 2015).  However, 
the study also showed that EGDT paradoxically increases the hospital length of stay 
(LOS) (Chelkeba et al., 2015). 
Angus et al. (2015) conducted a meta-analysis of RCTs published from January 
2000 to January 2015 (N=4735 patients) to determine whether EGDT compared with 
usual care reduces mortality for ED patients with septic shock.  The study showed that 
EGDT is not superior to usual care for ED patients with septic shock, as it has no effect 
on primary (EGDT: 23.2% versus control: 22.4%), or 90-day mortality rates, but 
increases ICU resources utilization (Angus et al., 2015). 
Zhang, Zhu, Han, and Fu, (2015) conducted a systematic review and meta-
analysis of 10 RCTs on EGDT from 2001 to 2014 involving 4,157 patients and found no 
significant difference in mortality between the EGDT and the control group.  In this study 
EGDT was found to be associated with a higher mortality rate in comparison with the 
early lactate clearance group (RR 1.52, 95% CI: 1.06 to 2.18, P = 0.02).  In the first six 




(P = 0.04), fluid administration (P = 0.05), and red cell transfusion (P < 0.01).  There 
were no significant differences in length of ICU stay (P = 0.73) or in-hospital stay 
(P = 0.57), ventilation rate (P = 0.53), and vasopressor support (P = 0.63).  Zhang et al. 
(2015) point out that contrary to most recent meta-analyses, earlier studies showed that 
EGDT was associated with a survival benefit; however, previous studies were either 
retrospective or before-after studies, or meta-analyses with imperfect methodologies or 
designs.  For example, one meta-analysis included 13 RCTs, but only 7 studies were in 
the EGDT subgroup; also, some included protocols that differed from the one 
recommended by the SSC guidelines, included non-sepsis patients, or did not include the 
latest ARISE study (Zhang et al., 2015). 
Gu, Wang, Bakker, Tang, and Liu, (2014) included 13 trials involving 2,525 adult 
patients in their meta-analysis.  The results suggested that EGDT significantly reduces 
overall mortality in patients with sepsis, especially when initiated early (P = 0.01); 
however, strong and definitive recommendations could not be made given the variable 
quality of the studies.  Another meta-analysis of RCTs by Yu, Chi, Wang, & Liu (2016) 
the included five studies (N = 4,303) that utilized the EGDT protocol recommended by 
SSC Guidelines.  Overall, there were slight decreases in mortality within 28 days, 60 
days and 90 days in the random-effect model in patients with severe sepsis or septic 
shock receiving EGDT resuscitation; however, none of the differences reached statistical 
significance (Yu et al., 2016).  The authors pointed out that the included trials were not 
sufficiently homogeneous and suggested that potential confounding factors in the 
negative trials (ProCESS, ARISE, and ProMISe) might bias the results and diminish the 




eliminate or reduce potential sources of bias to determine if EGDT has a mortality benefit 
(Yu et al., 2016).  Similar results and conclusions were reported in another recent meta-
analysis (Xu, Yang, & Qiu, 2016) that included nine studies involving 5,202 patients with 
severe sepsis and septic shock.   
A multivariable model was used to assess outcome differences between the serial 
lactate and no serial lactate cohorts to assess clinical outcomes.  Lack of serial lactate 
monitoring was independently associated with mortality.  Serial lactate monitoring is 
associated with an increase in crystalloid administration, resuscitation interventions, and 
improved clinical outcomes in ED patients with severe sepsis and septic shock (Dettmer, 
Holthaus, & Fuller, 2015). 
EGDT has been endorsed in the guidelines of the SSC as a key strategy to 
decrease mortality among patients with septic shock.  However, Peake et al., (2014) 
suggest that the value of incorporating EGDT into sepsis guidelines as a standard of care 
is questionable.  
IV Fluids.  As of today, aggressive fluid resuscitation is a hallmark of sepsis 
treatment and the standard of care in the management of patients with severe sepsis and 
septic shock (Waechter et al., 2014).  Bundled with timely antimicrobial treatment, 
lactate measurement and blood cultures, the SSC recommends aggressive IV fluid 
resuscitation; specifically, intensive fluid resuscitation to achieve a CVP greater than 8 
mm Hg.  Waetchter et al. (2014) retrospectively analyzed data from 24 ICUs in three 
countries to determine how hospital mortality was influenced by combined use of fluids 
and vasoactive agents.  Results showed that these two treatments had strong, interacting 




resuscitation for septic shock should be aggressive fluid administration, only thereafter 
starting vasoactive agents, while continuing aggressive fluid administration.  These 
recommendations are based on expert opinion without adequate experimental or 
controlled human evidence (Hilton & Bellomo, 2012).  Conversely, recent clinical trials 
have demonstrated that this approach does not improve outcomes for patients with sepsis 
(Marik & Bellomo, 2015).  
Patients are often intravenously infused very large amounts of fluids (5-10 L) 
early in the process of sepsis treatment (Marik, 2014).  Hilton & Bellomo (2012) 
observed that there is no evidence of research on humans that fluid resuscitation with 
such massive amounts of fluids (recommended at least 30 mL/kg: Grade 1C) can reliably 
improve blood pressure or end-organ perfusion.  More recent publications suggest that 
this particular measure may instead be harmful, causing iatrogenic injury, that the “less is 
more” paradigm is perhaps more applicable in many sepsis cases, and recommend 
limiting IV fluids to 20-30 mL/kg in small 500mL boluses (Marik, 2014, p. 1409).  While 
the multicenter clinical trials described previously, as well as subsequent meta-analyses 
of EGDT, demonstrated a lack of improvement in outcomes using aggressive fluid 
resuscitation, this approach is mandated by current SSC guidelines.  
Marik and Bellomo (2015) argued that sepsis is primarily not a volume-depleted 
state; rather, sepsis is associated with arterio- and venodilation together with 
microcirculatory and myocardial dysfunction.  Recent evidence demonstrates that most 
patients are poorly responsive to fluids, based on the pathophysiology of sepsis, with the 
loss of arterial tone, venodilation, reduced compliance, and reduced preload 




sequestered in the tissues, resulting in severe edema and increasing the risk of organ 
dysfunction.  Therefore, a physiologic, hemodynamically guided conservative approach 
to fluid therapy, coupled with assessment of fluid responsiveness in patients with sepsis, 
is likely to reduce morbidity and improve outcomes (Marik & Bellomo, 2015).  Initiation 
of a vasopressor agent (norepinephrine) in patients who remain hypotensive (MAP <65 
mm Hg) after receiving an initial bolus 20 to 30 mL/kg of crystalloid solution may be 
more appropriate.  Furthermore, using additional boluses as needed and utilizing the 
passive leg-raising maneuver combined with minimally invasive cardiac output 
monitoring to assess volume responsiveness represents a proper, collective approach 
(Marik, 2014).  
Antibiotics.  Early studies on sepsis care suggested that with the implementation of a 
structured resuscitation focusing largely on IV fluid resuscitation, timely broad-spectrum 
antibiotics and vasopressor therapy improved outcomes (Rivers et al., 2001).  In 2006, 
following a retrospective medical records review of 2,154 adult patients with septic 
shock, Kumar et al. (2006) demonstrated that an effective antimicrobial administration 
within the first hour of documented hypotension was associated with increased survival.  
The relationship between hospital survival and duration of time between onset of 
recurrent or persistent hypotension and effective antimicrobial administration held 
whether the infection was:  
 Clinically suspected or documented,  
 Culture positive or negative,  
 Bacteremic or nonbacteremic,  




 Gram-positive, gram-negative, or fungal, or  
 Involving the respiratory, urinary, gastrointestinal/peritoneal and skin or soft 
tissue sites  
(Kumar et al., 2006).  
The effect also held for additional subgroups including those with neutropenia. 
Initiation of effective antimicrobial therapy within the first hour following the onset of 
septic shock-related hypotension was associated with 79% survival to hospital discharge 
(Kumar et al., 2006).  For every additional hour of delay to effective antimicrobial 
initiation in the first six hours after hypotension onset, survival dropped an average of 
7.6% (Kumar et al., 2006).  With effective antimicrobial initiation between the first and 
second hour after hypotension onset, survival had already jumped to 70.5%.  With the 
appropriate antimicrobial therapy delay to 5–6 hours after hypotension onset, the survival 
rate was just 42.0%, and by 9–12 hours, it was 25.4% (Kumar et al., 2006).  Presented 
data strongly support current international guidelines and suggest that empirical, broad-
spectrum antimicrobial administration should be considered an intrinsic component of 
initial resuscitation of septic shock.  
Ferrer et al (2014) and Gaieski et al. (2010) have suggested the dominance of 
well-timed antibiotics administration for improved mortality in severe sepsis and septic 
shock; specifically, that delay in first antibiotic administration was associated with 
increased in-hospital mortality.  These authors implied that timely administration of 
appropriate antimicrobials is the primary determinant of mortality in patients with severe 




Subsequent studies have failed to demonstrate such substantial results (Puskarich 
et al. 2011; Sterling, Miller, Pryor, Puskarich, & Jones, 2015).  Authors documented the 
association between timing of initial antibiotic treatment and mortality of patients 
undergoing sepsis protocol in emergency departments and found no association between 
time from triage to initial antibiotic administration and hospital mortality. 
Other studies have not demonstrated any increase in mortality with a delay of 
antibiotic administration based on triage time.  Contrary to Kumar et al. (2006), Sterling 
et al. (2015) found no significant mortality benefit of administering antibiotics within 
three hours of emergency department triage or within one hour of shock recognition in 
severe sepsis and septic shock.  
Despite many limitations, SSC guideline specific recommendations are to 
administer IV antibiotics within the first hour of recognition of septic shock (grade 1B) 
and severe sepsis without septic shock (grade 1C), and to initiate a “Sepsis Bundle”.  The 
bundle, in addition to other requirements also entails administration of broad-spectrum 
antibiotics within three hours from ED triage (Dellinger et al., 2013).  Whether the 
antibiotics were administered within specified time frame is now one of the benchmarks 
for the quality of care measure by Medicare.  Interestingly, sepsis symptoms are often 
quite subtle, especially in the early stage, and in many cases, it is impossible to denote the 
exact time of initial sepsis onset.  This may lead to inappropriate prescribing of 
antibiotics in order to comply with the measure. 
Mostly based on limited evidence and one aforementioned retrospective study by 
Kumar et al. (2006), the SSC international consensus guidelines recommends 




sepsis and septic shock (Dellinger et al., 2008, Levy et al., 2008).  However, Kumar’s 
inclusion of all ICU patients diagnosed with septic shock may have contributed to the 
mortality rate (56%) reported in this study, which is inconsistent with the overall 
mortality rate of 19% found in studies that included only ED cohort patients receiving 
early aggressive resuscitation (Puskarich et al, 2011).  
Appropriate antibiotic therapy in patients with severe sepsis and septic shock 
should mean prompt achievement of antimicrobial’s therapeutic concentration in blood, 
tissue penetration and maintenance of optimal exposure at the infection site with broad-
spectrum antibiotics administered in a timely manner – as per the guideline protocol.  
Once the causative pathogens have been identified and tested for in vitro susceptibility, 
subsequent de-escalation of antimicrobial therapy should be applied whenever feasible 
(Pea, & Viale, 2009).  The goal of appropriate antibiotic therapy must be pursued 
decisively and with continuity, in view of the ongoing problem of antibiotic-resistant 
infections and of the continued decrease in new antibiotics emerging (Pea, & Viale, 
2009). 
Despite an emphasis on the appropriateness of antibiotic administration,  
measuring effects of antibiotics’ appropriateness and effectiveness against pathogens is 
only possible with known culture and sensitivity data, not usually available for 24 to 96 
hours; therefore, performing this measurement in the ED is nearly impossible (Puskarich 
et al., 2011).  Consequently, Puskarich et al. (2011) argued that it is inappropriate to 





Sterling et al. (2015) reported no significant mortality benefit of administering 
antibiotics within three hours of emergency department triage or within 1 hour of shock 
recognition in severe sepsis and septic shock.  These results suggest that currently 
recommended timing metrics as measures of quality of care are not supported by the 
available evidence (Sterling et al., 2015).  
Current SSC SEP recommendations include a list of potent broad-spectrum 
antibiotics that are approved for monotherapy for sepsis.  According to the measure 
specifications, if within three hours of presentation a broad-spectrum antibiotic approved 
for monotherapy is not administered to a patient with severe sepsis, then a medical 
practitioner must consult the “Combination Antibiotic Therapy Table” to administer 
another approved antibiotic drug combination to satisfactorily meet the required measure 
(Calderwood, Coopersmith, & Gerardi, 2015).  This does not promote best practice and 
has raised serious concerns among medical communities due to the potential unintended 
consequences that may result (Calderwood et al., 2015) 
While many septic patients require broad-spectrum antibiotics, in some cases a 
more narrow-spectrum antibiotics that deliver a targeted therapy could be more 
appropriate if the pathogen is highly suspected or known.  However, the current measures 
do not allow for administration of antibiotics that are not on the list, and there is a risk 
that medical practitioners will be inappropriately prescribing antibiotics in order to avoid 
payment penalties and comply with the Medicare sepsis measure (SEP-1). 
Inappropriate antibiotic prescribing behaviors have led to the marked increase of 
antibiotic resistant bacteria and have negatively impacted LOS and patient mortality with 




CMS considered these concerns and showed some flexibility in attempting to incorporate 
utilization of narrower spectrum agents for documented known sources of infection, such 
as C. diff colitis and type II necrotizing fasciitis. 
Antibiotic Stewardship 
The choice of antibiotics is determined by many factors, such as the suspected or 
known source of infection, the patient’s immunologic status, whether the infection is 
nosocomial or community acquired, and knowledge of the local microbiology and 
sensitivity patterns (Marik, 2014).  Most of the time causative organisms are not known 
at the time of presentation, and a broad-spectrum, empirical therapy is most appropriate, 
and has been shown to reduce mortality when compared with the inappropriate therapy 
(Marik, 2014).  Once a pathogen is isolated, antibiotics should be de-escalated to more 
narrow-spectrum acting agents. There are instances that continuation of dual 
antimicrobial therapy is recommended, such as enterococcal infections, severe 
intraabdominal infections, severe pneumonia, pneumococcal bacteremia, neutropenia, 
and others.  Empiric broad-spectrum antimicrobial treatment is aimed at achieving an 
optimal therapeutic response, thus reducing mortality; however, this can expose patients 
to overuse of antimicrobials and promote sprouting of multi-drug resistant pathogens. 
Unfortunately, severe sepsis and septic shock are increasingly more and more 
frequently caused by antibiotic-resistant pathogens, including Gram-negative non-
fermenters, Methicillin Resistant Staphylococcus (MRSA), Vancomycin Resistant 
Enterococcus (VRE), and Candida species (Zhang, Micek & Kollef, 2015).  This 
development calls for the use of progressively more powerful empiric, broad-spectrum 




resistant organisms, and cause severe complications such as C-difficile colitis.  Aside 
from causing delays in the delivery of appropriate antibiotic therapy (AAT), this problem 
may eventually pose the risk of running into unavailability of appropriate, sufficiently 
powerful antimicrobials (Zhang, Micek & Kollef, 2015). 
The rising threat of antimicrobial resistance calls for rapid interventions with 
appropriate antimicrobial choices in sepsis treatment.  Therefore, robust antimicrobial 
stewardship programs in hospitals and healthcare facilities are beneficial in attempts to 
combat antibiotic resistance, reinfections, and superinfections.  Clinicians in 
collaboration with pharmacists and infection control departments should implement local 
strategies aimed at timely delivery of appropriate antibiotic therapy to improve outcomes 
and reduce the length of stay (Zhang Micek & Kollef, 2015). The hospital antibiotic 
stewardship program is a multidisciplinary approach and a key component to preventing 
increasing antimicrobial resistance (Fishman, 2006).  De-escalation has been proposed as 
a strategy to replace empirical broad-spectrum antimicrobial treatment by using a 
narrower antimicrobial therapy; however, more research is needed to establish direct 
evidence regarding safety and efficacy of early de-escalation of antimicrobial agents for 
adults with sepsis, severe sepsis or septic shock (Silva, Andriolo, Atallah, & Salomão, 
2013). 
Timely application of AAT while avoiding the unnecessary use of antibiotics, 
especially broad-spectrum agents when not warranted is necessary in the treatment of 
infections; however, in order to successfully de-escalate antibiotics to narrower spectrum, 




Lack of ability to identify microbes is an important barrier to the effective treatment of 
infections.  Advances in new antibiotic development along with progressing technology 
and evolving new rapid diagnostic techniques such as molecular diagnostics offer hope 
for better outcomes.  The transition from traditional, culture-based diagnosing methods to 
molecular diagnostics will yield faster results and consequently better patients’ outcomes.  
The advantage to such transition likely outweighs any risks; nevertheless, implementing 
such change has been meeting much resistance (Mancini et al., 2010).  
On September 18, 2014, the White House directed the federal government to step 
up the fight against antibiotic-resistant bacteria.  A science advisory was released, calling 
for reducing antibiotics overuse to preserve the efficacy of existing antimicrobials, to 
develop improved methods for conducting antibiotic stewardship programs in healthcare 
settings and to develop and promote the use of new, rapid diagnostic technologies such as 
molecular diagnostics and point-of-care diagnostics (Office of Press Secretary, 2014).  
By the end of the calendar year 2016, the Department of Health and Human Services will 
propose new regulations that require hospitals and other inpatient healthcare delivery 
facilities to implement robust antibiotic stewardship programs that adhere to best 
practices (Office of Press Secretary, 2014). 
Molecular Diagnostics Technology 
Human blood is naturally sterile.  Current standard blood culture procedures 
consist of inoculating blood cultures bottles and monitoring for the growth of 
microorganisms, and any growth is assumed pathologic unless contaminated.  Cultures 
are then Gram stained, plated to appropriate media, and allowed to grow for 24 to 72 




results (Dekmezian, Beal, Damashek, Benavides, & Dhiman, 2015).  This process creates 
a considerable delay in initiating AAT from the initial collection of blood sample from 
the patient to delivery of the most appropriate antimicrobial treatment.  Newer 
technologies such as molecular diagnostics offer rapid identification thus more efficient 
infection treatment.  Tests such as nucleic acid amplification tests, fluorescence in situ 
hybridization (FISH), and matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) provide rapid identification of pathogens and 
codetection of key resistance markers directly from positive blood cultures (Dekmezian 
et al., 2015).  For example, the Verigene Gram-Positive and Gram-Negative blood culture 
assays are approved by the Food and Drug Administration to detect common gram-
positive and gram-negative organisms, as well as associated resistance markers within 
three hours from positive blood cultures (Dekmezian et al., 2015). 
Molecular technologies have significantly shortened the time to antimicrobial 
isolate identification compared with conventional methods.  Sango et al. (2013) evaluated 
the impact of Enterococcus identification and resistance detection using Verigene Blood 
Culture Gram-Positive.  The intervention by an infectious disease and/or critical care 
pharmacist on 74 patients with enterococcal bacteremia led to a significant decrease in 
the meantime to appropriate antimicrobial therapy in the post-intervention group (23.4 h; 
P = 0.005) compared with the pre-intervention group (Sango et al., 2013). 
Bauer et al., (2010) in a single center study, evaluated clinical and economic 
outcomes of rapid diagnostic polymerase chain reaction (PCR) methods on 156 patients 
for methicillin-resistant S. aureus/S. aureus bacteremia and demonstrated that the mean 




methicillin-susceptible S. aureus bacteremia was 1.7 days shorter (P = 0.002), the mean 
length of stay was 6.2 days shorter (P = 0.07), and the mean hospital costs were $21,387 
less (P = 0.02) after PCR.  Therefore, PCR allows rapid differentiation of S. aureus 
bacteremia, enabling timely, effective therapy and is associated with decreased length of 
stay and healthcare costs (Bauer et al., 2010). 
A prospective randomized controlled trial evaluated outcomes associated with 
rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly 
from positive blood culture bottles, and demonstrated that the time from blood culture 
Gram stain to microorganism identification was shorter in the intervention group (1.3 
hours) vs control (22.3 hours) (P < .001) (Banerjee et al., 2015).  Compared to the control 
group, both intervention groups had decreased broad-spectrum antibiotic (control 56 
hours, rmPCR 44 hours, rmPCR/AS 45 hours; P = .01) and increased narrow-spectrum 
antibiotic (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P = .04) use, and less 
treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P = .015) 
(Banerjee et al., 2015).  Time from Gram stain to appropriate antimicrobial de-escalation 
or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, 
control 34 hours, rmPCR 38 hours, P < .001; escalation: rmPCR/AS 5 hours, control 24 
hours, rmPCR 6 hours, P = .04).  Groups did not differ in mortality, LOS, or cost 
(Banerjee et al., 2015).  Banerjee et al., (2015) reported decreased use of broad-spectrum 
antimicrobials with the implementation of PCR diagnostic method, and the addition of 
antimicrobial stewardship program enhanced antimicrobial de-escalation.  Molecular 
diagnostics allow rapid differentiation of bacteria, enabling timely, effective therapy; 




Discussion of Best Practice to Address Problems 
Sepsis is a rapidly growing public health problem for Americans.  There has been 
little change in long-term morbidity, despite changes in practice and technology.  
Clinicians should anticipate more frequent sequelae of severe sepsis in their patient 
populations, especially among elderly patients and in light of increasing antimicrobial 
resistance.  Although overall decreasing mortality has been a trend over the past decades 
as many of aspects of sepsis management has changed since Rivers et al. (2001), high 
incidence and difficult diagnostics of sepsis remains a major problem.  The management 
of patients with sepsis focuses on the early administration of antibiotics, IV fluids, and 
vasoactive agents, followed by source control; unfortunately, there is no high-quality 
evidence demonstrating that any of these interventions impact outcomes, especially when 
the interventions are bundled together (Marik, 2014).  However, it is likely that timely 
administration of appropriate antibiotics is the single most important factor in reducing 
both morbidity and mortality from sepsis (Marik, 2014). 
Antibiotic Resistance  
Since the invention of penicillin, we had access to many reliable antibiotics, and 
as resistance has developed to particular drugs, new and more potent antimicrobials were 
almost immediately manufactured.  Today, however, for some bacterial strains, the 
antibiotic market has shrunk, and in many cases of drug-resistant infections, the choices 
of antimicrobial agents are limited.  There are instances of highly resistant strains that 
currently available antibiotics are not effective at all.  Fewer antibiotics are available to 
treat complicated infections, and the reason for this problem is multifaceted.  




of resistant organisms.  Pharmaceutical companies are reluctant to make new antibiotics 
for economical reasons.  Medications are very expensive to develop and to undergo 
clinical trials.  Those that are prescribed for life, for example antihypertensive drugs, 
antihyperglycemics, or antilipids can be profitable for the companies who develop them; 
however, antibiotics are typically used for a short period of time and once used, 
resistance already starts to develop.  Pharmaceutical companies must be encouraged to 
return to the manufacturing of antibiotics to help to combat this global problem, thus 
initiatives are being proposed in the form of financial incentives and tax breaks.  
An H.R.3539 Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015 
was introduced to the House Committee on Ways and Means in September 2015, 
Sponsored by Rep. Boustany, Charles W., Jr. (See Appendix F, Figure F.1).  This bill 
amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing 
expenses for infectious disease products that are intended to treat a serious or life-
threatening infection, including one caused by an antibacterial or antifungal resistant 
pathogen, and in-vitro diagnostic devices that identify in less than four hours the 
presence, concentration, or characteristics of a serious or life-threatening infection 
(Boustany, 2015)  
In March 2015, the White House released an initiative on combating antibiotic-
resistant bacteria.  This initiative encourages new antibiotic use protocols, antibiotic 
stewardship programs implementation across healthcare facilities, and better diagnostics 
that can quickly detect bacterial infections and multiple antibiotic resistance genes.  The 
National Action Plan for Combating Antibiotic-Resistant Bacteria was issued and 




of rapid and innovative diagnostic tests for identification and characterization of resistant 
bacteria, accelerate basic and applied research, and development for new antibiotics (The 
White House, United States Government, 2015). 
Summary 
Despite some differences, overall there is an agreement in the literature regarding 
a core sepsis approach.  To reduce mortality rates, sepsis must be identified and treated as 
early as possible so that patients can receive optimal aggressive treatment (Lopez-
Bushnell, Demaray, & Jaco, 2014).  As specific recommendations evolve and change 
with advancing knowledge, and technology, and with emerging new evidence, the most 
critical aspects and the underpinning of sepsis care remains early recognition of 
symptoms and prompt initiation of aggressive measures with antibiotics (D’Amore, et al., 







Objectives of this project were to review scientific literature for the effects of 
sepsis protocols on health outcomes, then conduct data analysis and compare results of 
two groups of patients who were hospitalized in a community hospital with the diagnosis 
of sepsis before and after implementation of new sepsis guidelines.  The purpose of this 
project was to evaluate interventions in terms of utilization and effectiveness of current 
sepsis protocols on health outcomes, specifically on hospital length of stay, mortality, 
morbidity, readmissions, and appropriate antibiotics utilization; also, to assess whether 
implementing the mandated protocol actually influenced the timing of initiating early 
interventions.  Further, additional goals were to examine whether recommendations for 
improvements are indicated, explore evidence to guide practice change, and based on the 
project’s outcomes to validate best practice recommendation.  Ultimately, the 
prospective, indirect aim was to determine if a change in practice is necessary.  
Project Design 
This evidence-based project is a descriptive, retrospective, and a pre and post 




scholarly project was conducted at a 100-bed community hospital located in the coastal 
South Carolina region, which implemented the new sepsis protocol in October 2015.  
Through data collection and analysis, the focus of this quality improvement project was 
to evaluate the efficiency of interventions of current sepsis protocols and their effects on 
health outcomes, such as mortality, hospital length of stay (LOS), utilization of 
antibiotics, and morbidity among septic patients in pre- and post-implementation groups. 
The pre-implementation data was collected from September 1, 2014, through 
September 31, 2015, and compared to the post-implementation period from October 1, 
2015, through March 31, 2016.  The elements of data collection were organized into 
objectives one to six, measured in both pre- and post-intervention groups.  
(1) Objective One: Collect data and demonstrate descriptive statistics. 
(2) Objective Two: Summarize findings and compare outcomes: mortality, 
morbidity, health outcomes, antibiotics utilization, LOS, readmission rates.  
(3) Objective Three: Analyze outcomes between groups looking at selected 
individual variables and based on compliance with guidelines. 
(4) Objective Four:  Evaluate relationship between variables. 
(5)  Objective Five: Determine if there is a need for practice change. 
(6) Objective Six: Make appropriate recommendations based on current evidence.  
Sample 
The unit of analysis in this project is the patient and her or his health record data.  
One hundred fifty-eight electronic charts of patients admitted between September 1, 
2014, and March 31, 2016, were reviewed.  The sample population included two groups 




Inclusion and exclusion criteria.  Inclusion criteria were comprised of adults of 
both genders, 18 years of age or above who had an active sepsis diagnosis at the time of 
presentation to the hospital, or at any time during the hospitalization, and were 
hospitalized within the specified time frame.  To be included patients must have met the 
severe sepsis and sepsis shock criteria as per SEP-1 guidelines (Figure II.2).   
Included were those patients with the following ICD diagnostic codes: from ICD-
9 codes: 038.9 (unspecified septicemia), 995.91 (sepsis), 995.92 (severe sepsis), and 
785.52 (septic shock).  The ICD-10-CM codes ranged from A22 to A54 and B00.7 to 
B37.7, with additional multiple extension as applicable, also A41 (for other sepsis, with 
extensions from A41.0 to A41.9 for specific types of sepsis and due to particular or 
unspecified organisms).  In addition, the following ICD-10-CM codes: T81.4, T88.0; 
T80.2 were used to generate reports for completeness.  These included postprocedural 
sepsis, sepsis following immunization or infusion, or transfusion of therapeutic injection.  
Not included were codes describing bacteremia without sepsis, sepsis during labor, sepsis 
following abortion, neonatal sepsis and sepsis in children of any age below 18 since the 
target population did not include these aggregates.  Appendix I lists all the ICD-10-CM 
codes included for the purpose of generating accurate reports.  Since the new protocols 
were implemented on October 1, 2015, for the pre-implementation sample the case 
selection was from September 1, 2014, through September 31, 2015 (13 months) and for 
the post-implementation sample, the case selection was from October 1, 2015, through 
March 31, 2016 (6 months).  Patients who were admitted to ACU, PCU, or ICU, were 
included but admitted to L&D and all neonatal and pediatric patients were excluded from 





The setting for this project was a small, community hospital located in the coastal 
area of South Carolina.  The hospital opened its doors in 1975 as a private, 40-bed, 
accredited medical facility serving a small rural population.  Over the years with the 
growing demands of the region, the hospital transitioned to a larger facility, expanded its 
services, and is currently certified for nearly 100 acute care beds serving the local 
population and visitors.  
Data Collection 
With the intention to accomplish the project objectives, permission for data 
collection, extraction from electronic medical records (EMR), and analysis was requested 
from the Safety Officer /Director of Risk Management of the hospital, who presented the 
proposal before the facility’s Compliance Committee.  Once permission was granted by 
the Compliance Officer (Appendix G, Figure G.1), a comprehensive, retrospective 
electronic chart review and data collection of the electronic medical records was 
conducted.  The aforementioned facility utilizes Cerner® EMR software.  For the 
purpose of this project, access was granted to the EMR to selected patient databases to 
collect necessary demographics and clinical information.  The software has the capability 
to generate various reports; therefore, a list of patients was created by Medical Records 
director, de-identified and consequently received anonymous in its entirety.  The list was 
based on diagnosis codes for sepsis using International Classification of Diseases, Ninth 
Revision (ICD-9) and Tenth Revision (ICD-10-CM) (Appendix I).  Once de-identified 
reports were received, all pertinent information was manually entered into an Excel® 




spreadsheet was developed and designed to fit all data elements.  The demographic 
information was entered from the Cerner® reports.  All subjects were organized in rows 
by age and gender.   
Unique identifiers were assigned to individual cases to facilitate analysis and to 
provide an opportunity for retrieval of any missing or duplicated data.  Designs for both 
pre- and post-implementation groups data collection Excel® worksheets were identical 
(See Appendix J, Figure J.1 for worksheet template).  For each item in data collection, a 
distinctive name was created, items were organized in column headings, and classified as 
either categorical (nominal, ordinal, dichotomous) or continuous variables (interval or 
ratio).  Based on this classification, a specific number of sub-columns was set up for each 
variable to reflect the quantities of values.  Some variables were answers to yes-no 
questions, others had numerous subcategories with possibilities to pick either only one-
out-of-all, or all that apply.  
Data coding was performed by establishing a numerical value for each entry 
options, thus all values in each subcategory of every variable had a unique number 
assigned that was associated with the corresponding category.  For example, gender was 
coded as 1 = Female and 2 = Male, or number 1= answer Yes, and 2 = No.  Consecutive 
numbers (1, 2, 3 …) were assigned to items with multiple subcategories, such as 
antibiotic class: 1 = antibiotic A, 2 = antibiotic B, 3 = antibiotic C, respectively.  Please 
refer to Appendix J, Table J.1 that illustrates the template of the spreadsheet.  Table III.1 
below lists categories created on the worksheet for data collection, and Table III.2 shows 




Encryption of categories was conducted in a particular manner where each 
category had assigned a unique combination of letters that reflected in corresponding 
subcategory code along with previously established numerical values.  For example, the 
category “Race” was coded Race1-6, and corresponding variables had numbers assigned 
to them as follows: 1=Caucasian (Race1); 2=African American: (Race2); 3=Asian: 
(Race3), 4 = Hispanic (Race4) et cetera.  The category: “Functional status at discharge” 
was coded: OutcFS 0-3, and the corresponding subcategories received the following 
codes: No change from pre-hospitalization = 0: (OutcFS0); Worse, lost independence, 
declined = 1 (OutcFS1); Better then prior to hospitalization = 2 (OutcFS2); Deceased = 3 
(OutcFS3).  Please refer to Appendix K, table K.1 for examples of the variables’ coding 
system, Appendix E, Table E.1 for a list of data collection elements with corresponding 
codes and Appendix M, Table M.6 for the coding legend. 
Table III.1.5List of Variable Categories for Data Collection 
 







Functional status at discharge  
Discharge destination 
Immune status impairing diagnoses  
Comorbidities  
Sepsis cause  
Hospital course  
Progression of sepsis  
Treatment with initial Antibiotics  
Number of days on empiric antibiotics  
Number of empiric antibiotics 
Deescalation of antibiotics 
Appropriateness of antibiotics  
Bundle compliance 
IV fluids timing and rate 
First lactic acid measurement 
Second lactic acid measurement  
Blood cultures sampling 
Duration waiting time for results    
Culture results  
C-diff  
Site of positive cultures  
Identified pathogen  
Multi-drug resistant organisms  
Antimicrobial class  
Healthcare-acquired infection 
Nosocomial complications 
Potential costs savings  




Data were collected over 19 months from September 1, 2014, to March 31, 2016, 
and a total of 158 subjects were included in raw data batch, which consisted of two 
separate, independent samples of patients hospitalized before and after launching the new 
sepsis protocols.  The first sample (n=86) was collected prior to the sepsis guideline 
implementation on October 1, 2015, and the second sample (n=72) was collected from 
October 1, 2015, after guideline inauguration.  Only patients meeting the inclusion 
criteria were included in data collection and outcome measures.  
Measured Variables and Outcomes 
The primary goal relevant to this project was to compare health outcomes before 
and after implementation of new sepsis management protocols.  With the intention of 
producing a meaningful final report, outcomes of several data elements were collected 
and measured in both samples (Table III.1). 
Selected outcomes measured were those patients results that were expected to 
change after sepsis protocols were implemented.  The main variables included death and 
survival rates, the difference in mortality between patients with sepsis and septic shock, 
the proportion of sepsis progressing to septic shock while hospitalized, hospital length of 
stay, outcomes such as patients’ functional status at the time of discharge, discharge 
destination and readmission.  These variables were arranged in categories and supporting 
subcategories were added as shown in Table III.2.  The role of several different 




Table III.2.6Categories and Subcategories of Variables and Outcomes Measured 
 
Categories and Subcategories Of 
Variables And Outcomes Measured 
Categories and Subcategories Of Variables 
And Outcomes Measured 
 The number of days patient 
stayed in hospital (LOS) 
 Patient survival (Mortality) 
 Overall functional status at 
discharge (Declined, no change, 
improved)  
 Final discharge destination  
o Deceased while 
hospitalized 
o Returned home with 
home health, or more 
help than prior  
o Went to a nursing 
facility, long or short 
term  
o Admitted to Hospice 
Care and Deceased  
o Prior living 
arrangements without 
change 
 Immune status (impaired, 
normal) 
 Diagnosis or conditions 
affecting immune status 
o None  
o Cancer (Ca)  
o Status post organ 
transplant or 
splenectomy 
o Chronic Obstructive 
Lung Disease (COPD) 
o Diabetes Mellitus (DM) 
o Rheumatoid arthritis or 
on steroids for other 
reasons 
o On chemotherapy 
 Comorbidities 
o 0 None   
o Vasopressors 
o Focused exam 
 Fluid status reassessment 
 Number of hours pathogen was first 
identified as Gram-negative or Positive 
(preliminary results) 
 Number of hours final culture results 
available including sensitivity (MIC) 






o CNS fluid 
o C-diff infection  
o Pleural fluid 
o Peritoneal fluid 
o Other intraabdominal infection  
 Identified pathogen or pathogens 
o Gram-negative pathogen  
 Escherichia coli 
 Klebsiella pneumonia 
 Enterobacter 
 Acinetobacter 








o Gram-positive pathogen  
 Staph aureus MSSA  
 Staph aureus MRSA 





o Ca  
o COPD 
o DM 
o Coronary Artery 
Disease (CAD) 
o Malnutrition 
o Alcohol (ETOH) abuse, 
chronic 
o Readmitted, recurrent 
infection 
o History of previous 
sepsis 
o History of multi-drug 
resistant infection 
o Underlying dementia 
o End Stage Renal 
Disease (ESRD), on 
dialysis 
o Obesity 
o Congestive Heart 
Failure (CHF) 
o Peripheral Vascular 
Disease (PVD) 
o Other 
 Initial presentation 
o Sepsis 
o Severe sepsis 
o Septic shock 
 Acute mental status change 
(AMS) 
 Sepsis cause 
o Pneumonia 




o Skin (cellulitis) 
o Post-surgery 
complications 
o Wound infection 
o Meningitis 
o Neutropenic fever  
o Fever of unknown 
origin (FUO)  
 Streptococcus 
pneumococcus 
 Strep viridians 
 Strep group A pyrogens 
 Corynebacterium 
 Enterococcus faecium 










o Fungal  





 ESBL  
 Other 
 Antimicrobial class  
o Penicillin (PCN)  
o Extended PCN (Zosyn)  
o B-lactamase inhibitor PCN 
(Unasyn)  
o Cephalosporin 1st generation  
o Cephalosporin 2nd generation 
o Cephalosporin 3rd generation 
o Cephalosporin 4th generation 
o Cephalosporin 5th generation 
(Ceftaroline) 
o Fluoroquinolone 2nd generation 
(Cipro) 
o Quinolone 3rd generation 
(Levaquin/Moxifloxacin) 
o Macrolides 
o Tetracycline  
o Sulfonamides 
o Carbapenems 




o Bacteremia without 
identified source 
o Osteomyelitis 
 Hospital course 
o ICU with vasopressors  
o Mechanical ventilation  
 Progression of sepsis 
o Severe sepsis 
progressed to septic 
shock despite treatment 
o Better, status did not 
deteriorate during 
hospitalization 
 Antimicrobial stewardship 
o Deescalation of 
antibiotics 
o Number of antibiotics 
o Number of days on 
antibiotics 
 Sepsis protocol compliance 
o Initiation of treatment 
with antibiotics, timing 
o IV fluids infusion rate 
and timing 
o Lactic acid sampling, 
results and timing 
o Blood culture sampling, 
results and timing 
o Glycopeptide (Vanc) 
o Liptopeptide (Cubicin/Dapto) 
o Oxazolidinone (Zyvox/linezolid) 
o Lincosamide (Clindamycin) 
o Other antibiotics (Tigecycline) 
o Nitroimidazole (Flagyl) 
 Other Treatment 
o Antifungal (fluconazole) 
o Antiviral 
o Other atypical 
 Appropriate antibiotic for culture results 
 Healthcare-acquired infection 
 Hospital complications 
o C-diff 




o Abscess  
o Renal failure  
o Respiratory failure  
o Multisystem failure  
o Cardiac complications  
 Potential costs savings   
o On LOS 
o On antibiotics 




Strategies to Reduce Barriers 
Facilitators and barriers were identified and examined.  No major impediments 
were identified to data collection and analysis with the exception of the time required to 
complete this project.  Elements that could have affected outcomes of this project may be 
possible flaws in data based on inaccurate documenting of clinical findings in EMR.  
Other issues affecting outcomes are noncompliance with guidelines, infeasible 
approaches, and ineffectiveness of some components of the guidelines along with long 
waiting time for culture results possibly leading to inappropriate antibiotic prescribing.  
Managers, as well as staff in general, are often wary of challenges and risk averse, 
therefore resistant to change. 
A number of barriers exist to the adoption of recommendations resulting from the 
data analysis and evidence review, including the absence of an innovation culture in the 
organization, lack of abundance of supportive evidence, financial constraints, and a 
budget that does not allow additional spending and administration that does not 
encourage innovation or change.  To overcome barriers, the project’s findings have to be 
integrated with collaborative sepsis team efforts to improve sepsis outcomes in this 
setting, and use data to validate best practice recommendations.  To help reduce barriers 
to change, forming a team of supportive colleagues who take ownership of quality and 
safety initiatives is critical to successful implementation of evidence-based practice and 
ongoing quality improvement.  
Instruments 
Data was collected retrospectively in a systematic fashion as described above 




Microsoft® Office Excel® 2007 program, and Statistical Analysis Software (SAS®) 
statistical software.  The Cerner® was utilized for generating reports, access to clinical 
records, review and collection of pertinent information for this project.   
Data was organized, sorted and statistically described using Excel® worksheet for 
editing, formatting, developing graphs and charts, also its spreadsheet functionality such 
as descriptive statistics and basic mathematical and sorting tools and formulas.  Finally 
SAS® was used for statistical data analysis of both the pre-implementation and the post-
implementation samples. 
Procedure 
The purpose of this comprehensive retrospective records review and data 
collection for this project was to analyze differences in outcomes before and after the 
introduction of the new sepsis protocol.  Eighty-six electronic charts were reviewed in the 
pre-implementation data set (n = 86), and 72 in the post-implementation data set (n = 72)  
Charts were reviewed in the context of septic patients’ outcomes based on timely 
approaches and administration of mandated treatments as opposed to the standard 
practice.  Variables such as mortality, LOS, morbidity, patients’ outcomes including loss 
of function, hospital complications, AAT, MDR infections, and readmissions strongly 
affect outcomes, and were the principal aspects analyzed in this project.  In addition, 
compliance with each component of the new Sepsis Bundle protocol is now a benchmark 
for the quality measure and mandated by Medicare. 
After data entry was completed, data quality and reliability were examined 
through a series of procedures including random re-checks of all the records, and 




spreadsheet’s sorting functionality.  Data was double-checked for errors and omissions by 
hand, also using the spreadsheet functionality all numerical values were sorted and 
checked for accuracy of data entry.  Less than 1% of records within the entire collection 
were found to be missing or incorrectly coded, and errors were corrected and re-checked 
for accuracy based on expected ranges of values in each category before data was 
analyzed.   
Data Analysis Methods.  This post-hoc analysis consisted of comprehensive 
literature review, retrospective data collection and analytical approach to data.  Initial 
descriptive statistics were run using Excel® functions within the spreadsheet such as 
AVERAGE (arithmetic mean), RANK (list of values ranked by order relative to other 
values), STDEV (sample standard deviation), SUM (sum of numbers in a range of cells), 
COUNTIF (count of numbers that meets given conditions), MAX, MIN (largest and 
smallest values), MEDIAN (middle number), MODE (most frequently occurring value), 
QUARTILE, SUMIF (sum given specified condition), CORREL (correlation coefficient 
between two data sets), PEARSON (Pearson correlation coefficient), PERCENTILE, and 
T.TEST.  
Sorting and calculations performed on the raw data allowed formatting of data 
elements for appropriate entry into the statistical software for data analysis.  Data from 
the two groups (pre-implementation and post-implementation) were arranged and 
organized in sets by age, gender, LOS, mortality, hospital course, discharge status and 
other outcomes, then ranked accordingly, thus prepared for processing by statistical 




functions were plugged into the Statistical Analysis Software (SAS®) for detailed 
analysis.   
The frequency tables were developed, the t-test, and means procedures were used 
for descriptive statistical analysis and data distribution analysis.  Pearson’s Correlation 
Coefficient and Spearman’s Correlation Coefficient procedures were used for comparison 
of outcomes.  
Figures are presented in the following chapter illustrating the descriptive statistics 
and data analysis; further, data analysis outcomes are shown and demonstrate whether 
there was a statistical difference in comparing variables in categories and subcategories 
between pre-implementation and post-implementation groups.  Inferential data is 
presented in tables and graphs in the following chapter.  P value at the level of p < 0.05 is 
used to indicate a statistically significant difference. 
Human Subject Protection 
The purpose of this scholarly project was to evaluate the effectiveness of current 
sepsis protocols on patients’ outcomes.  This project included health data of human 
beings, which involved electronic chart reviews, health record information extraction, 
and analysis; however, as a Quality Improvement project specific to the setting and 
without intent to produce generalizable results, no Institutional Review Board review was 
necessary.  A request for permission to use data from EMR was filed with the Safety 
Officer /Director of Risk Management and granted by the Compliance Officer of the 
hospital (Appendix G, Figure G.1).   
The collection of data required to some degree participant identification, but only 




identifying data was collected or stored and individual cases were assigned unique 
identifiers for purposes of data analysis.  Data was located on a password-protected 
computer and the access to this information was only through the secure password-
protected server.  
This Quality Improvement project does not involve any known risks to subjects.  
The outcomes of this project or the entire process of data collection and analysis do not 
affect the rights or welfare of the subject.  All evaluation information was kept 
anonymous and was disseminated by aggregate data only.  Obtaining consents was not 
indicated and it would be impractical to carry out this project if consents were required; 
further, having written consents would risk potentially linking participants with records 
in the final project.  There were no known physical, psychological, or social risks 
involved during the implementation of this intervention.  The project involves a 
considerably small sample; however, data was only reported in aggregate, thus 







Description of Sample 
This project was designed to compare outcomes of patients with sepsis treated in 
a hospital before and after the launching of the newest sepsis guidelines, to evaluate the 
effectiveness of the guidelines, and based on results, to assess the need for improvement 
and practicability of recommending practice change.  The study was completed at a 
medical center located in the coastal South Carolina region, and utilized the EMR for 
retrospective data collection.  A total of 158 electronic charts were reviewed, which 
included charts of 86 patients with sepsis who were treated prior to the newest mandatory 
Sepsis Bundles were made a part of the hospital protocol (pre n=86), and 72 charts of 
septic patients who were treated after the protocols were implemented (post n=72).   
Data including descriptive statistics for the relevant variables and outcomes are 
displayed below in tables, charts and graphs.  Table IV.1 shows percentages of all 
patients admitted with sepsis, patients who developed septic shock, and those who had 





Table IV.1.7Incidence of Sepsis, Severe Sepsis and Septic Shock 
 
Sepsis, incidence Pre (n=86) Post (n=72) 
 
% % 
Septic Shock 41 31 
Severe Sepsis 42 58 
Sepsis NOS 17 11 
* Note: some patients had more than one diagnoses 
 The major finding in this data set is that while 16% more patients with severe 
sepsis were treated in this hospital prior to Sepsis Bundle implementation than after, 10% 
fewer patient presented with or developed septic shock. 
Demographic Data 
Demographic data is displayed below in Table IV.2.  In the pre-implementation 
sample, there were 42% females and 58% males, 91% of Caucasians, and 7% African 
Americans, as opposed to the post-implementation sample of 44% females and 56% 
males, 86% Caucasians and 8% African Americans.  The average age of all participants 
was 74.45 years.  Data shows that 43% of patients were female and 57% were male, and 
the majority of patients in both groups were Caucasian (88.5%).   
The mean age of the entire sample was 74.42 years, and the overall range was 23 
to 97 years.  The age range in the pre-implementation group was from 23 to 97 years, and 
in the post-implementation group, it was 33-97 years.  The mean age in the pre-
implementation group was 72.14, and post-implementation was 76.71 years.  The 




Table IV.2.8Demographics. Distribution of Age, Gender and Race by Group 
 





       Female 42 44 
       Male 58 56 
Race 
  
Caucasian 91 86 
African American 7 8 
Hispanic 2 6 
Asian 0 0 
Other 0 0 
Age years years 
       Age, average 72.1 76.8 
 
Distribution among genders is not equal among males and females in both groups.  
The male gender predominance is observed in both groups.  Sixteen percent more men 
than women were treated for sepsis in the pre-implementation group, and 12% more men 
than women were treated in the post-implementation group.  A disproportional 
percentage of Caucasians is noted in both groups as compared to other races.  Ninety-one 
percent of patients hospitalized with sepsis in the first group were Caucasians, as 
compared to 9% of all other races combined in the same group.  Similarly, 86% of 
patients were Caucasians, as compared to 14% of all other races combined in the second 
group  
Figure IV.1 shows two histograms displaying the distribution of ages of the patients 





Figure IV.1.5Distribution of Age by Group 
Both groups’ characteristics in reference to age distribution are similar and representative 
of the known population in this setting; however, what stands out in this figure is that the 
post-implementation group was older. 
Descriptive data consisted of individual observations collected for the project 
objective (Objective One) also included mortality, LOS, most common antibiotic 
prescribed, antibiotic treatment duration and most frequently occurring causative 
pathogens.  
Mortality Rate and Length of Stay 
Overall hospital mortality rate for patient population carrying sepsis diagnosis and 
hospitalized within the specified time period from September 1, 2014, to March 31, 2016, 




Table IV.3.9Mortality by Group 
 
Mortality Pre (n=86) Post (n=72) 
Mortality by group Frequency % Frequency % 
Alive 51 59.3 57 79.17 
Deceased 35 40.7 15 20.83 
 
Mortality, overall, both groups 
Outcome Frequency Percent 
        Alive 108 68.35 
        Deceased 50 31.65 
 
The mortality rate for the pre-implementation group was 40.7% with a survival rate of 
59.3%, and in the post-implementation group, the mortality rate was 20.83% with a 
survival rate of 79.17%.  A difference of 19.87% in mortality rate was noted between the 
two groups.   
Table IV.4 shows septic patients’ mortality in relation to age and LOS. A t-test of 
mortality with regard to age in both pre- and post-implementation groups (Table IV.4) 
showed that the average age of patients who were deceased was 78.16 years and the 
average age of survivors was 72.4 years (p<0.05).   
Table IV.4.10Mortality by Age and LOS 
 
  Alive Deceased T-test 
p-
value Variable N Mean SD N Mean SD 
Mortality by age 108 72.40 14.8103 50 78.16 13.25 <0.05 




The difference in the LOS between the patients who survived and who were deceased 
(0.024 days) was not statistically significant (p=0.9).  More details regarding mortality 
and LOS are shown in the Appendix M. Table M.1 and M.2 and Figures M.1 and M.2 in 
Appendix M. Data in charts graphically demonstrate the distribution of mortality by LOS 
and LOS by age between groups. 
Table IV.5 shows the difference between means of ages of septic patients 
hospitalized before and after implementation of the sepsis protocol.  The mean age in the 
pre-implementation group was 72.14 years and in the post-implementation was 76.71 
years; resulting in a statistically significant age difference of 4.57 years between the two 
groups (p <0.05).   






N Mean SD N Mean SD 
Age 86 72.14 15.17 72 76.71 13.44 <0.05 
LOS 86 7.38 5.46 72 6.68 4.85 0.4 
Number of prescribed empiric 
IV antibiotics per patient per 
stay 
86 3.03 1.17 72 3.17 1.41 0.5 
Number of days on empiric IV 
antibiotics 
86 6.62 4.33 72 6.94 5.02 0.66 
Number of hours until pathogen 
was identified 
82 33.70 12.63 71 31.59 12.00 0.3 
Number of hours final results of 
cultures are known 




The average LOS for the pre-implementation group was 7.38 days and post-
implementation was 6.68 days.  A minimum number of days patients were hospitalized 
was one day for both groups.  The maximum number of days for the pre-implementation 
group was 26 days, and for the post-implementation group was 27 days.  The difference 
in LOS between the two groups was 0.7 day (p=0.4), which while statistically 
insignificant, may represent a considerable difference in resource consumption for 
hospitals (Table IV.5).  The average number of empiric antibiotics prescribed before the 
launch of new guidelines was 3.03 with minimum 0 and maximum 5, as opposed to the 
average number 3.17, minimum 1 and maximum 7 after guidelines were in place, and the 
difference was 0.13 (p=0.5), (Table IV.5).  The average number of days each patient 
received empiric antibiotics in the first group was 6.62 and in the second group 6.94.  The 
minimum number of days was 0 and maximum 22 for the pre-implementation group; for 
the post-implementation, 1 and 27 days, respectively.  With a 0.33 day difference, this 
finding is also not significant (p=0.66), (Table IV.5).   
Waiting Time for Blood Cultures  
The number of hours of waiting time before the causative pathogen was first 
identified in a cultured specimen, and the number of hours before the final results for 
culture and sensitivity were available are shown in Table IV.5.  The average waiting time 
for the initial identification was 33.7 hours for the first group and 31.59 hours for the 
second group, with a minimum of 2 hours, and a maximum of 72 hours respectively.  The 
difference was 2.1 hours (p=0.3). 
The final culture results were available, on average, 64.68 hours after specimen 




group, with a minimum of 2 hours and a maximum of 100 hours in the first group, and a 
minimum of 40 and a maximum of 92 hours in the second group.  The calculated 
difference for this measure between the two groups was 4.91 hours and the difference 
was statistically significant (p=0.05, Table IV.5).  Additional data regarding the most 
frequently used antibiotics and their utilization in sepsis is presented in Appendix M, 
Figure M.3, and Table M.3.  
For supplementary and supportive purposes to aid with the explanation of results, 
ancillary data was collected regarding sepsis-related conditions, including the most 
frequently occurring disease associated with sepsis as well as the most frequent causative 
organisms, including C. diff. and MDR organisms.  Pneumonia and urinary tract infection 
(UTI) were the most frequently occurring conditions for both groups.  Escherichia coli 
(E. coli) bacterium and Candida fungus were the most often identified pathogens isolated 
in septic patients (Appendix M, Figure M.4, Table M.4 and Table M.5). 
For Objectives Two and Three, outcomes were summarized, and then analysis 
was conducted while the pre-implementation and post-implementation groups’ outcomes 
were compared.  Compliance with each element of the new sepsis guidelines was 
measured in the post-intervention group and compared to prior performance. 
To achieve a clearer picture of the Sepsis Bundle’s impact on health outcomes, 
additional data were gathered, including patient’s condition upon discharge from the 
hospital, discharge destination, and readmission rates.  For Objectives Four and Five, 
results were examined for relationships, similarities, and differences, and conclusions 




An additional secondary, but noteworthy, finding was the occurrence of a mental 
status change in older patients with sepsis.  Seventy-six percent of patients with sepsis 
experienced mental status changes.  The average age of those with acute delirium was 79 
years as opposed to 69 years among those without acute confusion in the post-
implementation group.  Similarly, 7.9 years difference in age between patients with and 
without mental status change associated with sepsis was noted in the pre-implementation 
group.  
Health Outcomes 
This project aimed to answer the PICO question: In adult patients presenting with 
sepsis before and after October 1, 2015, does implementation of a new sepsis protocol 
reflect in improved outcomes such as reduced hospital LOS, decreased mortality, 
morbidity, readmissions, and appropriate antibiotics utilization, and does it result in 
initiating early treatments as compared to previous approaches?  
Morbidity.  Table IV.6 shows outcome variations between both groups in 
patients’ mortality, functional status change at the time of discharge, the difference in 
required level of care at discharge, as well as hospital course, in-hospital complications, 
and readmissions.  Additionally, differences in means of patients’ ages in each group in 
relation to functional status at discharge and required level of care at discharge were 





Table IV.6.12Outcomes of Patients with Sepsis 
 
Sepsis Outcomes Pre (n=86) Post (n=72) 
   
Functional status at discharge % % 
Better 2 0 
Same 19 15 
Worse 38 64 
Deceased 40.7 20.83 
Discharged destination %  %  
Prior living arrangements 23 21 
SNF 12 19 
Higher level of care/ transfer to tertiary hospital 5 1 
Home Health 20 32 
Hospice 9 6 
Hospital course 
  Nosocomial/healthcare acquired infection 13 36
ICU, intubated 38 10 
ICU, pressors 35 43 
PCU 50 47 
Of all pneumonia cases, HAP 13 47 
Of all pneumonia cases, readmitted 15 56 
Readmission among patients with sepsis 17 47 
Sepsis progressed, worsened during treatment 46 28 
Septic shock-only mortality 57 36 
Sepsis mortality 40.7 20.83 
   
Average age of those with functional status change years years 
Better 71.5 n/a 
Same 71.1 61.8 
Worse 64.6 78.6 
Deceased 77.6 81.7 
Average age of those discharged to other settings   
Prior living arrangements 62.3 65.1 
SNF 78.4 81.8 
Deceased 75.3 81.7 
Higher level of care/ transfer to tertiary care 58.3 72.0 
Home Health 74.1 76.7 




Figures in Table IV.6 show differences in patient outcomes prior to and following 
implementation of the sepsis protocol.  Sixty-four percent of sepsis survivors in the post-
implementation group experienced worsening of their functional status, as compared to 
38% in the pre-implementation group, at the same time observing 20.83% mortality in 
the post-implementation group and 40.7% in the post-implementation group.  This is in 
the context of 57% and 36% mortality rate of patients with septic shock for pre-
implementation and post-implementation groups and respectively. 
The average age of patients experiencing worsening of their functional status in 
pre- and post-implementation groups was 64.6 and 78.6 years, respectively.  Other 
noteworthy findings include a higher percentage of patients who lost or had a decrease in 
independence after hospitalization (26%) and a higher nosocomial (hospital acquired) 
infection rate (23%) in the post-implementation group.  In addition, a much lower 
percentage of patients requiring intubation and ventilator support (28%) and a higher 
incidence of sepsis associated with pneumonia were observed in the post-implementation 
group.  A substantial increase in nosocomial complications was noted (13%), and the 
leading cause was healthcare-acquired pneumonia, which increased from 13% to 47%.  
Of all deceased patients, over 70% had sepsis caused by pneumonia.  The readmission 
rate increased 30% with an increase in pneumonia cases as a major cause for 
readmissions.  While the readmission rate went up from 17% to 47% in the post-
implementation group, the mortality rate among those who were readmitted decreased 
from 78% to 29.4%.  Protocol compliance and antibiotic utilization are addressed in 




Utilization of Antibiotics and the Sepsis Protocol Data 
Table IV.7 shows the percentage of patients who had antibiotics administered 
within the first three hours from the onset of sepsis, the percentage of the number of 
antibiotics deescalated during hospitalization, as well as the percentage of the times that 
the initially prescribed antibiotic turned out to be inappropriate based on culture results. 
Table IV.7.13Antibiotics Prescribing Trends 
 
Prescribing trends Pre (n=86) Post (n=72) 
 
% % 
Antibiotics deescalated 43 65 
Inappropriate antibiotic choice for culture results 31 58 
Antibiotic administered within 3 hrs 72 58 
 
In the post-intervention group, there was a 22% increase of antibiotics which had 
been deescalated from empiric to a narrower spectrum antibiotics.  There was also a 27% 
increase in inappropriate antibiotic choice for culture results, and a 14% greater delay in 
antibiotics administered within three hours in the post-implementation group as compared 
to the pre-implementation group.   
The mean LOS for patients’ who received appropriate antibiotic therapy (AAT) 
was 5.8 days and patients who received inappropriate antibiotics had an average hospital 
stay of 9.1 days (p<0.0001).  Among those who received AAT, the difference in LOS 
between the two groups is 3.33 days (Table IV.8).  
Patients who received AAT on time received empiric IV antibiotics on average 
for 5.84 days, but those who had antibiotics prescribed inappropriately received empiric 
IV antibiotics on average for 8.33 days(p<0.001).  Patients who were treated for sepsis 




hospitalization, and those on AAT received on average 2.67 empiric antibiotics 
(p<0.0001).  The inappropriateness of antibiotics was determined based on final culture 
results if shown the treatment was ineffective or inappropriate against causative 
organisms The difference in days on empiric antibiotics was 2.48 day between groups 
(Table IV.8). 
Table IV.8.14Antibiotic utilization 
 
  Yes No 
p-value 
Variable N Mean SD N Mean SD 
Received AAT (yes, no)/ 
LOS 
96 5.80 4.14 61 9.13 5.99 <0.0001 
Received AAT (yes, no)/ 
Number of days on 
empiric IV antibiotics 
96 5.84 3.82 61 8.33 5.36 <0.001 
Received AAT (yes, no)/ 
Number of prescribed 
empiric IV antibiotics 
96 2.67 1.00 61 3.82 1.32 <0.0001 
 
The difference in an average number of empiric antibiotics prescribed per patient 
between two groups was 1.15 (Table IV.8).  Additional data regarding distribution and 
frequency of individual antibiotic utilization for both groups can be found in Appendix 
M, Figure M.3, and Table M.3. 
Sepsis protocol utilization.  Utilization of the new sepsis protocol was measured 
using the elements of the Sepsis Bundle guidelines for early management, as shown in 
Table IV.9.  The percentages of patients receiving treatments on time according to the 




Table IV.9.15Sepsis Protocol Compliance: Early Interventions 
 
Sepsis Protocol Compliance: Early Interventions Pre (n=86) Post (n=72) 
 
% % 
1st Lactic Acid measures within 3 hrs 73 90 
2nd Lactic Acid measured within 6 hrs when indicated 11 49 
Lactic Acid results > 2 60 65 
IVF initiated per protocol 58 65 
Blood cultures drawn before antibiotic and within 3 hrs 80 80 
Antibiotic administered within 3 hrs  72 58 
Vasopressors per protocol 78 81 
Focused exam n/a 45 
.  
Noteworthy is the change in the collection of the lactic acid performance measure 
between the two groups from 73% to 90% compliance obtaining the first specimen and 
from 11% to 49% compliance obtaining the second lactic acid specimen.  There was no 
change in drawing blood cultures before and after implementation of sepsis protocols, but 
the administration of antibiotics within the first three hours from sepsis onset dropped 
from 72% to 58%. 
Figure IV.2 is a graphical display demonstrating utilization of the sepsis protocols 
including the early interventions: receiving antibiotics within three hours from initial 
sepsis onset, having blood specimen drawn for blood cultures, first lactic acid level 
within three hours, and second lactic acid level within six hours of sepsis presentation.  





 Abt<3h LA1_3h LA2_6h Cult<3h 
 
 
%                %                               %                % 
 Pre Yes 72 73 11 80 
No 28 27 89 20 
Post Yes 58 90 49 80 
No 42 10 51 20 
 
Figure IV.2.6Sepsis Guidelines Compliance. 
*(Abt<3h: antibiotic administered within three hours from presentation; LA1_3h and LA2_6: 
lactic acid collected within three and six hours respectively; Cult<3h: blood cultures were drawn 
within three hours). 
The first set of columns in Figure IV.2 represents the percentage of patients who 
either received or did not receive antibiotics within three hours from sepsis presentation 
in the pre-implementation group, followed by columns representing the post-
implementation group.  This distribution demonstrates a decrease in the percentage of 
patients who received antibiotics on time after implementation of the sepsis protocol.  On 
the contrary, the percentage of patients having lactic acid drawn within the first three and 
six hours increased after the new sepsis guidelines were put in place.  The timing of 
















Summary of outcomes.  Figure IV.3 is a graphical display demonstrating 
patients’ outcomes, specifically patients’ condition and functional status at the time of 
discharge, as well as discharge destination.  The chart shows a comparison of those 
elements between both groups. 
 
 
Figure IV.3.7Patients’ Outcomes After Discharge Chart – Comparing Both Groups.  
*(Dark gray bar = pre-implementation group; light gray = post-implementation group) 
The most important differences within Figure IV.3 are the variations between groups in 
patients’ mortality and health at the time of discharge from the hospital.  While mortality 
improved in the post-implementation group, there were considerably more patients whose 
health status worsened and who were consequently discharged to higher levels of care 
than before admission, whether it was a skilled nursing facility or home health agency 












Relationships between variables.  Multiple variables including age, LOS, 
patients’ outcomes at discharge, initial presentation, empiric antibiotic utilization, and 
waiting time for culture results were compared to each other to investigate the 
dependence between them.  The table below shows the matrix containing correlation 
coefficients between the possible pairs of variables (Table IV.10) accompanied by the 
scatter plot for visualization of the matrix (Figure IV.4). 
Table IV.10.16Correlation Coefficients among Both Groups Outcomes 
 
 
Age LOS OutcmFS IniPre AbtEmpD AbtEmp CulthrID CulFIN 
Age 1               
LOS -0.0245 1             
OutcmFS 0.2363 0.1369 1           
IniPres -0.0847 0.1153 0.3524 1         
AbtEmp#D -0.0924 0.8797 0.0385 0.0806 1       
AbtEmp# -0.0434 0.4931 0.0821 0.1367 0.5192 1     
Cult#hrID -0.0749 0.1005 0.1785 -0.0093 0.0835 0.1071 1   






Figure IV.4.8Correlation Coefficients among Both Groups Outcomes Scatter Plot. 
The scatter plot above  (Figure IV.4) corresponds to items included in the 
correlation coefficient matrix in Table IV.10. It demonstrates the strongest relationship 
between the LOS and the number of days empiric antibiotics were prescribed and 
between the LOS and the number of antibiotics prescribed.  The correlation between 
these variables is positive, meaning that the longer the LOS, the more empiric antibiotics 
were prescribed, and empiric antibiotics were received for a greater number of days.  
Table IV.10 shows a very strong positive correlation between the duration of treatment 
with antibiotics (AbtEmp#D) (0.8797) and the number of empiric antibiotics prescribed 
(AbtEmp) and the patient’s LOS (0.4931).  A positive but weaker relationship exists 
between patients’ ages and declined functional status (OutcmFS) at the time of discharge 
(0.2363), as well as patients’ condition at the time of initial presentation and discharge 















negligible.  (-0.0245).  A strong positive correlation exists between the number of empiric 
antibiotics prescribed and the duration of treatment with antibiotics (0.5192).  
Summary 
The focus of this project was retrospectively evaluating outcomes of patients with 
severe sepsis before and after implementing the Sepsis Bundle.  The results of this 
analysis apply to a predominantly Caucasian population sample in a treatment setting 
whose average age is 74 years old.  In this sample population, the impact of the 
mandatory sepsis protocol utilization on health outcomes was measured.  While 
substantial improvements were noted in some areas, a decline or no differences were 
noted in others.   
Mortality, the length of stay and health outcomes.  The mortality rate 
unsurprisingly has consistently been higher in the older population in both groups, but an 
overall considerable improvement in the mortality rate was noted after the sepsis 
protocols were implemented.  The duration of hospitalization for patients with sepsis, on 
average, was 0.7 days shorter.  Although the improved mortality rate could have been 
anticipated with new protocols, a decline of health outcomes of sepsis survivors was 
noted in the post-implementation group.  While LOS shortened after new guidelines were 
implemented, patients were discharged in a generally worse condition than those 
discharged prior to implementation.  An increased number of patients who survived 
sepsis were unable to return to their prior living arrangements, were discharged to nursing 
facilities instead, or required additional help at home.  Nevertheless, a substantial number 




Notably, among sepsis survivors, a considerably higher rate of readmission was recorded 
in the post-implementation group.  
Utilization of antibiotics and the protocol.  There was no noteworthy difference 
in antibiotic prescribing behaviors despite the fact that the post-implementation group’s 
average duration of hospitalization was shorter, and there were fewer patients in septic 
shock.  Whereas a higher percentage of patients had blood samples collected for lactic 
acid on time, unexpectedly fewer patients received timely initial antibiotics, and 
considerably fewer patients received AAT after the new Sepsis Bundle was initiated.  The 
blood culture collection times and wait time for blood culture results were not affected by 
the bundles.  
Other secondary findings.  While a decrease in MDR infections was noted, a 
major increase in healthcare acquired infections was seen, which occurred in the context 
of a higher readmission rate, with pneumonia being a leading cause for both readmissions 
and healthcare acquired infections.  An expected change in mental status often associated 
with sepsis was noted in a higher percentage among older patients in both groups.  
Finally, the results show a negligible relationship between age and LOS, a weak 
correlation between patients’ outcomes at discharge and age, and a weak correlation 
between LOS and outcomes at discharge, but a strong relationship between LOS and the 
number of antibiotics prescribed.  
The following chapter presents the discussion of findings outlined in this section, 







Sepsis is a serious and often fatal condition affecting millions of people nationally 
and across the globe, and despite advances in medicine and technology, the outcomes of 
patients affected with sepsis remain poor.  Patient outcomes not only depend on targeting 
the pathogen but on controlling the host response and reducing collateral organ and tissue 
damage.   
The incidence of sepsis has been increasing over past decades, primarily as a 
result of an aging population and a milieu of antimicrobial resistance and growing 
numbers of drug-resistant pathogens.  Wider use of immunosuppressive therapies, more 
accessible medical technology and interventions, and improved recognition of sepsis are 
other factors contributing to increased incidence and diagnosis of sepsis.  Sepsis 
guidelines have been evolving with changing recommendations derived from emerging 
trials and evidence-based research.  Efforts by healthcare organizations, government 
officials, and researchers to improve sepsis outcomes have been put forth in attempts to 
improve short-term and long-term survival.  While there is a general consensus that the 
optimal approach to sepsis management is early recognition and rapid interventions, the 
methods of initial resuscitation and hemodynamic monitoring remain controversial.  
This evidence-based project’s focus was to evaluate the effectiveness of the 




LOS, antibiotic utilization, and readmission rates before and after the protocol 
implementation in a community hospital in the coastal region of South Carolina.  In 
addition, this project’s goal was to assess whether implementing the mandated protocol 
actually influenced the timing of initiating early interventions.  The protocol is a 
mandatory quality improvement measure known as the Sepsis Early Management Bundle 
(SEP-1) that went into effect on October 1, 2015, to monitor the quality of sepsis care in 
hospitals nationwide.  The Sepsis Bundle is enforced by Medicare and adherence is 
measured by the timeliness of interventions.   
A retrospective data analysis was performed that included 158 patients’ medical 
records and compared patients’ outcome before and after implementation of the sepsis 
protocols. The results presented in this paper apply to a population sample whose average 
age is 74 years, predominantly Caucasian, and hospitalized with sepsis in the setting 
noted above.  In this sample population, the impact of mandatory sepsis protocol 
utilization on health outcomes was measured.   
The expectations for this project’s results were that outcomes of all aspects of 
sepsis care would improve with the use of the new sepsis protocols, including hospital 
length of stay (LOS) mortality, morbidity, and readmissions.  Additionally, it was 
anticipated that having introduced the mandated protocol for timely carrying out specific 
therapeutic approaches to sepsis management would improve the timeliness to initiation 
of these interventions.  The outcomes of this project showed that uniform improvement 
was not achieved.  Given the results of this project, it can be assumed that the guidelines 
have made an impact on some aspects of sepsis management and care and outcomes but 




Evaluation of Findings 
While results of this project do not necessarily infer causality, since the new 
protocol was made mandatory, considerably decreased mortality and reduced LOS were 
reflected in the post-implementation group as compared to the pre-implementation group.  
However, overall patients’ outcomes, including long-term morbidity such as a functional 
status at the time of discharge and readmissions rates had worsened.  Increased sepsis 
survival rates and shorter hospital stay after implementation of the sepsis protocol may, in 
fact, have contributed to these phenomena, because patients who would have otherwise 
died did survive, but did so with multiple negative health consequences. 
Results of this project are consistent with  evidence in literature (Delaney et al., 
2013; Mouncey et al., 2015; Yealy et al., 2014) in which no significant decrease in sepsis 
morbidity or mortality was demonstrated when patients were treated with a strict 
protocol-based resuscitation strategy over individualized care at the discretion of the 
treating physician.  Results showed a marked improvement in mortality, but overall 
worse health outcomes of those who survived sepsis.   
Mortality.  Major findings of this project included a considerably increased 
overall incidence of sepsis and septic shock survival rates after the new sepsis protocol 
was implemented.  In reviewed literature, one study since Rivers et al. (2001) EGDT 
trial, showed a marked reduction of mortality (Chelkeba, 2015).  This project showed a 
20 % decrease in mortality rates after the Sepsis Bundle protocol was in place (41% 
mortality in the pre-implementation group and 21% in the post-implementation group).  
Proportionally 10% fewer patients went into a septic shock and were critically ill, but 




compared to the pre-implementation group.  These findings can be attributed to the EMR 
alert module and mandated measures.  A substantial 28% decrease in the number of 
patients who were treated in the ICU, intubated and on a ventilator requiring respiratory 
support were recorded in the second group.  It can be speculated that faster recognition of 
sepsis by providers may have improved the mortality outcome by preventing more 
patients from progressing to septic shock and death.  Aside from the availability of more 
sophisticated treatments, the software generated sepsis alert, and the mandated measures, 
the potential explanation for the decreased mortality rate seen in this project’s outcomes, 
which is supported by the literature, may be multifactorial (Vincent et al., 2013).  
Uniformly increased incidence of sepsis observed nationwide might be attributed to 
increased awareness of sepsis, but also overdiagnosis.  Outcomes of this project show 
that after implementation of the new sepsis protocols in the community hospital, 
mortality rates were reduced and LOS shortened. 
The length of stay.  There are conflicting results in the literature that include 
questionable benefits of components of EGDT on LOS (Zhang et al., 2015); however, 
this project’s findings did not reflect it.  The average LOS for patients in this project 
decreased by a 0.7 day from pre-implementation to post-implementation time.  Although 
the 0.7-day reduction in hospital LOS seems trivial, it is substantial for quality and cost-
effectiveness of care.  Such a difference can contribute to lower patients' exposure to 
iatrogenic complications.  Furthermore, given the estimated costs associated with a day in 
the hospital, a 0.7-day reduction would translate into approximately $1,500 in savings for 




These findings can be associated with more efficient resource utilization and cost-
effectiveness of sepsis care.  This is likely to be attributed to improved sepsis awareness, 
earlier recognition, and prompt treatment.  Interestingly, on average, patients in the post-
implementation group were 4.7 years older and, hypothetically, the final results might 
show greater improvement if adjusted for age.  These findings alone are optimistic and 
encouraging, and if accurately owed to the protocol and enduring, they will likely 
contribute to substantial cost savings on the utilization of healthcare resources.  However, 
while mortality and LOS were substantially lower in the post-implementation group, the 
health outcomes of survivors were generally worse.   
Morbidity.  Although more patients survived sepsis, they often lost their 
independence and required long-term care or assistance at home.  A large percentage of 
sepsis survivors were unable to return home and were discharged to rehabilitation nursing 
facilities.  They were also more likely to be rehospitalized with recurrent infections.  
Older age and multiple comorbidities, disabling consequences of sepsis, as well as 
possible premature discharges (shorter LOS) may be attributed to sepsis survivors’ poorer 
health at the time of discharge preventing them from returning to their previous 
functional status. 
Sepsis has been associated with the development of at least one new physical 
limitation for survivors and with a 3-fold risk of developing moderate to severe cognitive 
impairment (Iwashyna et al., 2010).  Sepsis survivors report deterioration in the quality of 
life related to poor physical function and overall declined health (Turi & Ah, 2013).  In 
regards to morbidity, this project’s finding is consistent with the evidence in the literature 




treated for sepsis after protocols were put in place, as many as 64% of those who 
survived were discharged in lower functional status than prior to hospitalization, as 
compared to a 38% in the pre-implementation group.  Overall, this accounts for a 26% 
difference.  The decreased functional status in the second group appears to be explainable 
by higher survival rates.  While mortality in the same group was reduced by 20%, the 
survivors were likely left with more severe comorbidities as a result of sepsis.  
Interestingly, among the sepsis survivors in the post-implementation group whose 
functional status was worse at the time of discharge as compared to their functional status 
prior to admission, were on average 17 years older from those in the same group but 
whose status did not change.  There was an average 14 years difference in age between 
those patients with worse outcomes at the time of discharge in the post-implementation 
group than in the pre-implementation group was 14 years.  Age seems to be playing an 
important role not only in the incidence and mortality but also in the sepsis morbidity.  
Evidence in literature also shows that older age is an independent predictor of poor 
outcomes of sepsis (Martinal, 2006).  Persons older than 65 years of age with multiple 
comorbidities are at a higher risk for complications from infections than the general 
population.  Therefore, since worse outcomes in the post-implementation group could be 
explained by the higher survival rates as well as the overall older age, in the future, it 
could be useful to adjust for these differences in evaluating outcomes. 
Only 21% of patients in the post-implementation group were discharged to prior 
living arrangements compared to 23% in the pre-implementation group.  Patients in the 
post-implementation group were more frequently discharged to nursing facilities (19% in 




required home health or higher level of care (32% in contrast to 20% in the pre-
implementation group).  These patients were at higher risk of developing recurrent 
infections and further complications and were consequently more prone to 
rehospitalizations. 
Readmissions.  Hospitals are paid by Medicare, Medicaid and third party payers 
based on a formula that is specific to categories of diagnoses referred to as Diagnosis 
Related Groups (DRG’s) (Case Management Innovations, 2016).  The payments for the 
DRGs are predetermined, and the amount does not change regardless of the cost of care.  
Hospitals make profits by providing medically appropriate care and discharging patients 
in a timely manner, but at the same time keeping the costs below the amount of the DRG 
payment.  If the cost exceeds the payment, then the hospital will lose money in that case 
(Case Management Innovations, 2016).  Early discharges may be driven by high costs of 
acute care hospitalization, especially in intensive care units, and diagnosis- related 
recommended average LOS.  This project demonstrated disproportionally higher (47%) 
readmission rates in the post-implementation group as compared to the pre-
implementation group (17%).  This finding could be explained by patients being 
discharged too soon in an effort to control costs based on DRGs as indicated by the 
finding of a 9% reduction in LOS following implementation of protocols. 
Readmission rates among sepsis survivors increased substantially in the period 
measured after implementation of the sepsis protocol, from 17% to 47%.  High 
readmission rates are also documented  in the literature.  A retrospective cohort study of 
adults hospitalized with severe sepsis showed that 26% of severe sepsis survivors were 




mean cost of each readmission was $25,505 (Goodwin, Rice, Simpson, & Ford, 2015).  
In this project, of the 34 of the 72 patients with sepsis in the post-implementation group 
were readmitted.  These high readmission rates can lead to significant health care 
expenditures. Based on the average cost of readmissions, an estimated cost for 
readmissions in this setting could reach $870,000 including only those rehospitalized 
patients from the post-implementation group, as compared to an estimated $380,000 prior 
to the protocols being in place.  It should be taken into consideration, however, that the 
sepsis survivors in the second group were on average 4.7 years older and generally in 
poorer health. 
Patients presenting with sepsis often are also burdened with multiple 
comorbidities that may contribute to readmissions.  Under the Hospital Readmissions 
Reduction Program (HRRP), hospitals with excess readmissions for selected common 
diagnoses such as heart failure, myocardial infarction, pneumonia, chronic obstructive 
lung disease, and total hip or knee procedures are penalized up to 3% of all Diagnosis-
Related Group payments (Adamson, Bharmi, Dalal, & Abraham, 2015).  Severe sepsis 
readmission places a substantial burden on the healthcare system, with one in 15 and one 
in five severe sepsis discharges readmitted within 7 and 30 days, respectively (Donnelly, 
Hohmann, & Wang, 2015).  Hospitals pay a high price in penalties for readmissions.  
Hospitals and clinicians should be aware of this important sequela of severe sepsis 
(Donnelly, Hohmann, & Wang, 2015). 
Impact on protocol utilization.  Uniform improvement in utilization of the 
elements of the sepsis protocol and timeliness in initiating treatments were expected since 




preceding staff education and EMR updates to include sepsis alerts and prompts for 
protocol exploitation.  However, in this particular hospital, implementation of mandatory 
sepsis protocols did not improve intervention processes when the interventions were 
bundled together.  While individual elements of the bundle, such as drawing lactic acid, 
improved (on average, the first lactic acid sample collection within three hours of 
presentation improved 17%, and obtaining repeat lactate within six hours improved 
38%), unfortunately the timeliness of initiating antibiotics and the appropriateness of 
antimicrobial agent choice substantially deteriorated.  Moreover, with the new protocol in 
place, 49% of qualifying patients had the second lactic acid collected, which is a major 
improvement from 11% in the pre-implementation group, but still short of meeting 
standard protocol.  Initiation of appropriate IV fluids improved 7% in the post-
implementation group, and there was no difference (80% for both groups) between 
groups in drawing blood samples for cultures within three hours and prior to initiation of 
antibiotics.   
No clear explanation for these phenomena or associations with other variables 
could be established based on the results of data analysis in this project.  This protocol is 
positively influencing some aspects of sepsis care that could continue to improve with 
consistent use, but did not have much of an impact on the other aspects, such as the 
antibiotics utilization warranting the necessity for continued attention to this issue. 
Potentially, if better antibiotic utilization was possible in combination with the protocol, 
improvements in both mortality and morbidity could be achieved.  
Appropriateness of antibiotics utilization.  No significant change was seen in 




therefore there was no difference in the time until pathogens were identified.  No change 
in the current long waiting time for the culture results was anticipated since this is 
dependent on the hospital microbiology techniques and currently available technology, 
not on the new protocols.  A long waiting time for cultures results in a greater period of 
time that empiric, broad-spectrum antibiotics are utilized.  Moreover, the necessity to 
treat unidentified pathogens probably contributes to inappropriate antibiotic choices, 
which in turn encourages breeding resistant microbes and leads to an increase in multi-
drug resistant organisms.  The proportion of patients receiving AAT within the first three 
hours of sepsis onset decreased from 72% in the pre-implementation group to 58% in the 
post-implementation group.  Nearly 60% of patients in the post-implementation group 
received inappropriate antibiotics based on subsequent cultures results. 
This problem occurs similarly in this facility and across the nation in facilities that 
still use traditional methods to obtaining blood cultures results.  Current standard blood 
culture procedures consist of inoculating blood cultures bottles and monitoring for the 
growth of microorganisms.  Cultures are allowed to grow for 24 to 72 hours or longer, 
with subsequent subcultures and susceptibility to antibiotics testing results (Dekmezian, 
Beal, Damashek, Benavides, & Dhiman, 2015).  This process creates a considerable 
delay in initiating AAT from the initial collection of blood sample from the patient to 
delivery of the most appropriate antimicrobial treatment.  Newer technologies such as 
molecular diagnostics offer rapid identification and might be more efficient diagnostic 




Additional Findings  
The most common source of infection among adults is the lung or lungs, and 
pneumonia is the leading cause of sepsis nationwide.  While community-acquired 
pneumonia is the most frequently seen cause of sepsis, pneumonia can also be caused by 
a healthcare-associated infection that affects 1.7 million hospitalizations in the United 
States every year (Sepsis Alliance, 2016).  In this setting, the incidence of pneumonia in 
septic patients accounted for 50% of all sepsis causes in both groups, followed by urinary 
tract infections.  While a trivial decline in the incidence of MDR infection was recorded 
in the post-implementation group, there was a major increase in nosocomial infections, 
from 13% in the pre-implementation group to 36% in the post-implementation group.  
Pneumonia was seen as the most frequent reason for readmissions (56% in the post-
implementation group, compared to 15% in pre-implementation group), and 47% of those 
readmitted cases in the post-implementation group were associated with healthcare-
acquired pneumonia compared to 13% in the pre-implementation group.  Furthermore, of 
all deceased patients in both the pre-intervention and post -intervention groups, over 70% 
had a diagnosis of sepsis related to pneumonia.  These findings may be associated with 
increased survival rate but a poorer health status of survivors.  As more people survive 
sepsis, survivors are frequently struggling with serious health issues and they are prone to 
recurrent infections including pneumonia and sepsis.  
Another noteworthy unexpected finding was that 76% of septic patients also 
experienced a mental status change and those patients were on average 9.8 years older 
than those who did not experience acute mental status change associated with sepsis.  




was an association found between the number of empiric antibiotics prescribed and the 
LOS.  While the results cannot demonstrate causality, an assumption can be made that 
sicker patients did not respond to treatments as expected.  This is likely due to their more 
severe presentation, multiple comorbidities or immunocompromised status, thus the 
necessity to use a greater number of broad-spectrum antibiotics and longer 
hospitalization. 
Limitations 
One of the limitations of this study was that the overall sample size was small.  
This project involved patients with a mean age of 74.  In addition, patients in Labor and 
Delivery, Gynecology, Neonatal, and Pediatric wards were not included in this study, 
which could have influenced the results consequently yield different results as these 
individuals are very likely different from the participants chosen for this project.   
Post-implementation group participants were on average 4.7 years older which 
should be taken into consideration when comparing both groups.  Other confounding 
variables such as comorbidities may have also affected patients’ outcomes.  Since 
comorbidities were not included in the analysis, it is important to acknowledge that 
certain aspects of the participants’ health history may have affected the outcomes. 
With objectivity in data collection, potential measuring bias is low.  The access to 
the data in a retrospective review reduces the possibility of data collection, calculation or 
transcription errors.  Reliability can be established with accuracy of the tools used for 
data analysis that produces stable and consistent results, and validity with concepts 
accurately measured, although clinicians’ judgments and charting error cannot be 





Recommendations for Practice.  Results of this project suggest the need for 
improvement and innovative approaches to therapeutic and diagnostic methods that could 
facilitate earlier and more targeted interventions in this acute care hospital setting.  
Methods such as an antimicrobial stewardship program and rapid diagnostic technology 
can generate a better response to treatment, and potentially improve sepsis outcomes, 
save resources, and help to reduce MDR organisms.  Utilization of antimicrobial 
stewardship programs in inpatient settings has many benefits including improved patient 
outcomes, reduced adverse events such as Clostridium difficile infection, improvement in 
rates of antibiotic susceptibilities to targeted antibiotics, and optimization of resource 
utilization across the continuum of care (Calderwood et al., 2015).  Antibiotic 
stewardship programs are designed to implement guidelines and strategies to reduce 
antibiotic therapy to the shortest effective duration and increase both appropriate uses of 
oral antibiotics and the timely transition of patients from empiric to narrow spectrum 
targeted treatment.  The rising threat of antimicrobial resistance calls for rapid 
interventions with appropriate antimicrobial choices in sepsis treatment.   
In this setting, an interdisciplinary team dedicated to improving sepsis outcomes 
has been functioning, but a more robust, dedicated antimicrobial stewardship program 
would be beneficial in sepsis treatment as well as in attempts to combat antibiotic 
resistance, reinfections, and superinfections.  This stewardship program should be formed 
by a multidisciplinary team consisting of practicing clinicians, such as a hospitalist 
physician or a nurse practitioner, in collaboration with clinical pharmacists, clinical 




team should implement local strategies aimed at timely delivery of appropriate antibiotic 
therapy and timely de-escalation of empiric antimicrobials to narrower spectrum agents 
to improve outcomes and reduce the length of stay (Zhang Micek & Kollef, 2015).  Local 
strategies include collaboration between prescribers, pharmacists, and the entire team, 
and knowledge of antimicrobial susceptibilities of local bacterial isolates and resistance 
patterns to aid inappropriate empiric antibiotic selection.  The team should focus on 
prompt de-escalation of antibiotics based on cultures and sensitivities, and continue to 
explore innovative diagnostic technologies to allow earlier identification of pathogens. 
Rapid diagnostic testing in addition to conventional cultures combined with active 
antimicrobial stewardship program support has the potential for considerable 
improvement of sepsis management and patients’ outcomes (Barlam et al., 2016).  
Advantages to transition to rapid diagnostic technology such as molecular diagnostics 
would far outweigh any disadvantages including cost because this technology has the 
potential to have readily available, objective, and reproducible tests that guide specific 
treatment of infections (Wilson, 2015).  This project’s findings have to be integrated with 
collaborative sepsis team efforts to improve sepsis outcomes in this setting, and use data 
to validate best practice recommendation.   
Not all sepsis is created equal and a cookie cutter approach should not be used in 
the treatment approach.  Sepsis does not follow any algorithm and does not always 
progress in a predicted direction.  It is a misconception that sepsis always progresses 
gradually from sepsis to severe sepsis to septic shock; therefore, applying treatment 
templates would not always yield desired results.  There are no specific thresholds to 




condition is likely to fail in achieving uniform improvement in outcomes.  Enforcing 
obligatory standardized measures as templates to combat sepsis proved unsuccessful in 
many aspects of health outcomes, as shown in this project’s results and supported by the 
evidence-based literature.  Therefore, applying individualized clinical judgments to 
treatments such as aggressive fluid resuscitation and empiric antibiotic use, utilization of 
knowledge of individual patient’s history and local antibiogram make-up, in addition to 
evidence-based guidelines and protocols could result in the most favorable outcomes. 
Recommendation for Future Research.  Healthcare providers should anticipate 
seeing more sepsis cases in the future, partially as a result of better recognition of the 
condition, but primarily because people are now living longer with multiple 
comorbidities that are currently treatable.  Future studies are needed to identify 
approaches that can help the increasing older population of sepsis survivors to regain 
independence, return to prior living arrangements, and avoid rehospitalizations.  Again, a 
possible assumption can be drawn that a relationship exists between the rate of patients 
experiencing worse outcomes and readmissions.  Further analysis to estimate these 
associations and an intervention research related to discharge planning and prevention of 
readmissions would be beneficial to approaches to sepsis care. 
Whereas early diagnosis of sepsis and prompt initiation of antibiotic treatment 
improve survival, methods of initial resuscitation and hemodynamic monitoring remain 
controversial.  The nuances of aggressive fluid administration to all septic patients, and 
using vasopressors in early septic shock are divisive and not completely defined; 
therefore, more research is needed to further validate the most practical methods for 




direct evidence regarding safety and efficacy of early de-escalation of antimicrobial 
agents for adults with sepsis, severe sepsis or septic shock (Silva, Andriolo, Atallah, & 
Salomão, 2013).   
Sepsis in the elderly population is a common problem associated with 
considerable mortality and major consumption of healthcare resources.  These findings 
have implications for resource prioritization and provide insights for expanded scientific 
investigation (Martin et al., 2006).  A separate study utilizing sepsis data would be useful 
to evaluate sepsis outcomes given advanced age and pre-existing conditions.  In addition, 
a study researching altered mental status in elderly patients as a sign of impending sepsis 
would be helpful for healthcare providers in recognizing sepsis in this vulnerable 
population.  Since pneumonia was the leading cause of sepsis and death from sepsis, it 
could be beneficial to further investigate this problem, including for example 
investigation of pneumonia occurrences, preventative measures, and vaccination rates.  
Despite extensive research, advances in medicine and technology, knowledge of 
sepsis pathophysiology and complexity of its mechanisms is still limited, and finding 
optimal sepsis management strategies is challenging.  More research is needed addressing 
best evidence practice, as currently available therapies do not provide a cure.  Future 
study on more individualized approaches for better therapeutic response is needed 
(Iskander, et al., 2013). 
Recommendation for Policy.  Given the limitations to current guidelines as 
outlined in this project, recommendation for the general policy is to consider updating 
sepsis definitions; specifically, clarifying SIRS and severe sepsis definitions before 




physiological criteria and causative microorganism detection based on culture assays.  
This results in diagnosis and treatment delays, and improper use of antibiotics.  Since 
symptoms of sepsis can be vague especially in its early stage, it is difficult, if not 
impossible to denote the exact time of initial sepsis onset, which is an important point of 
reference in current treatment guidelines and a marker for quality measures.  This may 
lead to inappropriate prescribing of antibiotics in order to comply with the measure.   
The key to effective treatment of sepsis is fast detection and rapid initiation of 
treatment.  Recommendations for policy improvement for this hospital include 
consideration to establishing a Code Sepsis call in addition to current sepsis guidelines, 
and a medical sepsis team dedicated to the rapid recognition and timely initiation of 
appropriate treatments.  Ongoing staff education is fundamental because tight 
coordination and communication are needed among the entire team.  The risk of having 
Code Sepsis is that the code can inadvertently be called to patients who do not have 
sepsis but meet severe sepsis criteria, and unintentionally captured by the sepsis measure 
matrix. Consequently, this raises concerns about antibiotic overuse.  Therefore, other than 
simply accepting the risk, it is imperative to have a policy in place regarding appropriate 
antibiotic use and de-escalation once deemed safe for patients and coordinated by 
designated antimicrobial stewardship program team.   
Despite an emphasis on the appropriateness of antibiotic administration, 
measuring effects of antibiotics’ appropriateness and effectiveness against pathogens is 
only possible with known culture and sensitivity data, is not usually available for 24 to 96 
hours (Puskarich et al., 2011).  Therefore, the antimicrobial stewardship team needs to be 




investing in the innovative diagnostic technology to allow earlier identification of 
pathogens and, in the spirit of antimicrobial stewardship, better-targeted antibiotic 
treatment.   
Hospital administration should also consider assessing discharge practices to 
evaluate for potential premature discharges.  While each additional day of hospital stay 
over the recommended LOS based on DRG is not cost effective as it falls outside of the 
bundle payments for the hospital, readmissions can be much more expensive and 
premature discharges can have serious negative health consequences for patients.   
Based on results of this project, drawing the second lactic acid was especially 
deficient in both the pre- and post-implementation measures.  Therefore, another 
recommended innovation, in order to improve compliance with sepsis guidelines, 
includes building into the existing sepsis power plan in the EMR software an additional 
automated reflux order prompting providers to repeat a lactic acid level for qualified 
patients.   
Standardizing sepsis care proves to be challenging.  Proportionally more 
diagnoses of severe sepsis were made after the protocol went into effect.  This could be 
attributed to overdiagnosis based on the protocol’s controversial criteria for SIRS and 
severe sepsis.  The concepts of SIRS and severe sepsis with their low specificity and high 
sensitivity can lead to misinterpretations and discrepancies in reported incidence and 
observed mortality. Therefore, data collected retrospectively for the quality measure 
could inadvertently include patients that were perhaps not septic at all, thus incorrectly 
showing more survivors among patients labeled with severe sepsis.  Hospitals not treating 




on the mandatory quality improvement measure known as the Sepsis Early Management 
Bundle (SEP-1).  Hospitals will likely be struggling with this measure; therefore, the 
severe sepsis definition should be clarified for the purpose of the accuracy of data 
collection for quality measures.  In the case of severe sepsis (SIRS with infection and 
evidence of organ damage), it should be made clear that the organ dysfunction is a new 
condition related to current infection, and quality procedures should leave room for 
individual clinical judgment.  Measures of sepsis guideline effectiveness should focus on 
not only immediate results and improved mortality rates, but also long-term debilitating 
effects affecting survivors.  Both short-term survival and long-term morbidity, including 
a return to function, should be considered as important outcomes. 
Conclusions 
This report summarizes the retrospective review of effects of sepsis protocols on 
health outcomes, particularly mortality, hospital LOS, morbidity, readmissions, 
antibiotics utilization, and the protocol’s impact on the early initiation of treatment in a 
South Carolina community hospital.  This project showed that implementation of 
mandatory sepsis protocols did not uniformly improve intervention processes.  Moreover, 
results did not clearly demonstrate that the Sepsis Bundle interventions improved overall 
outcomes.  The mortality and LOS improved, but health outcomes of survivors did not.  
While the utilitarian goal to reduce mortality is reasonable, the increasing numbers of 
sepsis survivors are at high risk for worse long-term negative health outcomes.  These 
patients may be discharged into nursing facilities from the hospital prematurely and in 




remaining in long-term care homes and prone to readmissions because of the debilitating 
nature of sepsis.  
This project is an exploration of a PICO question that addresses a current problem 
with sepsis management in the South Carolina’s community hospital, which is relevant to 
DNP practice.  The methodology described above is an attempt to determine the impact 
of the newest Sepsis Management Bundle on patient outcomes and feasibility to 
recommend practice change in this facility.  Sepsis is common in hospitals and its 
outcomes are frequently fatal.  Prompt recognition and effective treatment are serious 
issues that this and other hospitals are facing across the nation.  This project offers the 
stakeholders an educational opportunity to gain new knowledge regarding the severity of 
the problem of sepsis and its management among inpatient adults in this hospital, and the 
effects of the current sepsis protocol on patients’ outcomes. 
Evidence in the literature supports the conclusion that enforcing protocols alone is 
unlikely to bring anticipated results.  An open-minded approach is needed to sepsis 
interventions, with criteria and guidelines that allow room for clinical judgment.  Sepsis 
guidelines should focus not only on survival but also on long-term consequences for 
survivors and their return to their prior level of functioning.  Administration of 
appropriate antibiotics may be the single most important factor in reducing both long- 
and short-term morbidity and mortality from sepsis (Marik, 2014).  Antibiotic treatment 
efficiency can be best achieved with robust antibiotic stewardship programs and can be 
improved with rapid diagnostic technology.  Nevertheless, no single sepsis-specific 
treatments exist and core management of patients still relies mainly on early recognition, 




identification of causative pathogens, and initiation of appropriate antibiotic treatment are 
paramount approaches to sepsis, but the protocol’s interventions remain a source of 
controversy, and timely recognition remains a challenge for healthcare professionals.  
Although the Sepsis Bundles have already been enforced by CMS, new clinical trials are 
needed to update sepsis criteria and definitions, to evaluate the effect of interventions on 
short and long-term health outcomes and determine best evidence-based approaches.  
As the knowledge of sepsis pathobiology improves and technology continues to 
advance, the recommendations for sepsis treatment will continue to evolve and change 
based on emerging new evidence as they have over past decades (Lopez-Bushnell, 
Demaray, & Jaco, 2014).  This quality improvement project might serve an introductory 
work in developing a research study that can be generalizable to other settings and more 
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positive blood cultures 
were included, randomized 
to three groups: control, n 
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Intervention group had 
shorter time to microbe 
ID (1.3 hr) vs. control 
(22.3 hr) (P < .001) and 
decreased broad-spectrum 
antibiotic use (control 56 
hr, rmPCR 44 hrs, 
rmPCR/AS 45 hr; P = 
.01) and increased 
narrow-spectrum (control 
42 hr, rmPCR 71 hr, 
rmPCR/AS 85 hr; P = 
.04) use, control 24 hours, 
rmPCR 6 hours, P = .04).  
Groups did not 
differ in 
mortality, LOS, 
or cost. rmPCR 


























analysis of RCT 
IA 
Trial included RCTs, total 
of nine trails comprising 
4783 patients that 
compared EGDT with 
usual care 
Six studies low risk 
of bias, remaining 
studies unknown 
risk of bias. None of 
the these included 
nine trials were 
double blinded as it 
is difficult to blind 
the clinicians in 
such difficult 
situations, and we 
believe that such act 
did not influence the 
outcomes of 
interest. 
The study found that 
EGDT significantly 
reduced mortality in a 
random-effect model (P = 
0.008); significantly 
reduced mortality in low 
to middle economic 
income (P = 0.002) 
compared to those in 
higher income countries 
(P = 0.28).On the other 
hand, patients receiving 
EGDT had longer length 
of hospital stay compared 
to the usual care (P = 
0.07); 






































Designed to test the EGDT 
hypothesis as compared to 
usual care, this trial was 
conducted at 51 tertiary 
care and non-tertiary care 
metropolitan and rural 
hospitals across Australia 
and New Zealand. 796 
patients were assigned to 
the EGDT group and 
received care based on the 
original EGDT 
resuscitation algorithm, and 
804 control patients 
received usual care at the 
discretion of the treating 
physician 
Trial could not be 






patients in the EGDT 





However, despite an 
increased rate of 
aggressive therapy, there 
was no significant 
difference in 28- and 90- 
day mortality, hospital 
mortality, organ support 





not offer a 
survival 
advantage over 































The study evaluated 
whether lactate clearance 
could be an equally 
effective measure of tissue 
oxygen delivery and an 
alternative to central 
venous oxygen saturation 
(ScvO2) measurement. 
Included in data analysis 
were 294 patients, 147 
patients were assigned to 
the control ScvO2 group, 
and 147 to the lactate 
clearance group.  
None identified Study results 
demonstrated no 
difference in frequency of 
any treatments 
administered during the 
six-hour resuscitation 
period and throughout the 
initial 72 hours of 
hospitalization to 
maintain high compliance 
with the target goals 
(CVP, MAP, and ScvO2, 






































Trial conducted in 56 
hospitals in England from 
February 16, 2011, to July 
24, 2014, enrolled 1260 
patients, 630 in EGDT 
group and 630 in usual care 
Interventions could 
not be blinded, but 




Since lower than 
anticipated death 
rate, this study 
outcome may not 
apply to settings 
with higher 
mortality  
Mortality was 29.5% in 
EGDT group and 29.2% 
in the usual care, and no 
significant difference in 
any other outcomes 
including health-related 
quality of life, or rated in 
serious adverse events. 
Moreover, on average, 
EGDT was associated 










mortality is a 
trend in recent 
years, and many 
aspects of sepsis 
care have 
evolved since 
Rivers et al. 
























From October 5, 2008, to 
April 31, 2014, a trial was 
conducted in 51 tertiary 
and non-tertiary 
metropolitan and rural 
hospitals 
 
Trial could not be 




In critically ill patients 
presenting to the 
emergency department 
with early septic shock, 
EGDT did not reduce all-
cause mortality at 90 days 




guidelines as a 
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11 included studies, 16,178 
patients were evaluable for 
antibiotic administration 
timing from emergency 
department triage. The 
study sought to determine 
the association between 
timing of antibiotic 
administration and 
mortality in severe sepsis 
and septic shock. 
None identified Contrary to Kumar et al. 
(2006) study, this study 
found no increased 
mortality in the pooled 
odds ratios for each 
hourly delay from less 
than 1 to more than 5 









within 3h of ED 
triage or within 









as measures of 
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Care for Early 





The study evaluated 
whether all aspects of the 
original EGDT protocol 
(by Rivers, 2001) were 
necessary. 31 academic 
EDs across the United 
States participated, in this 
study. 1,341 patients 
meeting criteria for severe 
sepsis and septic shock 
were included in data 
analysis; 439 patients 
received EGDT according 
to the original protocol, 
456 control patients 
received standard care, and 







and outside of the 
United States is 
uncertain, more 
evidence is needed. 
Despite more aggressive 
therapy in the protocol-
based groups, there was 
no significant difference 
in 60- and 90-day 
mortality between the 
treatment groups; no 
significant differences in 
the incidence and 
duration of 
cardiovascular or 
respiratory failure, LOS, 
in sepsis morbidity or 
mortality when patients 
were treated with a strict 
protocol-based 
resuscitation strategy 
over usual care at the 






of fluid and 
vasoactive 





































analysis of RCTs 
IA 
10 RCTs included from 
2001 to 2014 involving 
4,157 patients 
Among all RCTs, 
none of them were 
double-blinded. 
However, blinding 
of patients and 
clinicians was 
extremely difficult 
in these studies to 
evaluate a complex 
intervention such as 
EGDT protocol, and 
the authors judged 
that the primary 
outcome (mortality) 
is not likely to be 
influenced by lack 
of blinding 
EGDT was associated 
with a higher mortality 
rate in comparison with 
the early lactate clearance 
group (P = 0.02). In the 
first 6h EGDT received 
more inotropic agents 
(P = 0.04), fluid 
administration (P = 0.05), 
and red cell transfusion 
(P < 0.01). There were no 
significant differences in 
length of ICU stay 










EGDT and the 
control group 
Gu, W. J., 
Wang, F., 
Bakker, J., 
Tang, L., & 





13 trials involving 2,525 





cannot be made 
given variable 








benefit was seen only in 
the subgroup of early 
GDT within the first 6 
hours 


























R., ... & 
Jones, A. E. 
(2011). 
Pre-planned 









Study was designed to 
assess the non-inferiority of 
lactate clearance versus 
central venous oxygen 
saturation, evaluated adult 
septic patients in 3 urban 
EDs in the United States 
Non-blinded. Only 
able to draw 
conclusions 
regarding 
associations and not 
causation. 
The study found no 
increase in mortality with 
each hour delay to the 
administration of 
antibiotics after triage. 
However, delay in 
antibiotics until after 
shock recognition was 








not change with 










Nine studies compared 
EGDT with control care, 
and 5202 severe sepsis and 




controlled trials are 
needed to determine 
the effects 
A non-significant trend 
toward reduction in the 
longest all-cause 
mortality was observed in 
the EGDT group 





of firm evidence 
for a beneficial 








Yu, H., Chi, 
D., Wang, 





5 studies enrolled 4303 
patients with 2144 in the 
EGDT group and 2159 in 
the control group. The trial 
was conducted to 
determine whether patients 
with severe sepsis or septic 
shock could benefit from 
the EGDT protocol 
recommended by SSC 
Guidelines. 





in the negative trials 
(ProCESS, ARISE, 
and ProMISe) might 
bias the results and 
diminish the 
treatment effect of 
EGDT 
Overall, there were slight 
decreases in mortality 
within 28 days, 60 days 
and 90 days in the 
random-effect model in 
patients with severe 
sepsis or septic shock 
receiving EGDT 
resuscitation. However, 




Data from five 










of bias to 
determine if 















The study included 263 
patients who met criteria 
for severe sepsis and septic 
shock; 130 subjects 
received EGDT and 130 
controls received standard 
care. Study  examined the 
effects of Early Goal 
Directed Therapy (EGDT) 
to evaluate the efficacy of 
the therapy prior to 




threat due to single 
center study. 
Potential bias 
resulting from the 
direct influence 
of the investigators 
on the care of the 
patients 
in the treatment 
group 
In-hospital mortality was 
30.5% in the group 
assigned to EGDT, 
compared to 46.5% in the 
standard therapy group in 
short-term treatment 
(p=0.009). Mortality was 
33.3% in EGDT group 
(p=0.01) compared to and 
49.2% in control group in 
28 day mortality rate , 
and 44.4% EGDT group 
(p=0.03) to 56.9% 
standard therapy groups 
in 60-day long-term 












stages of sepsis 
while patients 
are still in ED 
and prior to 
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analysis of RCT 
IIB 
The study sought to 
measure the treatment 
effect of quantitative 
resuscitation on mortality 
from sepsis. Nine RTCs 
were included and total 





study rather than 
within-study 
comparisons. 







The study demonstrated a 
survival benefit afforded 
by quantitative 
resuscitation to treat 
sepsis at or near the time 
of recognition. There is 
lost if the intervention is 
initiated late. Study 
demonstrated support for 






















Multivariable model was 
used in this study of 243 
adult patients with severe 
sepsis and septic shock to 
assess outcome differences 
between the serial lactate 
and no serial lactate cohorts 
to assess clinical outcomes 
Small sample. This 
is a retrospective 
study which limits 
causal inference 
Lack of serial lactate 
monitoring was 
independently associated 
with mortality. Serial 
lactate monitoring is 
associated with an 





outcomes in ED patients 








lactate levels to 
normal, is a 
generalizable 
resuscitation 












Article reviews the 
haemodynamic 
changes associated with 
sepsis and provides an 
approach to fluid 
management 
 Sepsis is primarily not a 
volume-depleted  state 
and most septic patients 
are poorly responsive to 
fluids that are sequestered 
in the tissues, resulting in 




approach to fluid therapy 
is prudent, would likely 
reduce the morbidity and  


































The study sought to 
determine how hospital 
mortality was influenced 
by combined use of these 
two treatments, and 
retrospectively analyzed 
data from 24 ICUs in three 
countries.  







Results showed that 
fluids and vasoactive 
agents had strong, 
interacting associations 
with mortality (p < 
0.0001).  
Mortality was lowest 
when vasoactive agents 
were begun 1–6 hours 
after onset, with more 
than 1 L of fluids in the 
initial hour after shock 
onset, more than 2.4 L 
from hours 1–6, and 1.6–
3.5 L from 6 to 24 hours.  
The lowest mortality rates 
were associated with 
starting vasoactive agents 
1–6 hours after onset  
the focus during 


























cohort study  
IIIB 
From January 2008 to 
December 2012, the study 
was conducted to assess the 
timing of AAT, included 
1058 subjects in 1200-bed 
academic hospital. Timing 
of appropriate antibiotic 
therapy was determined 
from blood culture 
collection time to the 
administration of the first 
dose of antibiotic therapy 
with documented in vitro 
susceptibility against the 
identified pathogen 
Retrospective study 
which limits causal 
inference 
The median time from 
blood culture collection 
to the administration of 
AAT was 6.7 hours The 
time AAT is an 
independent determinant 
of postinfection ICU 
LOS; (p < 0.001) and 
postinfection hospital 
LOS increased per hr of 
time to deliver AAT; (p < 
0.001). Other indep. 
determinants increasing 














































Review of medical records 
of 2,731 adult patients with 
septic shock in fourteen 
intensive care units (four 
medical, four surgical, six 
mixed medical/surgical) 
and ten hospitals (four 
academic, six community) 
in Canada and the United 
States. Study sought to 
determine the prevalence 
and impact on mortality of 
delays in initiation of 
effective AAT from initial 




may have played a 
role in outcomes 







Among 2,154 septic 
shock patients (78.9% 
total) who received 
effective antimicrobial 
therapy only after the 
onset of recurrent or 
persistent hypotension, a 
strong relationship 
between the delay in 
effective antimicrobial 
initiation and in-hospital 





















APPENDIX B: EVIDENCE LEVEL AND QUALITY GUIDE 
Table B.1.18Evidence Level and Quality Guide 
 
Evidence Levels Quality Guides 
Level I 
Experimental study, randomized 
controlled trial (RCT) 
Systematic review of RCTs, with 
or without meta-analysis 
 
A High quality: Consistent, generalizable results; 
sufficient sample size for the study design; adequate 
control; definitive conclusions; consistent 
recommendations based on comprehensive literature 
review that includes thorough reference to scientific 
evidence 
B Good quality: Reasonably consistent results; 
sufficient sample size for the study design; some control, 
fairly definitive conclusions; reasonably consistent 
recommendations based on fairly comprehensive 
literature review that includes some reference to 
scientific evidence 
C Low quality or major flaws: Little evidence with 
inconsistent results; insufficient sample size for the study 
design; conclusions cannot be drawn 
Level II 
Quasi-experimental study.  
Systematic review of a 
combination of RCTs and quasi-
experimental, or quasi-





Systematic review of a 
combination of RCTs, quasi-
experimental and non-
experimental studies, or non-
experimental studies only, with or 
without meta-analysis 
Qualitative study or systematic 







Opinion of respected authorities 
and/or nationally recognized 
expert committees/consensus 
panels based on scientific 
evidence 
Includes: 
 Clinical practice guidelines 
 Consensus panels 
 
A High quality: Material officially sponsored by a 
professional, public, private organization, or government 
agency; documentation of a systematic literature search 
strategy; consistent results with sufficient numbers of 
well-designed studies; criteria-based evaluation of overall 
scientific strength and quality of included studies and 
definitive conclusions; national expertise is clearly 
evident; developed or revised within the last 5 years 
B Good quality: Material officially sponsored by a 
professional, public, private organization, or government 
agency; reasonably thorough and appropriate systematic 
literature search strategy; reasonably consistent results, 
sufficient numbers of well-designed studies; evaluation of 
strengths and limitations of included studies with fairly 
definitive conclusions; national expertise is clearly 
evident; developed or revised within the last 5 years 
C Low quality or major flaws: Material not sponsored 
by an official organization or agency; undefined, poorly 
defined, or limited literature search strategy; no evaluation 
of strengths and limitations of included studies, 
insufficient evidence with inconsistent results, conclusions 
cannot be drawn; not revised within the last 5 years. 
Level V 
Based on experiential and non-
research evidence 
Includes: 
 Literature reviews 
 Quality improvement, 
program or financial evaluation 
 Case reports 
 Opinion of nationally 




A High quality: Clear aims and objectives; consistent 
results across multiple settings; formal quality 
improvement, financial or program evaluation methods 
used; definitive conclusions; consistent recommendations 
with thorough reference to scientific evidence 
B Good quality: Clear aims and objectives; consistent 
results in a single setting; formal quality improvement or 
financial or program evaluation methods used; reasonably 
consistent recommendations with some reference to 
scientific evidence 
C Low quality or major flaws: Unclear or missing aims 
and objectives; inconsistent results; poorly defined quality 
improvement, financial or program evaluation methods; 
recommendations cannot be made 
Literature Review, Expert Opinion, Case Report, 
Community Standard, 
Clinician Experience, Consumer Preference: 
A High quality: Expertise is clearly evident; draws 
definitive conclusions; provides scientific rationale; 
thought leader(s) in the field 
B Good quality: Expertise appears to be credible; draws 
fairly definitive conclusions; provides logical argument 
for opinions 
C Low quality or major flaws: Expertise is not 
discernable or is dubious; conclusions cannot be drawn 





APPENDIX C: MICROORGANISMS ASSOCIATED WITH RISK OF MORTALITY 
Table C.1.19Type of Organisms Associated with Risk of Mortality 
 
Organism Frequency (%) OR (95% CI) 
Gram-positive  46.8  
Staphylococcus aureus  20.5  0.8 (0.6–1.1) 
MRSA  10.2  1.3 (0.9–1.8) 
Enterococcus  10.9  1.6 (1.1–2.3) 
S. epidermidis  10.8  0.9 (0.7–1.1) 
S. pneumonia  4.1  0.8 (0.5–1.4) 
Other  6.4  0.9 (0.7–1.2) 
Gram-negative  62.2  
Pseudomonas species  19.9  1.4 (1.2–1.6) 
Escherichia coli  16.0  0.9 (0.7–1.1) 
Klebsiella species  12.7  1.0 (0.8–1.2) 
Acinetobacter species  8.8  1.5 (1.2–2.0) 
Enterobacter  7.0  1.2 (0.9–1.6) 
Other  17.0  0.9 (0.7–1.3) 
Anaerobes  4.5  0.9 (0.7–1.3) 
Other bacteria  1.5  1.1 (0.6–2.0) 
Fungi   
Candida  17.0  1.1 (0.9–1.3) 
Aspergillus  1.4  1.7 (1.0–3.1) 
Other  1.0  1.9 (1.0–3.8) 
Parasites 0.7  1.3 (0.5–3.3) 
Other organisms  3.9  0.9 (0.6–1.3) 
OR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant S. aureus (Mayr, Yende, & 





APPENDIX D: PDCA TEMPLATE AND PDSA WORKSHEET 
 
Figure D.1.9PDCA Template 







Figure D.2.10PDSA Worksheet 




APPENDIX E: DATA COLLECTION ITEMS 
Table E.1.20Data Collection Items 
Patient’s unique # (PtID) 
1,2,3,4,5,6,7,8,9… 
Appropriate ABT for Dx (AbtAppr)  
1 yes;                                 
2 no 
Age:  
# number of years  
IVF (IVF1-3) 
1 yes 30 ml/hr;        
2: no;        
3: contraindicated 
Gender   
1 male 
2 female  
Lactic Acid 1
st
 drawn w/in 3 hrs  (LA1_3h) 
1-yes,  
2 - no 
Race (Race1-6)  
1 Caucasian 
2 African American 
3 Asian 
4 Hispanic 
5 Native American;                
6 Other 
Lactic Acid sample #1 > 2 (LA1>2) 
1 yes 
2 no 
0 not done 
Repeat Lactic Acid 6 hrs (LA2_6h)  
1 yes 
2 no;                                   
0 N/A, not indicated  
LOS (Length of stay in # of days) 
# number of days spent in hospital 
 Blood Cultures (Cult<3h) (0-2) 
1 yes  <3h cultures drawn prior to 
administration of antibiotics 
2 no >3h blood cultures drawn/ or not before 
antibiotics 
0 -- Blood cultures were not done 
Outcomes  
Mortality (OutcMort) 
1 yes - Alive 
2 no - Deceased 
Functional status at discharge (OutcFS 0-3)  
0 same as pre-hospitalization 
1 worse, lost independence, needs more help, 
declined  
2 better than prior to hospitalization 
3 Deceased 
 Cultures (Cult#hrID) 
# number of hr pathogen group described or 
identified in sample  
Cultures (Cult#hrFIN) 
# number of hours final results of cultures 




 Discharge (D/C1-6) Discharge to:  
1 Prior living situation/home, independent 
2 Extended care facility/ SNF (new) 
3 Deceased 
4 Higher level of care (transfer to another 
hosp) 
5 Home w/ Home Health/caregivers/more 
help 
6 Discharged to Hospice 
Culture results: (CR0-5)  
0 negative cultures 
1 positive cultures: bacteria 
2 positive cultures: fungal 
3 positive cultures: viral 
4 positive cultures other 
5 unknown 
 C-diff  
1 yes 
2 no 
Immune status impairing diagn (ImDx0-2)  
0 – Immunocompetent (ImDx0) 
1 – Immunocompromised with one Dx likely 
affecting immune status  
2 – Immunocompromised with two or more 
Dx likely affecting immune status 






6 CNS fluid 
7 Pleural fluid 
8 Peritoneal;                               9 other 
Dx: (ImmDx0-7) 
0 None (ImDx0)  
1 Ca, (ImDx1)  
2 transplant/ spleenless (ImDx2)  
3 COPD, (ImDx3) etc..  
4 DM 




Gram negative pathogen (Gn1-12)  
1 E-coli 
2 Klebsiella pneumoniae 
3 Enterobacter 
4 Acinetobacter 








Gram positive pathogen (G(+)1-13)  
1 Staph aureus MSSA  
2 Staph aureus MRSA 
3 Staph coagulase (-) epidermidis 
4 Streptococcus pneumococcus 
5 Strep viridians 
6 Strep group A pyrogens 
7 Corynebacterium 
8 Enterococcus faecium 






0 None (Cmb0)  





6 ETOH chronic 
7 Readmitted, recurrent infection 
8 h/o sepsis 
9 h/o MDR infection 
10 Underlying dementia 








Initial presentation (IniPres1-3) 
1 Sepsis 
2 Severe Sepsis 
3 Septic shock 





1 Viral (OthVir 
2 Fungal (OthFung) 
Acute mental status change (AMS) 
1 yes 
2 no 
Sepsis cause (SCs1-13)  
1 Pneumonia (SCs1) 
2 UTI (SCs2) etc  
3 Pyelonephritis 
4 GI/intraabdominal 
5 Skin (Cellulitis) 
6 Post- Surgery complications 
7 Wound infection 
8 Meningitis 
9 other 









5 ESBL  
6 Other 
Hospital course (Hcr1-3) 
 1 ICU w/ pressors and mechanical ventilation 
 2 ICU w/o mechanical ventilation 
 3 no pressors, no vent, PCU/other 
Antimicrobial class (Ab1-21) 
1 – PCN (Ab1)  
2 – Extended PCN (Zosyn) (Ab2)  
3 – B-lactamase inh PCN (Unasyn) 
(Ab3)etc.. 
4 – Cephalosporin 1
st
  
5 – Cephalosporin 2
nd
  
6 – Cephalosporin 3
rd
  
7 – Cephalosporin 4
th
  
8 – Cephalosporin 5
th
 (Ceftaroline) 
9 – Fluoroquinolone 2
nd
 (Cipro) 
10 – Quinolone 3
rd
 (Lavo/Moxi) 
11 – Macrolides 
12 – Tetracycline  
13 – Sulfonamides 
14 – Carbapenems 
15 – Monobactam (Aztreonam) 
16 – Glycopeptide (Vanc) 
17 – Liptopeptide (Cubicin/Dapto) 
18 – Oxazolidinone (Zyvox/linezolid) 
19 – Lincosamide (Clindamycin) 
20 – Other antibiotics (Tigecycline) 
21 – Nitroimidazole (Flagyl) 
Progression of Sepsis 
1 yes - worse: severe sepsis progressed to 
septic shock despite tx (or death) 
2 no – better, status did not deteriorate during 
hospitalization 
Treatment w/ initial Antibiotics (Abt<3h) 
1 Yes:  <3h from time 0 first antibiotic 
administered* (not ordered) 
2 No:   >3h from time 0 first abt 
administered* 
Days on Abt (AbtEmp#D)  
# number of days on empiric antibiotics 
Number of empiric antibiotics (AbtEmp#) 
#number of prescribed antibiotic 
ABT Deescalated: (AbtDesc)  








Other Treatment (OthTx 1-3) 
1 – Antifungal (fluconazole)  
2 – Antiviral   




6 Abscess  
7 Renal failure  
8 Respiratory failure  
9 Multisystem failure  
10 Cardiac complications  
11 Other 
Potential costs savings   
On LOS (Sav$LOS) 
1 yes;  
2 no 
On ABT de-escalation  (Sav$Abt) 
1 yes; 
2 no 




Readmitted w/in 30 days (Readm30)  
1 yes; 
2 no 






APPENDIX F: CONGRESSIONAL BILL 
 
 




APPENDIX G: IRB STATEMENT 
 
 
Figure G.1.12IRB Statement 
A screenshot of the email received from the Safety Officer /Director of Risk Management as per 
the Compliance officer.
 
MONIKA MROZ <monikamroz1@gmail.com> 
 
Statement about IRB 
 
GASIOROWSKI, BETH <beth.gasiorowski@tenethealth.com> 
Wed, May 4, 2016 at 8:04 
AM 
To: MONIKA MROZ <monikamroz1@gmail.com> 
Per our Compliance Officer: 
  
Beth: 
I don't have any objections to this audit, as long as, all data is scrubbed of any patient 
identifiers. Reading her proposal, it appears patient's PHI is not necessary. 
 
Jim Riley, RN 
Hospital Compliance Officer 





Director of Risk Management/Patient Safety Officer 
Hilton Head Hospital 
25 Hospital Center Boulevard 
Hilton Head, South Carolina 29926 
Office (843) 689-8412 
Pager (843) 525-8789 
Beth.gasiorowski@tenethealth.com 
CONFIDENTIALITY NOTICE:  This e-mail transmission, including attachments, if any, is intended for 
use only by the address(s) named herein and contains confidential and/or privileged information.  
Any unauthorized review, use, disclosure or distribution is strictly prohibited.  If you are not the 
intended recipient, please notify the sender immediately by reply e-mail or telephone and delete 
the original and destroy all electronic and other copies of this message.  If you are the intended 
recipient but do not wish to receive communications through this medium, please so advise the 
sender immediately. 







APPENDIX H: PERMISSION TO USE IMAGES  
 
Figure H.1.13Permission to use images 





APPENDIX I: ICD-10-CM DIAGNOSIS CODES 
Diagnosis codes included in reports: 
 Other sepsis A41 
 postprocedural sepsis (T81.4) 
 sepsis following immunization (T88.0) 
 sepsis following infusion, transfusion or therapeutic injection (T80.2-) 
 sepsis (due to) (in) actinomycotic (A42.7) 
 sepsis (due to) (in) anthrax (A22.7) 
 sepsis (due to) (in) candidal (B37.7) 
 sepsis (due to) (in) Erysipelothrix (A26.7) 
 sepsis (due to) (in) extraintestinal yersiniosis (A28.2) 
 sepsis (due to) (in) gonococcal (A54.86) 
 sepsis (due to) (in) herpesviral (B00.7) 
 sepsis (due to) (in) listerial (A32.7) 
 sepsis (due to) (in) melioidosis (A24.1) 
 sepsis (due to) (in) meningococcal (A39.2-A39.4) 
 sepsis (due to) (in) plague (A20.7) 
 sepsis (due to) (in) tularemia (A21.7) 




Additional codes included: 
 A41 Other sepsis 
 A41.0 Sepsis due to Staphylococcus aureus 
 A41.01 Sepsis due to Methicillin susceptible Staphylococcus aureus 
 A41.02 Sepsis due to Methicillin-resistant Staphylococcus aureus 
 A41.1 Sepsis due to other specified staphylococcus 
 A41.2 Sepsis due to unspecified staphylococcus 
 A41.3 Sepsis due to Hemophilus influenzae 
 A41.4 Sepsis due to anaerobes 
 A41.5 Sepsis due to other Gram-negative organisms 
 A41.50 Gram-negative sepsis, unspecified 
 A41.51 Sepsis due to Escherichia coli [E. coli] 
 A41.52 Sepsis due to Pseudomonas 
 A41.53 Sepsis due to Serratia 
 A41.59 Other Gram-negative sepsis 
 A41.8 Other specified sepsis 
 A41.81 Sepsis due to Enterococcus 
 A41.89 Other specified sepsis 
 A41.9 Sepsis, unspecified organism 
 sepsis NOS (A41.9) 
 streptococcal sepsis (A40.-) 




 sepsis during labor (O75.3) 
 sepsis following abortion, ectopic or molar pregnancy (O03-O07, O08.0) 
 bacteremia NOS (R78.81) 
 neonatal (P36.-) 
 puerperal sepsis (O85) 
Source: ICD10Data.com 







APPENDIX J: EXAMPLES OF DATA COLLECTION WORKSHEETS SET 
 
 
Figure J.1.14Data collection worksheets 








Patient’s unique # (PtID) --CATEGORICAL  
1,2,3,4,5,6,7,8,9… 
Age: --NUMERIC  
# number of years  
Gender   --CATEGORICAL  
1 male   2 female  
Race (Race1-6)  --CATEGORICAL  
1 Caucasian 
2 African American 
3 Asian 
4 Hispanic 
5 Native America;                             or: 6 Other 
LOS (Length of stay in # of days)  --NUMERIC  
# number of days spent in hospital 
Outcomes  
Mortality (OutcMort)  YES-NO   Yes=1 No=2  
1 yes – Alive   2 no - Deceased 
Functional status at discharge (OutcFS 0-3)  --CATEGORICAL  
0 same as pre-hospitalization 
1 worse, lost independence, needs more help, declined  
2 better then prior to hospitalization 
3 Deceased 
 Discharge (D/C1-6)   --CATEGORICAL  
Discharge to:  
1 Prior living situation/home, independent 
2 Extended care facility/ SNF (new) 
3 Deceased 
4 Higher level of care (transfer to another hospital) 
5 Home w/ Home Health/caregivers/more help 
6 Discharged to Hospice 
Immune status impairing diagnoses (ImDx0-2) --ORDINAL  
0 – Immunocompetent (ImDx0) 
1 – Immunocompromised with one Dx likely affecting immune status  
2 – Immunocompromised with two or more Dx affecting status 
Dx: (ImmDx0-7)  --CATEGORICAL  
0 None (ImDx0)  
1 Ca, (ImDx1)  
2 transplant/ spleenless (ImDx2)  
3 COPD, (ImDx3) etc..  
4 DM 
5 RA- on prednisone 
6 Chemotherapy; or: 7 other 
Comorbidities (Cmb0-15)  --CATEGORICAL  
0 None (Cmb0)  





6 ETOH chronic 
7 Readmitted, recurrent infection 
8 h/o sepsis 
9 h/o MDR infection 
10 Underlying dementia 
11 ESRD on dialysis 
12 Obesity 
13 CHF 
14 PVD;                              or: 15 Other 
Initial presentation (IniPres1-3)  --ORDINAL  
1 Sepsis 
2 Severe Sepsis 
3 Septic shock 
Acute mental status change (AMS)   --YES-NO   Yes=1 No=2  
1 yes   2 no 
Sepsis cause (SCs1-13)  --CATEGORICAL  
1 Pneumonia (SCs1) 
2 UTI (SCs2) etc  
3 Pyelonephritis 
4 GI/intraabdominal 







6 Post- Surgery complications 
7 Wound infection 
8 Meningitis;  
10 Neutropenic Fever  
11FUO  
12 Bacteremia 
13 Osteomyelitis;                                  or: 9 other 
Hospital course (Hcr1-3)  --CATEGORICAL  
 1 ICU w/ pressors and mechanical ventilation 
 2 ICU w/o mechanical ventilation 
 3 no pressors, no vent, PCU/other 
Progression of Sepsis  -- YES-NO   Yes=1 No=2  
1 yes - worse: severe sepsis progressed to septic shock or death 
2 no – better, status did not deteriorate during hospitalization 
Treatment w/ initial Antibiotics (Abt<3h) Yes=1 No=2  
1 Yes:  <3h from time 0 first antibiotic administered* (not ordered) 
2 No:   >3h from time 0 first antibiotic administered* 
Days on Abt  --NUMERIC  
# number of days on empiric antibiotics (AbtEmp#D)   
Number of empiric antibiotics (AbtEmp#)  --NUMERIC  
#number of prescribed antibiotic 
ABT Deescalated: (AbtDesc) Yes=1 No=2  
1 – yes     2- no 
Appropriate ABT for Dx (AbtAppr) Yes=1 No=2  
1 – yes     2 no 
IVF (IVF1-3)  --CATEGORICAL  
1 yes 30 ml/hr     2 no     3 contraindicated 
Lactic Acid 1
st
 drawn w/in 3 hrs  (LA1_3h) Yes=1 No=2  
1-yes,    2 - no 
Lactic Acid sample #1 > 2 (LA1>2)  --CATEGORICAL  
1 yes     2 no     0 not done 
Repeat Lactic Acid 6 hrs (LA2_6h)   --CATEGORICAL  
1 yes     2 no     0 N/A, not indicated   
 Cultures (Cult<3h)  --CATEGORICAL  
1 yes   <3h &BLOOD cultures drawn prior to admof antibiotic 
2 no    >3h &BLOOD cultures drawn/ or not before administration of 
antibiotic 
0 -- Blood cultures were  not done 
Cultures (Cult#hrID)  --NUMERIC  
# number of hr pathogen group described or identified in sample  
NUMERIC  
Cultures (Cult#hrFIN)  --NUMERIC  
# number of hours final results of cultures known, including MIC 
Culture results: (CR0-5)  --CATEGORICAL  
0 negative cultures 
1 positive cultures: bacteria 
2 positive cultures: fungal 
3 positive cultures: viral 
4 positive cultures other;                                      or:5 unknown 
C-diff   --YES-NO   Yes=1 No=2  
1 yes     2 no 






6 CNS fluid 
7 Pleural fluid 
8 Peritoneal;                                or: 9 other 
PATHOGEN:  
Gram negative pathogen (Gn1-12)  --CATEGORICAL  
1 E-coli 
2 Klebsiella pneumoniae 
3 Enterobacter 
4 Acinetobacter 




9 Haemophilus influenzae 
10 Campylobacter 
11 Neisseria; or: 12 other 







1 Staph aureus MSSA  
2 Staph aureus MRSA 
3 Staph coagulase (-) epidermidis 
4 Streptococcus pneumococcus 
5 Strep viridians 
6 Strep group A pyrogens 
7 Corynebacterium 
8 Enterococcus faecium 
9 Enterococcus faecalis 
10 Clostridum 
11 Corynobacterium 
12 Bacillus;                          or: 13 other 




Other     --CATEGORICAL 
1 Viral (OthVir 
2 Fungal (OthFung) 





5 ESBL;                                       or: 6 Other 
Antimicrobial class (Ab1-21)  --CATEGORICAL  
1 – PCN (Ab1)  
2 – Extended PCN (Zosyn) (Ab2)  
3 – B-lactamase inh PCN (Unasyn) (Ab3)etc.. 
4 – Cephalosporin 1
st
  
5 – Cephalosporin 2
nd
  
6 – Cephalosporin 3
rd
  
7 – Cephalosporin 4
th
  
8 – Cephalosporin 5
th
 (Ceftaroline) 
9 – Fluoroquinolone 2
nd
 (Cipro) 
10 – Quinolone 3
rd
 (Lavo/Moxi) 
11 – Macrolides 
12 – Tetracycline  
13 – Sulfonamides 
14 – Carbapenems 
15 – Monobactam (Aztreonam) 
16 – Glycopeptide (Vanc) 
17 – Liptopeptide (Cubicin/Dapto) 
18 – Oxazolidinone (Zyvox/linezolid) 
19 – Lincosamide (Clindamycin) 
20 – Other antibiotics (Tigecycline)                              
21 – Nitroimidazole (Flagyl) 
Other Treatment (OthTx 1-3) 
1 – Antifungal (fluconazole)  
2 – Antiviral;                                               3 Other atypical 
Appropriate antibiotic for culture results (AbtAppr)Yes=1 No=2  
1 Yes;                 2 No 
Healthcare Acquired infection (HCaq) Yes=1 No=2  
1 yes;                  2 No 
Complications (cmp1-11)   --CATEGORICAL  
1 C-diff 




6 Abscess  
7 Renal failure  
8 Respiratory failure  
9 Multisystem failure  
10 Cardiac complications                11 Other 
Potential costs savings  On LOS (Sav$LOS) Yes=1 No=2  
1 yes;           2 no 
On ABT de-escalation  (Sav$Abt) Yes=1 No=2  
1 yes;           2 no 
Readmitted w/in 30 days (Readm30)  Yes=1 No=2  




APPENDIX K: EXAMPLES OF VARIABLE CODING SYSTEM 
Table K.1.21Variable Coding System 
 
Variable/category Code Subcategory codes 
Patient’s # (PtID) (#1, 2, 3, 4, 5…n) 
Race (Race1-6)  
 
1=Caucasian: Race1;  
2=African American: Race2;  




(OutcFS 0-3) 0=No change from pre-hospitalization: OutcFS1;  
1=Worse, lost independence, declined: OutcFS1;  




(D/C1-6) 1=Prior living situation or home, independent: D/C1; 
2=Extended care facility/ SNF (new): D/C2;  
3=Deceased: D/C3;  
4=Higher level of care, transfer to another hospital: D/C4;  
5=Home with Home Health, requires more help: D/C5;  
6=Discharged to Hospice: D/C6 
Comorbidities (Cmb0-15) 0=None: Comb0;  
1=Cancer Comb1;  
2=Chronic Obstructive Lung Disease Comb2;  
3=Diabetes Comb3; …Comb15 
Complications (cmp1-11) 1=C-diff: comp1;  
2=MDR organism: comp2;  
3=Surgery: comp3;  
4=Neutropenia: comp4; …: comp11) 
Site of positive 
cultures 
(P+1-9) 1=Blood: P+1;  
2=Urine: P+2;  
3=Wound: P+3;  
4=Sputum: P+4 l … : P+9 
Gram negative 
pathogen  
(Gn1-12) 1=E-coli: Gn1;  
2=Klebsiella pneumonia: Gn2;  
3=Enterobacter: Gn2; 
4=Acinetobacter: Gn4; … : Gn12) 
Gram positive 
pathogen 
G(+)1-13) 1=Staph aureus MSSA: G(+)1;  
2=Staph aureus MRSA: G(+)2;  
3=Staph coagulase (-) epidermidis: G(+)3 ; 
4=Streptococcus pneumococcus: G(+)4 ; … : G(+)13 
Antimicrobial 
class 
(Ab1-21) 1= PCN: (Ab1);  
2=Extended PCN: Ab2;  




APPENDIX L: PERMISSION TO REPRINT  
Permission to reprint the PDSA Model for improvement 
 
 










APPENDIX M: DESCRIPTIVE STATISTICAL DATA 
Mortality and Length of Stay Data 
Table M.1.22Mortality by Age.  
 
OutcmMort N Mean Std Dev Std Err Minimum Maximum 
Alive 108 72.3981 14.8103 1.4251 23.0000 97.0000 
Deceased 50 78.1600 13.2532 1.8743 43.0000 97.0000 
Diff (1-2)  -5.7619 14.3394 2.4528   
 
OutcMort Method Mean 95% CL Mean Std Dev 95% CL Std Dev 
Alive  72.3981 69.5730 75.2233 14.8103 13.0640 17.0997 
Deceased  78.1600 74.3935 81.9265 13.2532 11.0708 16.5153 
Diff (1-2) Pooled -5.7619 -10.6069 -0.9169 14.3394 12.9095 16.1284 
Diff (1-2) Satterthwaite -5.7619 -10.4301 -1.0936    
p<0.05. * T-Test Variable: OutcmMort: Mortality 
 
Table M.2.23Mortality by LOS 
 
OutcmMort N Mean Std Dev Std Err Minimum Maximum 
Alive 108 7.0556 4.8872 0.4703 1.0000 26.0000 
Deceased 50 7.0800 5.8269 0.8240 1.0000 27.0000 
Diff (1-2)  -0.0244 5.2007 0.8896   
 
OutcmMort Method Mean 95% CL Mean Std Dev 95% CL Std Dev 
Alive  7.0556 6.1233 7.9878 4.8872 4.3110 5.6427 
Deceased  7.0800 5.4240 8.7360 5.8269 4.8674 7.2611 
Diff (1-2) Pooled -0.0244 -1.7816 1.7328 5.2007 4.6821 5.8495 
Diff (1-2) Satterthwaite -0.0244 -1.9119 1.8630    




Age in Relation To LOS and Mortality Between Groups 
 
Figure M.1.17Mortality by Age and Group. 




Figure M.2.18LOS by Age and Group 
*(Dark gray bar = pre-implementation group; light gray = post-implementation group).  
UP TO 50 51-70 71-80 81-90 91-100 







Figure M.3.19Antibiotics Distribution 
*(Dark gray bar = pre-implementation group; light gray = post-implementation group). 
 
Table M.3.24Most Frequently Used Antibiotics 
 
Most Frequent Empiric 
Antibiotics used 
Pre (n=86) Post (n=72) 
 
% % 
Vancomycin 23.3 26.5 
Levaquin 19.7 22.1 
Zosyn 18.8 16.2 
Rocephin 13.9 12.7 
Cefepime 7.6 7.4 
Cipro 6.3 5.4 
Merem 5.8 5.4 
Flagyl 4.5 4.4 
  




Sepsis Associated Diseases and Causative Pathogens 
Table M.4.25Sepsis Cause 
 
Sepsis Cause Pre (n=86) Post (n=72) 
 
% % 
Pneumonia  48 50 
UTI   38 47 
Bacteremia 22 35 
GI/intraabdominal 21 11 
Post-operative complications 10 3 
Wound infection 9 10 
Other 9 3 
Neutropenic Fever  7 1 
Skin (Cellulitis) 6 14 
Pyelonephritis 5 7 
FUO  3 3 
Osteomyelitis 1 3 
Meningitis <1 1 
 
 
Figure M.4.20Most Frequently Occurring Microorganisms Responsible for Sepsis.  











Table M.5.26Most Frequently Occurring Pathogens 
 
Most Frequent Causative Pathogens Observed Pre (n=86) Post (n=72) 
Pathogen % % 
E-coli 17.4% 23.6% 
Candida/Fungal  14.0% 12.5% 
Staph coagulase (-) epidermidis 9.3% 0.0% 
Enterococcus faecalis 8.1% 0.0% 
Staph aureus MRSA 5.8% 2.8% 
Viral (OthVir 5.8% 1.4% 
Klebsiella pneumoniae 5.8% 0.0% 
Pseudomonas aeruginosa 4.7% 0.0% 
Strep viridians 4.7% 1.4% 
Enterobacter 3.5% 0.0% 
Haemophilus influenzae 3.5% 0.0% 
Staph aureus MSSA  3.5% 5.6% 
Streptococcus pneumococcus 3.5% 15.3% 
other 3.5% 6.9% 
Proteus 2.3% 2.8% 
Enterococcus faecium 2.3% 2.8% 
Acinetobacter 1.2% 0.0% 
Strep group A pyrogens 1.2% 1.4% 
Corynebacterium 1.2% 1.4% 
Corynobacterium 1.2% 1.4% 
other 1.2% 5.6% 
Bacillus 1.2% 0.0% 
Serratia 0% 1.4% 
Morganella 0 0.0% 
Campylobacter 0 2.8% 
Neisseria 0 0.0% 
Clostridum 0 2.8% 
Mycoplasma 0 2.8% 
Chlamydia 0 0.0% 
Ricketts 0 0.0% 
C-diff 2% 3% 
MDR 17% 14% 
All Sepsis w/ MRSA 10% 7% 
MRSA cases among MDR associated with sepsis 60% 50% 
ESBL 7% 10% 
VRE 7% 0% 
* E-coli: bacterium Escherichia coli; MRSA: resistant strain, Methicillin Resistant 
Staphylococcus aureus; MSSA: Methicilin Sensitive Staphylococcus aureus; C-diff: Clostridium 




Table M.6.27Legend for Data Collection:  
 
Code: Applies to: 
OutcMort  Outcomes, Mortality  
OutcFS  Functional status at discharge  
D/C  Discharge  
ImDx   Associated diagnoses affecting immune status 
Cmb  Comorbidities   
IniPres  Initial presentation 
AMS  Acute mental status change  
SCs  Sepsis cause  
Hcr  Hospital course 
SpsPrgs  Progression of Sepsis  
Abt<3h  Treatment with initial Antibiotics per protocol <3 hours from sepsis onset 
AbtEmp#D  Number of days on empiric antibiotics 
AbtEmp#  Number of empiric antibiotics prescribed 
AbtDesc  Antibiotics Deescalated 
AbtAppr  Appropriate antibiotic for diagnosis  
IVF  Intravenous fluids per protocol at 30mL/hr and <3 hours from sepsis onset  
LA1  Lactic Acid 1
st
 drawn <3 hours from sepsis onset 
LA1>2  Lactic Acid first sample results > 2  
LA2_6h  Repeat Lactic Acid in 6 hours  
Cult<3h  Blood cultures drawn prior to administration of antibiotic and <3 hours from 
sepsis onset 
Cult#hrID  Number of hours pathogen group described or identified in a sample  
Cult#hrFIN  Number of hours until final cultures results available, including MIC 
CR  Culture results 
C-diff  Clostridium difficile  
P+  Site of positive cultures  
Gn  Gram negative pathogen 
G(+)  Gram positive pathogen 
OthVir  Viral  
OthFung  Fungal 
MDR  Multi-drug resistant organisms  
Ab  Antimicrobial class 
OthTx  Other Treatment 
AbtAppr  Appropriate antibiotic for culture results 
HCaq  Healthcare Acquired infection 
Cmp  Complications  
Sav$LOS  Potential costs savings on length of stay 
Sav$Abt  Potential costs savings on antibiotics de-escalation  
Readm30  Readmitted within 30 days 
 
